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Oral anticoagulants are used to treat and prevent blood clots. All 
anticoagulants carry the risk of bleeding if the systemic exposure is too high, 
while inadequate exposure will increase the risk of thrombosis. Therefore, the 
safe and effective use of all oral anticoagulants will require dose 
individualisation and monitoring. The overarching goal of this thesis is to 
critically evaluate and explore dose individualisation methods for warfarin and 
dabigatran therapy to improve patient outcomes.  
For warfarin, methods for predicting the maintenance dose were 
investigated. Specifically, Chapter 2 investigates the predictive performance of a 
Bayesian dose individualisation tool for warfarin. It was found that the 
maintenance dose was over-predicted especially in patients requiring higher 
daily doses and further studies into the source of bias were conducted. Chapter 
3 further evaluates whether published warfarin maintenance dose prediction 
algorithms can accurately predict the observed maintenance dose in patients 
who require ≥7 mg daily (the upper quartile of dose requirements). A systematic 
review and meta-analysis was conducted to answer this question. It was found 
that all warfarin dosing algorithms included in the study under-predicted the 
maintenance dose in this group of patients. 
One common metric to measure predictive performance of a model is the 
mean prediction error, which is a measure of bias. The work conducted in 
Chapter 2 and 3 suggests that the mean prediction error may not capture non-
constant bias. This is when the predictions systematically deviate away from the 
line of identity in one direction in relation to the observed data. Chapter 4 
proposes new method to assess predictive performance to analyse non-constant 
systematic deviation from the line of identity. The proposed method is not 





For dabigatran dosing, aspects of concentration monitoring as a means of 
determining a suitable dosing rate were explored. In Chapter 5, an assay using 
liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
was developed to measure all active entities of dabigatran concentrations in 
human plasma. The assay was used to measure dabigatran concentrations 
collected from a previous study. A de novo population pharmacokinetic model 
was not pursued in the first instance as the data were fairly sparse. Instead, the 
measured concentrations were used in Chapter 6 in a simulation based study to 
select an appropriate prior population pharmacokinetic model that might be 
used in a future Bayesian dose individualisation method for dabigatran. The 
overall intention of Chapter 6 was to develop a Bayesian dose individualisation 
method for dabigatran. 
In conclusion, this thesis has identified the limitations of current methods 
for predicting warfarin maintenance dose and has explored dabigatran 
concentration monitoring as a means of improving dabigatran dosing. Models 
for predicting warfarin maintenance dose were critically evaluated and it was 
found that all existing models can not accurately predict the maintenance dose 
in patients requiring higher daily doses. An improvement in the method to 
assess predictive performance was proposed. The work conducted in this thesis 
on dabigatran dosing provides the basis for future research to individualise 
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 Elimination rate constant  
 Rate of disassociation of a drug receptor complex  
! Rate of formation of a drug receptor complex  
"# Maximum theoretical INR 
"#$  Predicted INR 
"#%! Baseline INR 
γ Hill coefficient 
τ Dosing interval 
&' Variance 





STRUCTURE OF THE THESIS 
 
The thesis is divided into six parts (Table P.1). Part I includes an 
introduction to dose individualisation methods, an overview of 
pharmacokinetics and pharmacodynamics and models for predicting drug 
responses, and a literature review on oral anticoagulants.  
Part II focuses on methods to individualise warfarin maintenance dose. 
Chapter 2 investigates a Bayesian forecasting method for warfarin dosing. The 
predictive performance of warfarin dosing tools will be evaluated in Chapter 3.  
Part III includes Chapter 4 which proposes a revision to the method for 
evaluating predictive performance using the mean prediction error. 
Part IV focuses on exploring aspects of dabigatran concentration 
monitoring. Chapter 5 describes the development and validation of an assay to 
measure dabigatran and its active metabolite (dabigatran acyl glucuronide) in 
human plasma and measures plasma concentration available from a previous 
study. Chapter 6 uses concentration measurements obtained from Chapter 5 in 
a simulation based study to determine an appropriate model for dose 
individualisation of dabigatran in the future.  
Part V concludes the thesis with a discussion of the findings and future 
research.   
Part VI includes the appendices which provide contain additional material 
related to the individual chapters, including author contribution for published 





Table P.1 Overview of the thesis 
  
Part I Introduction 
 Chapter 1. Introduction  
Part II  Warfarin dosing  
 Chapter 2. Investigating warfarin maintenance dose predictions 
using a Bayesian forecasting method 
Chapter 3. An evaluation of warfarin dosing tools in patients 
requiring ≥ 7mg daily 
Part III Predictive performance 
 Chapter 4. An approach for testing non-constant deviation 
associated with the magnitude of the observation 
Part IV Dabigatran dosing 
 Chapter 5. Quantification of dabigatran and dabigatran acyl 
glucuronides in human plasma by LC-MS/MS 
Chapter 6. Evaluation and selection of a prior dabigatran 
population pharmacokinetic model for dose 
individualisation 
Part V Discussion and Conclusion 
 Chapter 7. Discussion and Conclusion 
Part VI Appendices 
 Appendix 1. Appendices to Preface  
Appendix 2. Appendices to Chapter 3  
Appendix 3. Appendices to Chapter 4  
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1.1. Introduction to the thesis 
Anticoagulants are used to treat and prevent blood clots. The physiological 
response to anticoagulant therapy is a prolonged clotting time. Therefore, the 
use of anticoagulants will carry an increased risk of bleeding if drug exposure is 
too high while inadequate exposure carries an increased risk of thrombosis. 
Hence, successful treatment with anticoagulant drugs requires the prescriber to 
select a maintenance dose rate that will balance the need for adequate 
anticoagulation without over- or under-anticoagulating the patient.  
The overarching assumption of the work conducted in this thesis is that all 
anticoagulants will require monitoring of clotting times or drug exposure to 
ensure their safe and effective use. Two oral anticoagulants, warfarin and 
dabigatran, are examined in this thesis.  
Warfarin has been used clinically for over 70 years. Despite this long 
history, the dosing of warfarin remains a challenge in the clinic. A large number 
of warfarin dosing aids have been developed to improve anticoagulation control. 
Bayesian forecasting methods have been proposed as a means of guiding dose 
selection using routinely collected anticoagulation response data, such as 
clotting time [1, 2]. Chapter 2 investigates the predictive performance of a 
Bayesian dosing tool for warfarin therapy.  
Recent publications advocate for the a priori prediction of warfarin 
maintenance doses, using empirically-derived algorithms based on patient 
characteristics known to influence warfarin dosing requirements between 
patients [3, 4]. There have been a large number of dosing algorithms published 
over the past 10 years but there is a limited understanding of how these tools 
perform in routine clinical practice. In particular, there are few studies to date 
comparing the predictive performance of different warfarin dosing algorithms 
against each other. Work conducted in this thesis raises the concern that warfarin 
dosing aids may not perform well in patients who require larger daily doses. 
Chapter 3 presents a meta-analysis of published dosing algorithms with a 
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particular emphasis on the predictive performance in those patients who require 
doses greater than 7 mg daily (the upper quartile of dose requirements). 
Chapter 4 presents a new methodology to evaluate the performance of tools 
designed to predict dose requirements. This method can be viewed as both an 
expansion of, and complimentary to, the method involving mean prediction 
error proposed by Sheiner and Beal [5]. 
Dabigatran is an oral anticoagulant first approved in October 2010 in the 
United States [6, 7] and in July 2011 in New Zealand [8, 9]. The manufacturer 
recommends a fixed dose for most patients, with dose modification based on 
patient characteristics such as renal function [9]. Importantly, the drug was 
marketed as an alternative to warfarin that did not require the monitoring of 
clotting time to evaluate anticoagulant response. There is evidence to suggest 
that the dosing guidelines for dabigatran may lead to over- or under-exposure 
of dabigatran and thus bleeding and thrombosis (treatment failure) [10], 
respectively. Therefore, this thesis will explore aspects of dabigatran dose 
individualisation, including the measuring and monitoring of plasma 
concentrations as a means of guiding dose selection. Specifically, Chapter 5 and 
6 describe the development of an assay for dabigatran and its active metabolite 
and an evaluation of published dabigatran pharmacokinetic models as a means 
of predicting dose requirements.  
1.1.1. Aims of the thesis 
The overarching goal of this thesis is to critically evaluate and explore 
aspects of dose individualisation for warfarin and dabigatran therapy.  
There are three specific objectives; 
a. To critically evaluate dose prediction methods for warfarin 
therapy (Chapters 2 and 3) 
b. To propose a method for evaluating the predictive performance 
of dose prediction methods (Chapter 4) 
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c. To explore aspects of dabigatran dose individualisation related 
to plasma drug concentration monitoring (Chapter 5 and 6).  
1.1.2. Structure of the introduction 
The introduction will present background material relevant to the experimental 
work conducted for this doctoral thesis as follows;  
• Section 1.2 - Models for predicting dose requirements  
• Section 1.3 - A conceptual framework for dose individualisation methods 
• Section 1.4 - Anticoagulants considered in this thesis 
1.2.   Models for predicting dose requirements  
1.2.1. A population pharmacokinetics-pharmacodynamics (PKPD) approach 
This section briefly describes salient points of a model based approach to 
dosing that are investigated in this thesis. Note that estimation of model 
parameters will not be covered (a minor part of the thesis presented here).  
Population pharmacokinetics-pharmacodynamic models provide a means 
of defining the typical time course of drug concentrations in the plasma, the time 
course of drug effects, and different sources of variability. In addition, a 
population model provides estimates of between subject variability in model 
parameters (e.g. clearance, volume), covariate effects, and random variability. 
This provides the basis for dose individualisation as it allows individual patient 
characteristics (i.e. covariates) that predict differences in drug response to be 
identified and accounted for. 
1.2.1.1. Pharmacokinetic models 
Pharmacokinetics describes the time course of drug concentrations in the 
body [11].  The simplest pharmacokinetic model is a one-compartment model 
where the drug is assumed to be distributed instantaneously throughout the 
compartment. The concentration at any time can be calculated as: 
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(+) = . × 01
23456 ×7 
Equation 1.1  Equation for one-compartment linear pharmacokinetic model after 
intravenous bolus 
where  is the plasma concentration as a function of +, . is the dose,  is the 
apparent volume into which the drug distributes, 8 is the clearance and + is 
time. Clearance links the rate of elimination and concentration of drug in body 
and is related to functional capacity of the body to remove drugs [12]. Volume 
of distribution reflects structural aspects of the body and is related to body 




For oral dosing, the fraction that reaches the circulation is often less than 
the dose taken due to incomplete absorption and first pass metabolism in the 
liver. Therefore 2 more parameters are needed for oral dosing; bioavailability (9) 
and absorption rate constant () and the concentration as a function of time can 
be given by: 
(+) = . × 9 ×  × ( − ) × (01
(3;<×) − 01(3;=×)) 
 Equation 1.2 The equation for a one compartment pharmacokinetic model with first-
order absorption and elimination 
When the drug is taken repeatedly, the concentration will approach a 
steady-state where the amount of drug entering the body and the amount of 
drug leaving the body are equal. Under these conditions, the steady-state 
average concentration (,) can be calculated using Equation 1.3: 
, =
.>? × 9
8 × @  
Equation 1.3 The equation for calculating steady-state concentration 
where @ is the dosing interval. 
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1.2.1.2. Pharmacodynamic models 
Pharmacodynamics is the science that describes the relationship between 
drug concentrations and the observed pharmacological response  [13]. Most 
drug action can be attributed to the binding of the drug to the receptor [14]. 
Mathematically, assuming 1:1 stoichiometry, the binding of drug to the receptor 
can be expressed using Equation 1.4 where the drug (.) binds to a receptor site 
(#) to form an activated drug-receptor complex (.#).   
 
Equation 1.4 Binding of a drug to a receptor 
where ! is the association rate constant of a drug to the receptor and   is 
the dissociation rate constant.  
At equilibrium, the dissociation constant ( ) represents the inverse of the 





Equation 1.5 Dissociation constant at equilibrium 
Subsequently, assuming that all receptors are available for the drug to bind, 
the receptor binding equation can be expressed as: 
 =  ×

 +  
Equation 1.6 Receptor binding equation, the Bmax model 
where  is the number of bound receptors,  is the drug concentration,  is 
the maximum binding capacity when all receptors are occupied.  
In clinical practice, receptor binding information is not available, but the 
pharmacological effect can be measured. If we assume the drug effect is 
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proportional to   [15], then drug effects ( O ) can be linked to   using a 
proportionality constant as follows: 
O =  ×  
Equation 1.7 Drug effect following receptor binding 
where   is a proportionality constant that links the receptor occupancy with 
effect (O).  
Drug effect (O) can be described using the O model: 
O = O ×

OPQ +  
Equation 1.8 An O model 
Here, two parameters of interest are O which is the maximum effect, and OPQ 
which is the concentration of drug at 50 % of maximum drug effect. 
The O model can be generalised to allow different steepness of the slope 
of the concentration-effect relationship. This is called the sigmoidal O model 
where concentration is exponentiated with the Hill coefficient.  




Equation 1.9 A sigmoidal O model 
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Figure 1.1 depicts the sigmoidal O  concentration-effect relationship 
with different Hill coefficients. 
 
Figure 1.1 The model showing the change in shape with different Hill coefficients. In 
this model Emax= 1, STUV= 0.15 units/L. 
1.2.1.3. Pharmacokinetic-pharmacodynamic models 
By linking pharmacokinetic and pharmacodynamic models, the time 
course of drug effect can be described. Figure 1.2 illustrates a concentration-time 
profile (pharmacokinetics), concentration-effect profile (pharmacodynamics) 
and effect-time profile which is a combination of pharmacokinetic and 
pharmacodynamic profile. 




Figure 1.2 An illustration of concentration-time profile pharmacokinetic model (A), 
concentration-effect profile pharmacodynamic model (B) and a combined effect-time 
profile pharmacokinetic-pharmacodynamic model (C).  
 Two general forms of a PKPD model will be described here;  
a) Immediate effects model 
b) Delayed effects model 
In an immediate effects model, the time to peak plasma concentration and 
the time to peak drug effect are considered to be essentially the same. In this 
scenario, the time course of drug effects can be described using a 
pharmacokinetic model linked to an O model, as shown in equation 1.8 or 1.9. 
Figure 1.3 illustrates the effect-time profile overlaid on the concentration-time 
profile of a hypothetical drug. 




Figure 1.3 The time course of concentrations (blue line) and drug effects (brown line) for 
an immediate effects model. The concentrations were generated using a one compartment 
model with first-order input. Dose = 10 units, CL = 5 L/hour, V = 5 L and ka= 1 hours. 
Emax= 1, STUV= 0.15 units/L. 
Delayed effects models are used to account for the delay in drug effect in 
relation to the plasma concentration. The delay in drug effect may reflect the time 
required for the drug to distribute from the plasma to the site of action (a 
pharmacokinetic phenomenon) or the slow turnover of a physiological 
intermediate. The mechanism of action for many drugs involves the activation 
or blockade of a receptor which, in turn, initiates a physiological response 
mediated by a series of secondary messengers or the turnover of biological 
intermediates. These physiological processes have a time course of their own and 
often constitute the rate-limiting step in the time course of drug effects. These 
models account for the delay in the observed drug effect with respect to the 
measured plasma concentration and are commonly referred to as ‘turnover 
models (and sometimes ‘indirect-response models’) [16]. There are several 
methods proposed on how delayed effects can be modelled and several excellent 
reviews have been published  [17, 18]. Therefore, delayed effect models will not 
be described in more detail here as they were not studied in this thesis. The 
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exception is a transit compartment model described in Chapter 2, which will be 
discussed below.  
Transit compartments were first introduced to describe delays in drug 
absorption in pharmacokinetics studies [19]. It has been used to account for 
delayed response–time profile where the stimulus is transmitted through a series 
of transit compartments to produce the response. A practical application of 
transit compartment models is to account for the delay between warfarin plasma 
concentrations and the resulting inhibition of vitamin K-dependent clotting 
factor synthesis [20]. Here, transit compartments were used to represent the 
depletion of clotting factors linked in series. Figure 1.4 depicts the structure and 
mathematical equations of the transit compartment model by Hamberg et al [20]. 
This is the model used in Chapter 2.  
   
Figure 1.4 A schematic of a transit compartment model. Reproduced from Wright et al  
[2]  with permission from Springer. The initial condition for amount of drug in the body 
(A) was 0, for C1m was 1 and C2m was 1. C1m and C2m are the mth compartment in the 
two transit chains, CLs is the s-warfarin clearance and Vs is the volume of distribution, 
DR dose driving rate, EDK50 dose rate for 50 % inhibition of coagulation, EFF inhibitory 
effect on vitamin K epoxide reductase, Emax maximum inhibition of coagulation,  first-
order elimination rate constant, MTT mean transit time,  Hill coefficient. 
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The transit compartment model in Figure 1.4 represents two transit 
compartment chains with three compartments each. C1 refers to the first transit 
chain and C2 the second transit chain. The inhibitory Emax model enters the model 
at the first transit compartment in each chain. The drug effect is then the average 
of the two chains (i.e. C13 and C23) as follows: 
"#$ = "#%! + "# (1 −
1X + 2X
2 ) 
Equation 1.10 INR calculation for the transit compartment 
where "#$  is the predicted International Normalized Ratio (INR), 
"#%!  is the baseline INR before treatment, "#  is the maximum 
theoretical INR (set to 20 as per Hamberg et al [20]).  
Each transit compartment has an intercompartmental transit time, but the 
overall process is parameterized as the mean transit time (MTT) of each chain. 
The transit compartment rate constant () is assumed to be the same for each 
compartment and assumed to be equivalent to  . The number of transit 
compartment and transit chains are usually empirically determined. 
1.2.1.4. Models for heterogeneity and residual variability 
Population pharmacokinetic and pharmacodynamic models include 
random effects parameters to describe the heterogeneity between individuals 
(termed between subject variability, BSV) of the corresponding population 
parameter, and measurement uncertainty (termed residual unexplained 
variability, RUV).  
 Consider an example of the model parameter for volume () in Equation 
1.1 above (i.e. (+) = Z6 × 01
32[\] ×7 ); here   is the population average of  
(^_^). The BSV for  can be modelled as follows: 
 = ^_^ × 01 (`); `~(0, d')  
Equation 1.11 A model to account for BSV of volume in the ith individual 
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where   is the individual’s   estimate, `  is the difference between individual 
parameter predictions for the eth individual from the typical value for the 
population.  `  is assumed to be normally distributed over all individuals with a 
mean of zero and variance d'.  
A population model includes a statistical model to account for the 
residual unexplained variability (RUV). Usually RUV is assumed to follow a 
normal distribution with a mean of zero and variance of  &' as follows;  
fg ~ (0, &') 
Equation 1.12 The distribution of hi 
where fg is the difference between model prediction to the jth observation of the eth 
individual. 
1.2.2. Bayesian forecasting 
Bayesian methodology provides the means of incorporating individual 
patient response data with prior knowledge of typical drug response in the 
population. Several Bayesian forecasting methods for dose individualisation 
have been published [1, 21-23]. A Bayesian forecasting approach involves 
predicting future responses for a given dose based on; 1) prior information about 
the patient’s response to drug therapy, 2) an underlying population 
pharmacokinetic and pharmacodynamic model and 3) parameter values 
obtained from a prior population [23]. A Bayesian method estimates the 
parameter values that provide the relative balance between the prior information 
and the new observed data for the patient from a posterior distribution. A 
maximum a posteriori (kl^) estimator provides a point estimate of an unknown 
quantity that is equal to the mode of the posterior distribution. Individualised 
parameter estimates of a model can be obtained by minimizing the kl^ 
objective function given by: 
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kl ̂%g = m










Equation 1.13 Maximum a posteriori objective function 
where kl ̂%g is the kl^ objective function, 0g  is covariate of the jth patient, ng is 
the jth observation, o((, 0g) is the model-predicted jth observation, ( is a vector of 
individual parameter estimates, &p'g  is the residual variance associated with the 
jth observation and calculated as &p'g =&$$'  x o((, 0g)' + &  ' , where &$$'  is the 
proportional variance and &  '  is the additive variance, st ($ is the natural log 
of the 1th parameter, st uvw  is the natural log of the prior of the population value 
of the 1 th parameter and dvw'  is the log-normal inter-individual variance  
associated with the 1th parameter.  
Note that when there is no information about the patient, the second term 
on the right-hand side of the equation disappears and the equation collapses to 
the prior population estimates. As more feedback about the drug response in the 
individual becomes available, the second term in the right-hand side equation 
dominates and predictions are based on more individualised posterior 
parameter estimates. This is an adaptive process which allows the Bayesian 
algorithm to incorporate new information. Theoretically, the more observations 
that is used, the more individualised the parameter estimates become and the 
more accurate the model predictions become.   
1.2.3. A linear regression approach 
This subsection relates to the work carried out in Chapter 3 where warfarin 
dosing algorithms developed using linear regression methods will be evaluated.  
Linear regression is a statistical approach to find a relationship between a 
dependent variable and one or more independent variables. This approach has 
been used to find the relationship between the maintenance dose of warfarin and 
Chapter 1: Introduction 
38 
 
variables that predict  differences in dose requirements between individuals (see 
Gage et al [24]  for an example). 
Let ng denote the dependent variable taken from the jth covariate value of 
0g, where j = 1, … . . , t. A linear model can be written as follows: 
ng = z(0g , {) +  g   
Equation 1.14 A linear regression model 
where n  is an t ×  1 vector of the dependent variable, {  is the regression 
parameters coefficient, 0  is a vector of t ×  1 of the independent variable (or 
predictor) and  is the error. The goal is to find the best estimate of { (where { is 
the slope of the regression line). The notation above is for regression for a single 
variable but the regression equation can be extended to include multiple 
variables using the same principles. This is termed multilinear regression. 
The standard assumptions of linear regression are that the independent 
variables are fixed and known with certainty. The errors in model prediction are 
uncorrelated with each other and are normally distributed with a mean zero and 
constant variance. These assumptions can be relaxed in some cases.   
Linear regression models are empirical in nature and therefore, in theory, 
are limited in the ability to extrapolate beyond the data used to develop the 
model. It is noteworthy, however, that many linear regression equations 
developed for the purpose of dose prediction are explicitly designed to be used 
in patients in other clinical settings.  
1.3. A conceptual framework for dose individualisation methods 
Holford and Buclin [25] have described a framework for understanding 
drug dosing methods. They propose three general methods; 1) the population 
method, 2) group dosing, 3) dosing based on individual patient response. 
Population dosing refers to a fixed dose for all patients, i.e. the entire 
‘population’.  Group dosing is used where the same dose is given to the same 
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group of patients, e.g. those with same renal function, body weight, or age. This 
method can also be referred to as ‘covariate based’ dosing. Dosing based on 
patient response requires feedback from the patient to adjust dosing.   
In revised framework, a further refinement to the framework described by 
Holford and Buclin [25] will be proposed. In this case, dosing method will be 
divided into two categories: covariate based methods or response based 
methods. Response can be in the form of plasma concentration or can take the 
form of a biomarker for drug effect (e.g. INR for warfarin therapy). A biomarker 
is an objectively measured indicator of a biological, pathological or 
pharmacological response to drug therapy [26]. Biomarkers such as the INR are 
useful for guiding dosing if the long term clinical endpoint (e.g. stroke or bleed) 
can take years to manifest.  
The following is a conceptual framework for dose individualisation that 
will be used in this thesis: 
1. Population dosing 
All patients receive the same dose. 
2. Covariate based dosing 
The dose is determined from patient characteristics that are known to 
influence dose requirements. 
i. Uni-dimension  
 Only single covariate is used to determine the dose 
 Example: weight-based dosing such as the initial dose of 
enoxaparin [27]. 
ii. Multi-dimension  
 More than one covariate is used for dosing. Each covariate 
adds an extra dimension to the dose prediction allowing 
more flexibility to the final dose calculation. 
 Examples : dosing based on body surface area (i.e. weight 
and height) for cisplatin [28], several multilinear regression 
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algorithms to predict the maintenance dose of warfarin [24] 
(see Section 1.4.3.1.2). 
3. Response based dosing 
Dosing based on response data (concentration or biomarker) as feedback 
i. Single feedback, no covariates, non-updating 
 Uses only the most recent response measure and does not 
account for previous response data 
 Example: Static INR nomograms (warfarin) by Tait and 
Sefcick [29]. This nomogram (see Figure 1.5) is specifically 
designed to be used in the first 8 days of therapy. It is based 
on a single INR response (hence ‘static’) and does not 
account for any covariate or previous INR measurement. 
  
Figure 1.5 An example of a nomogram by Tait and Sefcick [29] reproduced with 
permission from John Wiley and Sons 




ii. Single feedback, multi-dimension, non-updating 
 Combines information from response and patient 
covariates. Predictions cannot be updated. 
 Example: Warfarin algorithms that use a single INR 
response and multiple covariates to predict the maintenance 
dose fall into this group [30, 31]. 
iii. Multi-feedback, uni- or multidimension, non-updating 
 Dosing based on more than one feedback with one or more 
covariates. Predictions cannot be updated. 
 Example: Dosing based on creatinine clearance estimated 
using the Jelliffe and Jelliffe equation [32]. The equation is 
used in patients with unstable renal function and requires 
input of two serum creatinine concentrations (i.e. two 
feedbacks), body weight, and estimated creatinine 
production. 
iv. Multi-feedback, multidimension, updating 
 Dosing based on multiple response data, multiple 
covariates and can update the predictions as more 
information becomes available.  
 Example: Bayesian forecasting methods for dose 
individualisation [1, 2, 33, 34]. 
1.4. Anticoagulants considered in this thesis 
1.4.1. Introduction to the coagulation network 
Anticoagulants modify haemostatic mechanisms resulting in a prolonged 
clotting time. Common clinical indications include atrial fibrillation/flutter, 
mechanical heart valve replacement, post-orthopaedic surgery, deep vein 
thrombosis or pulmonary embolism. 
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All anticoagulants inhibit thrombin production either directly, or indirectly 
by inhibiting the upstream activation of coagulation proteins. The physiological 
mechanism of thrombin production is complicated as it involves multiple 
feedback and feedforward mechanisms. Only a brief description of the 
coagulation network is presented here as more detailed description are available 
in textbooks and other excellent reviews [35, 36]. A schematic of the coagulation 
network is presented in Figure 1.6.  
 
Figure 1.6 A schematic of the coagulation network. The scheme of the coagulation 
network model. APC, activated protein C; AT-III, antithrombin-III; CA, activator for the 
contact system; DP, degradation product; F, fibrin; Fg, fibrinogen; II, prothrombin; IIa, 
thrombin; K, kallikrein; P, plasmin; PC, protein C; Pg, plasminogen; Pk, prekallikrein; 
PS, protein S; TAT, thrombin–antithrombin complex; TF, tissue factor; TFPI, tissue 
factor pathway inhibitor; Tmod, thrombomodulin; VK, vitamin K; VKH2, vitamin K 
hydroquinone; VKO, vitamin K epoxide; XF, cross-linked fibrin. Figure reproduced from 
Wajima et al. [36] with permission from John Wiley and Sons 
 A clot formation starts as a response to an injury to the endothelium that 
lines the blood vessels. There are two pathways, classically known as contact 
activation (or intrinsic) pathway and tissue factor (or extrinsic) pathway. The 
contact activation pathway is activated when a negatively charged surface 
activator (labelled CA in a shaded box in Figure 1.6) activates factor XII. In the 
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tissue factor pathway, blood leaking through the endothelium activates the 
platelets and exposes subendothelial tissue factors to plasma Factor VII. In both 
pathways, there is a complex network of events that happen where each reaction 
takes place at very different time scales. Multiple blood proteins get activated 
and several co-factors (calcium, phospholipids and Vitamin K) participate and 
lead to the activation of factor X. Each molecule of factor Xa can catalyse (either 
directly or by forming a factor Xa:Va complex) the formation of approximately 
1000 thrombin molecules [37, 38]. Thrombin can be viewed as the hub of the 
coagulation network where it has multiple pro-coagulation effects to stimulate a 
thrombin burst, and anticoagulant effects by activating plasminogen and protein 
C via cofactor thrombomodulin.  
It is important to note that the variability in anticoagulation response is not 
only determined by the concentration of the anticoagulant in plasma but there is 
also innate variability in the sensitivity and concentration of clotting factors 
between individuals. This has been reviewed by Duffull 2012 [39]. It has been 
argued that all anticoagulants will have a narrow therapeutic range and will 
require monitoring to ensure a balance of antithrombotic effects and bleeding 
effects [39, 40]. This will be discussed further in section 6.1, and in Chapter 6.  
1.4.2. Warfarin dose individualisation 
Warfarin (3-α-acetonyl-benzyl)-4-hydroxycoumarin) is a synthetic 
analogue of bishydroxycoumarin (dicumarol) and is structurally related to 
natural coumarins found in many plants. Two other coumarins, phenprocoumon 
and acenocoumarol, are also used clinically in some European countries. 
Collectively, these are often referred to as ‘vitamin K antagonists’, although this 
is a misnomer as these drugs are inhibitors of the enzyme that reduces the 
oxidised form of vitamin (vitamin K epoxide reductase, VKOR) and not 
antagonizing the effects of vitamin K per se. 
Warfarin is used to prevent ischaemic stroke and thromboembolism events. 
The most common indication of warfarin is nonvalvular atrial fibrillation where 
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the risk of stroke may be increased by 5-fold [41-44]. Clinical trials have 
repeatedly shown that warfarin is effective at preventing stroke in patients with 
atrial fibrillation with a relative risk reduction of 68% [45] and 59% [46]  in two 
meta-analyses. 
1.4.2.1. Clinical pharmacology 
Warfarin is administered as a racemic mixture of S- and R- warfarin. 
Warfarin is almost completely absorbed from the gut with a reported 
bioavailability of nearly 100% [47]. Peak plasma concentrations occur 0.3 – 4 
hours after administration [48]. The apparent volume of distribution of racemic 
warfarin has been estimated to be about 10L/70kg [49].  A range of 0.098-0.48 
L/h/70kg has been reported for the oral clearance for racemic warfarin [49].  
Racemic warfarin has an estimated half-life of approximately 36-42 hours, but 
given separately, S-warfarin has a shorter mean half-life (about 30 hours) 
compared to R-warfarin (about 45 hours) [48]. S-warfarin is about 2-5 times more 
potent than R-warfarin and is generally considered to be the enantiomer 
responsible for the anticoagulant effect [50]. Warfarin is eliminated almost 
entirely by hepatic metabolism, but clearance mechanisms differ for each 
enantiomer. S-warfarin is metabolized mainly by the cytochrome P450 (CYP) 
enzyme, CYP2C9, while R-warfarin is metabolised primarily by CYP2C19, 
CYP3A4, and CYP1A2.  Following metabolism, hydroxylated metabolites are 
excreted in the faeces (20%) and urine (80%) [50]. 
The mechanism of action of warfarin involves inhibition of hepatic enzyme 
vitamin K epoxide reductase enzyme (VKOR) [51]. VKOR is required for the 
cyclic interconversion of vitamin K epoxide to a reduced form of vitamin K 
(Vitamin KH2) (see Figure 1.7). The reduced form of vitamin K is a cofactor for 
the post-translational carboxylation modification of vitamin K dependent 
precursor clotting factors II, VII, IX, X, and regulatory anticoagulation protein C 
and protein S. Carboxylation increases the affinity of the precursor clotting 
factors towards calcium, which is required for subsequent interaction with 
negatively charged phospholipid surfaces [35].  Depletion of carboxylated 
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clotting factors will prolong clotting time. However, since warfarin has no effect 
on fully carboxylated clotting factors, there is a delay between peak plasma 
warfarin concentrations and the peak effect on blood clotting. The time course of 
warfarin effect is therefore determined by the turnover of the circulating vitamin 
K dependent clotting factors.  
 
Figure 1.7 Schematic of warfarin effect on the vitamin K cycle and the production of 
carboxylated clotting factors. VKOR, vitamin K epoxide reductase; GGCX, Gamma-
Glutamyl Carboxylase. 
Several single nucleotide polymorphisms (SNP) have been found to 
influence the metabolism and sensitivity of warfarin. The most well described 
are SNPs in the CYP2C9 and Vitamin K epoxide reductase complex subtype 1 
(VKORC1) genes. The CYP2C9 variants produce single base substitutions at 
residue 144 (Arginine to Cysteine) for CYP2C9*2 and 359 (Isoleucine to Leucine) 
for CYP2C9*3 resulting in an enzyme with reduced activity [52]. The enzyme 
VKOR is coded by the gene VKORC1 and several polymorphisms in the 
promoter region of this gene have been found to significantly alter the amount 
of enzyme produced by the hepatocyte [53]. Most of these SNP appear to be in 
linkage disequilibrium (i.e. correlated) so most recent research has focused on 
the -1639G>A variant. Patients with the A allele have been demonstrated to 
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require lower warfarin doses compared to patients with GG allele in order to 
achieve the same INR [54]. 
1.4.2.2. Monitoring response and therapeutic range  
The physiological response to warfarin therapy is a prolonged clotting 
time. Warfarin clotting time is measured using the prothrombin time (PT). The 
PT is an ex vivo test that measures the time for blood to form a fibrin clot in a test-
tube after the addition of tissue factor and calcium. It is prolonged when there 
are deficiencies in factor II, VII, X. Thromboplastin reagent, which is a plasma 
protein, is also added to aid the conversion of prothrombin to thrombin. A 
normal PT is about 12-14 seconds but will vary depending on the sensitivity of 
the thromboplastin reagent used for the test. The PT is therefore commonly 
standardized to the INR.  The equation for calculating INR is given as follows: 
"# = ( 1|+et+ ^}~|t t>~|s ^})
 
Equation 1.15 Equation to calculate the international normalised ratio 
where mean normal PT is the geometric mean of PT from at least 20 normal 
subjects from both sexes determined using the same test conditions, and ISI is 
the International Sensitivity Index of the thromboplastin reagent used in the 
local laboratory to perform PT tests. A lower ISI value denotes a more sensitive 
local thromboplastin reagent [55].  
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Figure 1.8 Incidence rates of ischaemic stroke (A), intracranial haemorrhage (B) and 
combined data (C) among patients with nonvalvular atrial fibrillation who were taking 
warfarin versus to the INR at the time of the stroke produced based on data from Hylek 
et al 2003 [56] 
Figure 1.8 depicts a utility curve for warfarin therapy derived from a large 
published observational study [56]. Figure 1.8A represents the incidence of 
ischaemic stroke against the degree of anticoagulation. Figure 1.8B represents 
the incidence of haemorrhagic stroke as a function of the degree of 
anticoagulation. Both curves can then be combined to sum up the total 
thromboembolic and bleeding events which appear to be U-shaped (Figure 
1.8C). The region with lowest incidence rates for both under- and over-
anticoagulation can be targeted in practice. The example presented above 
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originates from a large observational data in patients who were taking warfarin 
[56], but as all anticoagulants carry the risk of bleeding this method of 
constructing a utility curve to define the therapeutic target generally applies.   
The target anticoagulation response for warfarin has been well studied and 
multiple studies have found that the target INR to be within the range of 2-3 for 
atrial fibrillation [45, 57, 58] and for most other indications [59]. Some patients 
who are at higher risk of thrombosis, such as those with mechanical heart valves, 
an INR of 2.5 - 3.5 may be targeted [60]. 
1.4.2.4. Current dosing methods 
In the absence of any dosing aids, warfarin dose adjustment will likely be 
largely heuristic (trial and error) where the adjusted maintenance dose for an 
individual patient is determined by the prescriber based on the magnitude of 
previously observed INR response. However, predicting the maintenance dose 
for a patient a priori is difficult as the INR response that is measured in the first 
1-3 weeks of treatment, or after a dose change, will reflect non-steady state 
conditions. Thus, heuristic dosing requires the prescriber to have a working 
knowledge of the time course of warfarin dose-response and an understanding 
of the patient factors that influence dose requirements.  
Several methods for improving INR control by predicting warfarin dose 
requirements have been described. For the purposes of this thesis (as outlined in 
Section 1.4) warfarin dosing methods are broadly divided into; 1) covariate-
based dosing methods, and 2) response-based dosing method.  
1.4.2.4.1. Covariate based dosing method 
In recent years, there is increasing number of studies that are designed to 
identify patient characteristics that predict differences in warfarin dosing 
requirements between individuals [3, 61]. Typically, these studies regress the 
maintenance dose against patient characteristics using multi-linear regression 
methods. The resulting algorithms will include all patient factors (covariates) 
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that were found to have a statistically significant impact on warfarin 
maintenance doses in the population studied.  The algorithms are therefore 
empirical by design and the covariates included in the regression algorithm may 
differ depending on the case mix and population included in the original study. 
Most published algorithms include CYP2C9 and VKORC1 genotypes, measures 
of body mass, age, warfarin indication, and, interacting drugs (e.g. amiodarone) 
[61]. In a recent review, Verhoef et al [4] identified 32 published algorithms for 
warfarin dosing. Similarly, Shin and Cao [61] found 34 warfarin dosing 
algorithms published between January 2004 to August 2009. In Chapter 3, a 
meta-analysis was conducted to pool the predictive performance from published 
dosing algorithms [62]. The large number of published algorithms may reflect 
the empirical nature of this method in that each algorithm is designed for use in 
either a particular population (e.g. Korean [63], Puerto Rican [64], Brazilian [65]) 
or for a particular indication (e.g. orthopaedic patients [31, 66]) or both (e.g. 
Korean patients with atrial fibrillation [67]). 
An important limitation in many of the covariate based algorithms is that 
once therapy has initiated, these dosing tools have no further function in guiding 
dose adjustments. Most of the algorithms are designed to predict warfarin doses 
that will produce an INR between 2 to 3 (see Klein et al. (2009) [68]). In this case, 
there will be no means of adjusting the dose if a higher target INR is required. 
The result is that these algorithms may underestimate warfarin doses for patients 
who are at increased risk of clotting and require higher INR targets such as 
patients with mechanical heart valves [60]. Some recently published algorithms 
including those published by Gage et al  [69]  and [24]  include a user-defined 
‘target INR’ in the algorithm which allows for targeting unique INR values.  
1.4.2.4.2. Response-based dosing method 
a. Dosing based on single feedback without covariates 
Dosing of warfarin based on a single INR response generally provide 
guidance for initial dose selection and for dose adjustment within the first few 
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days of therapy. These take the form of dosing tables or static nomograms (see 
an example in Figure 1.9), but can also include computerised decision-support 
tools such as the PARMA-5 system used in some European hospitals [70]. They 
are designed to standardise dose adjustment practices between prescribers and 
many (but not all, see Ryan et al 1989 [71]) are based on the assumption that 
warfarin dose and INR response are linearly related. This assumption does not 
hold true if the INR response lies outside the linear portion of the dose-response 
curve (<20% and >80% of maximum effect) which will likely be the case during 
warfarin initiation [72]. In addition, warfarin dosing nomograms do not account 
for differences in response between individuals and were designed with the 
implicit assumption that the magnitude of the INR response for a given warfarin 
dose is only dependent on warfarin dose and hence will be the same for each 
individual.  For example, the nomogram in Figure 1.9 assumes that a 91-year-old 
patient who weighs 45 kg and takes several interacting drugs will respond to the 
same dose of warfarin as a 28-year-old patient with a deep vein thrombosis 
(DVT) who weighs 80 kg, or a 50-year-old patient with a mechanical heart value 
who is a poor metaboliser. According to this nomogram, the patient can be 
initiated using either the 5 mg or 10 mg nomogram depending on the rapidity 
required to reach target INR. 
 




Figure 1.9 Two nomograms for initiating warfarin treatment by Crowther et al. [73] 
reproduced with permission from The American College of Physicians. 
b. Dosing based on single response and covariates  
After accounting for all known covariates that influence warfarin dose 
requirements, only approximately 50% of dose variability can be explained [24, 
68]. A small number of recent publications have added a single INR response in 
addition to covariates to improve the prediction of the maintenance dose [30, 74]. 
The INR measurement is a response measure that feeds back into the algorithm 
to capture further variability not accounted for by all the covariates and have 
been found to improve the predictive performance compared to algorithms 
without feedback  [3]. 
c. Dosing based on Bayesian forecasting 
Several studies have applied Bayesian forecasting methods to improve 
warfarin dosing [75-80], although it is unclear if any have been implemented in 
clinical practice. Wright and Duffull recently developed a Bayesian forecasting 
method for dosing warfarin [1, 2]. A more in-depth description of the underlying 
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model and details of the Bayesian dosing tool will be presented in Chapter 2. In 
a retrospective analysis, the Bayesian dosing tool was shown to provide precise 
and accurate predictions of INR response in a small cohort of patients (n=55) 
who were initiating warfarin [2]. Further work on this tool will be described in 
Chapter 2.  
1.4.2.5. The need for improved dose prediction 
Warfarin has been proven to be effective in preventing ischaemic strokes in 
patients with atrial fibrillation [45, 46]. However, predicting a suitable dose is 
problematic because the therapeutic range is narrow. The perceived difficulty in 
dosing warfarin has led some clinicians to avoid warfarin treatment in eligible 
patients. A Swedish study conducted in 2006 found that only 54% of eligible 
patients discharged from hospital with atrial fibrillation were appropriately 
treated with warfarin [81]. Amongst the reasons given for not prescribing 
warfarin were concerns about bleeding risk and a lack of understanding about 
the benefit of anticoagulation in stroke prevention. The lack of clear evidence-
based guidelines regarding the optimal dosing method for warfarin has also 
been suggested as one of the reasons for not initiating warfarin in patients at risk 
of thrombosis [82].   
The effectiveness and safety of warfarin treatment are currently measured 
by the time in the therapeutic range (TTR). It is a measure of how well a patient 
is anticoagulated within a specific time interval. TTR is increasingly viewed as a 
substitute for a clinical end point in clinical trials [83-85]. The TTR is derived by 
calculating the percentage of time the patient’s INR remains within the 
therapeutic range and is commonly estimated using a linear interpolation 
described by Rosendaal et al [86]. Several studies have shown that patients with 
TTR above 70% have a low risk of thromboembolism and bleeding [87-89]. 
Similarly, patients with lower TTR are associated with increased risk of 
ischaemic stroke [90]  and increase the incidence of venous thromboembolism 
and bleed [91]. The European Society of Cardiology Working Group on 
Thrombosis Anticoagulation Task Force have recommended that the individual 
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patient’s TTR should be above 70% [92], however current dosing strategies 
appear to only achieve approximately 40-65% [93]. In large clinical trials where 
patients were highly selected, the average TTR has been found to be in the order 
of about 60% [94]. This thesis is predicated on the assumption that accurate and 
precise method of determining the dose of warfarin will improve the TTR. 
1.4.3. Dabigatran dose individualisation  
1.4.3.1. Clinical pharmacology 
Dabigatran etexilate mesylate has low solubility in water (log P, pH 7.4 = 
3.8) and high intrinsic passive permeability. It is the prodrug of dabigatran, a 
highly polar molecule (log P, pH 7.4 = -2.4). The bioavailability of dabigatran 
etexilate is approximately 3-7%. Absorption of dabigatran etexilate is pH 
dependent where an acidic environment is required to increase solubility. It is 
therefore formulated in pellets coated with tartaric acid. The mean peak plasma 
concentrations of dabigatran etexilate is approximately 2 hours (Tmax). A high-
fat diet can delay the Tmax to approximately 4 hours but does not affect the extent 
of absorption [95]. 
Conversion from dabigatran etexilate to dabigatran requires hydrolysis of 
two esters; ethyl ester and carbamate ester (see Figure 1.10). Once absorbed, 
dabigatran etexilate is predominantly metabolised by carboxylesterase (CES) 2 
in the intestine which hydrolyses the carbamate ester to form the intermediate 
metabolite BIBR951, which is then hydrolysed by CES 1 in the liver to form 
dabigatran. Another pathway, where both esters of dabigatran etexilate are 
hydrolysed by CES 1 and CES 2 in the liver is also possible [96]. CES1, which is 
present at higher concentrations in the liver than the intestine [97], can hydrolyse 
both carbamate and ethyl ester, but CES 2 can only hydrolyse the carbamate ester 
[96]. This sequential conversion will be almost complete within approximately 2 
hours [98]. Intronic CES 1 SNP at rs2244613 minor allele occurs in approximately 
a third of the population (in a phase III trial (RE-LY)) and has been associated 
with decreased exposure to dabigatran and bleeding risk [99]. Further studies 
Chapter 1: Introduction 
54 
 
showed that another CES1 SNP at rs71647871 (at residue 143 - glycine to glutamic 
acid) is a loss-of-function variant that can impair dabigatran etexilate conversion 
in humans [96]. 
 
Figure 1.10 A schematic of the metabolic pathway of dabigatran etexilate 
On average, approximately 20% (range 15-35%) of circulating dabigatran is 
glucuronidated and the remainder is excreted renally unchanged. There are 
other trace metabolites from oxidation but the contribution to dabigatran 
exposure is negligible [100]. Approximately 35% of dabigatran is protein bound 
[100]. Volume of distribution is 1 L/kg. Apparent clearance has been reported to 
be 0.12 L/hr/kg (values in healthy young adults). The terminal half-life of 
dabigatran is approximately 12-17 hours, which is increased in 15 to 34 hours in 
patients with mild renal impairment to end-stage renal disease on haemodialysis 
[101]. 
Inhibition of thrombin is achieved by the ionic interaction between 
Aspartate 189 and the benzamidine ring of dabigatran [102]. Hydrolysis of the 
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carbamate ester (see Figure 1.10) by CES1 exposes the binding site of dabigatran 
to thrombin. This explains why the intermediate metabolite (BIBR951) is also 
found to be active, although its overall anticoagulation contribution is small 
since the cleavage of the other ethyl ester to form dabigatran occurs rapidly 
within ~2hrs. Dabigatran 1-O-acylcluronide is the major metabolite of 
dabigatran which can further undergo three positional isomers (2-O, 3-O and 4-
O) that are catalysed by basic pH and temperature (non-enzymatic 
isomerisation).  As the conjugation of glucuronide does not block the thrombin 
binding site (benzamidine ring), dabigatran acylglucuronides has been shown to 
be equally potent at inhibiting thrombin as measured using activated partial 
thromboplastin time test (aPTT) [103]. 
Dabigatran inhibits circulating free thrombin, fibrin- and clot-bound 
thrombin, and thrombin-induced platelet aggregation. This, in turn, prevents the 
conversion of fibrinogen to insoluble fibrin which is the last step of the clot 
formation. As thrombin also provides positive feedback to amplify the 
coagulation activation, promotes cross-linking of fibrin monomers via activation 
of factor XIII, activates platelets and inhibits fibrinolysis, dabigatran inhibits 
these processes as well [104]. 
1.4.3.2. Monitoring dabigatran therapy 
Current dosing guidelines for dabigatran do not recommend routine 
anticoagulation monitoring [9]. Nevertheless, there is a growing consensus that 
the concentration of dabigatran in the plasma could be used to guide therapy in 
patients at high risk of bleed or clotting [40, 105]. 
Concentrations of dabigatran can be measured using analytical chemistry 
methods such as liquid chromatography mass spectrometer/ mass spectrometer 
(LCMS/MS) or by inferring the concentration from a clotting time test. 
LCMS/MS assays are highly sensitive and specific but requires trained 
laboratory experience and instrument availability is often limited. An LCMS/MS 
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assay to measure dabigatran concentration in plasma and details on the 
principles of LCMS will be described in Chapter 5. 
Several publications have studied the relationship between dabigatran 
exposure and clotting time tests [106-109], including the INR, activated partial 
thromboplastin time (aPTT), and thrombin time (TT) test. Less commonly used 
coagulation tests, such as the dilute thrombin time (dTT) and Ecarin clotting time 
(ECT) test, have also been studied. The latter two clotting time tests are not 
routinely available in many clinical settings. Figure 1.11 depicts the relationship 
between each clotting time test and dabigatran plasma concentrations. 
 
 
Figure 1.11 Relationship of dabigatran plasma concentration and ECT ratio (a), INR (b), 
TT ratio (c) and aPTT (d). Reproduced from van Ryn et al 2010 [110] with permission 
from Schattauer. 
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The INR test correlates poorly to dabigatran concentrations [111] and is 
therefore not recommended for measuring of dabigatran anticoagulation. The 
aPTT test has several drawbacks that make it unsuitable for routine monitoring 
including; 1) aPTT can be sensitive to preanalytical (sampling time, temperature 
etc), biological (reagent activities) and acquired factor deficiencies and therefore 
standardisation between laboratories is difficult [112], 2) the prolongation of 
aPTT does not predict bleeding events or thrombosis events well, 3) the 
relationship is curvilinear [113]. The aPTT test may be best suited for qualitative 
assessment of dabigatran response, but is less useful for defining a quantitative 
clotting time. The TT test is overly sensitive to thrombin inhibition by dabigatran 
[114]. The test will produce clotting times beyond the upper limit of the reporting 
time For example, dabigatran plasma concentrations above 60 ng/mL [115] and 
90 ng/mL [116] have been reported to exceed the upper limit of reporting time 
of the TT test. A commercially available diluted version the TT test is the 
Hemoclot®. The Hemoclot® involves dilution (1 in 8 or 1 in 20 depending on 
protocol) of the test plasma with a normal pooled plasma. This compensates for 
the over sensitivity of TT and has been reported to show a good correlation to 
dabigatran concentration. However, since the dTT test involves dilution of a 
large pool of normal plasma, the impact of innate inter-individual variability, 
particularly fibrinogen concentrations, is not captured [107, 115]. ECT test 
correlates linearly with dabigatran concentrations [111]. The ECT test has 
historically been proposed as a general assay to measure concentrations of 
thrombin inhibitors [117]. The ECT test is sensitive to dabigatran thrombin 
inhibition but is expensive and there are currently no commercially available 
kits. This would require each laboratory to calibrate the test against measured 
dabigatran concentrations resulting in a standardisation between laboratories.  
In summary, the TT test, dTT test, and ECT test have linear relationship 
with dabigatran concentrations and could be used to assess clotting time in 
patient receiving dabigatran therapy. However, currently, there is currently no 
utility curve for dabigatran. The use of plasma concentration monitoring to 
guide dosing requires that a therapeutic range to be defined, which can be 
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obtained from a utility curve.   In limited studies to date, Chin et al [116] have 
proposed that the target steady state trough concentration of dabigatran to be 
between 30-130 ng/mL. This was derived by reanalysing published Phase III 
data – more details will be presented in Chapter 6. 
1.4.3.3. Current dosing methods 
The dabigatran product datasheet indicates that dabigatran etexilate can be 
prescribed as a fixed dose for many patients. Limited dose adjustments have 
been suggested at initiation which is based on covariates (i.e. renal function, age 
and concomitant P-gp inducer/inhibitor). The dosing recommendations also 
differ geographically. The drug labels published by the European Medical 
Agency (EMA) and Medsafe New Zealand include dosing recommendation for 
stroke prevention in atrial fibrillation and prophylaxis of venous 
thromboembolism following deep vein thrombosis/ pulmonary embolism, 
while the United States Food and Drug Administration (FDA) drug label does 
not distinguish between the two indications. Table 1.1 summarises current 
dosing guidelines for non-valvular atrial fibrillation by the FDA, EMA and 
Medsafe NZ. 
Table 1.1 Summary of current New Zealand Medsafe datasheet [9], FDA [118] and 
EMA [119] dosing guidelines for stroke prevention in atrial fibrillation 
Characteristics Medsafe NZ FDA EMA 
Standard 
maintenance dose 
150 mg bd 150 mg bd 150 mg bd 
CLCr 30-50 
mL/min 
110 mg bd 150 mg bd * 150 mg bd ** 
CLCr < 30 mL/min Contraindicated 75 mg bd*** Contraindicated 
Age > 80 y* 110 mg bd Not specifically discussed 110 mg bd 
P-gp inhibitors Variable† Not specifically discussed 110 mg bd 
* Reduce to 75 mg bd co-administered with P-gp inhibitor 
** Consider 110 mg bd if patient at high risk of bleeding) 
*** Avoid co-administration of P-gp inhibitors 
† In one part of the datasheet, no dose-adjustment is suggested when these are concomitantly 
prescribed, whereas in other parts, it is suggested that maintenance dose is reduced (strong P-
gp inhibitors) or that the combination is avoided (P-gp inducers, and ketoconazole, a P-gp 
inhibitor) 
CLCr, creatinine clearance; P-gp, P-glycoprotein; bd, twice daily 
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Alternative dosing methods have been proposed. Chin et al [120] have 
suggested an alternative a priori approach of dose adjustment based on a 
proportional increment or reduction of dose in relation to creatinine clearance 
(covariate based).  The dosing frequency remained similar to the datasheet (once 
daily for VTE prophylaxis and twice daily for AF patients), but doses suggested 
were up to 220 mg twice daily [120]. In a more recent publication, Chin et al. 
further proposed dose adjustments using thrombin time as a measure of 
response [116]. 
1.4.3.4. The need for improved dose prediction 
Dabigatran is claimed to have predictable pharmacokinetics [110] and 
therefore anticoagulation monitoring is not recommended. Yet published data 
have reported up to 7-fold variation of trough plasma dabigatran concentration 
between patients [114]. Table 1.2 summarizes trough concentrations from several 
studies.  
Table 1.2 Dabigatran trough concentration from several studies 
Dosing regimen 
Hawes et al 2013 
[114] 
van Ryn et al 
2010 (PETRO 
trial) [110] 
Reilly et al 2014 
[10] 
















It is noteworthy that a 5-fold variation in plasma concentration translates 
to approximately CV% of 40% across a patient population. This CV% has been 
proposed to be relatively ‘normal’ variation seen across many drugs [39, 121]. As 
noted above, it is argued that any drug that perturbs the coagulation network for 
the purposes of therapeutic anticoagulation will  have a narrow therapeutic 
range and therefore warrants monitoring [39]. 
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There have been published data that show a correlation between plasma 
dabigatran concentration and anticoagulation effect [10, 122]. The study by 
Reilly et al [10], found that renal function is the primary determinant of 
dabigatran plasma concentration and age is an important covariate. According 
to Cohen et al [123] the optimal dabigatran concentration should be between 40 
ng/mL and 215 ng/mL, based on unpublished information from the RELY trial. 
Moore et al [124] have presented numerous reports from regulatory agencies 
worldwide indicating that current dosing practices result in bleeds particularly 
in older patients above 80. Another study by Eikelboom et al [125]  also found 
that older patients on dabigatran are at higher risk of bleeding. Therefore, it 
could be argued that concentration monitoring, for patients at risk of thrombosis, 
should improve the safe and effective use of dabigatran. The possible therapeutic 
range for dabigatran compiled from several sources is presented in Table 1.3 




Unpublished emails between authors of Reilly et al 
[10] reported by Cohen et al [123] 
40 – 215 
Further internal author emails of Reilly et al [10] 
reported by Cohen et al [123] 
40-200  
EMA drug assessment report in 2010 [126] 48 - 200  




It is noted that dabigatran is currently only available in three dosage 
strength; 75, 110 and 150 mg. In New Zealand and Europe, all three dosage forms 
are available [9, 119, 127]. In the United State, the 110-mg capsule is not approved 
by the FDA for atrial fibrillation and hence is not available [128]. The primary 
concern, as stated in the summary review from the FDA’s Center for Drug 
Evaluation and Research [129], is that the 110 mg capsule maybe over-utilised 
and therefore preventing some patients of the potential benefit from the higher 
150 mg strength. Undoubtedly the restricted availability of dosage strength 
would limit the choice of dose adjustment. 
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 Part II of this thesis describes two studies that principally aim to improve 
warfarin dose predictions. Chapter II focuses on several investigations on the 
ability of a Bayesian forecasting method to predict the maintenance dose of 
warfarin and Chapter III evaluates the predictive performance of published 
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This chapter builds on work completed during my Postgraduate Certificate 
in Pharmacy (research). In my Postgraduate Certificate research work, the 
predictive performance of a Bayesian dosing tool was evaluated using a small 
sample of patients who were initiating warfarin therapy. This could be 
considered to be a pilot study. The work completed for this thesis extended this 
research into a full retrospective analysis of two datasets, including patients 
initiating warfarin from two different sites. The overarching aim of the thesis is 
to improve patient outcomes for patients receiving anticoagulation therapy. This 
chapter contributes to this aim by investigating whether a Bayesian forecasting 
method can be used to predict the maintenance dose of warfarin. The ultimate 
goal was to make this dosing method available for those involved in warfarin 
dosing and monitoring services. 
2.1. Introduction 
Warfarin has been the mainstay of oral anticoagulant therapy for the past 
seven decades and remains widely used for the treatment of thromboembolic 
diseases. The maintenance dose required to achieve therapeutic anticoagulation 
is difficult to predict and can vary by upwards of 15-fold between patients [68]. 
An additional challenge for prescribers is that each patient will have a relatively 
narrow range of doses that will produce safe and effective anticoagulation, 
usually monitored using the INR. Under- or over- dosing will result in INR 
values outside the target range (2-3 for most conditions) and may put the patient 
at risk of severe adverse outcomes such as bleeding or thromboembolism. 
Treatment is considered successful if the time that patients spend within the 
therapeutic range (TTR) is maximised. Conventional, heuristic, dosing methods 
have been found to result in a TTR of only 40-60% [130-133]. Not surprisingly, 
there is a large body of literature exploring strategies to improve warfarin dose 
prediction [3]. 
Bayesian forecasting methods for dosing warfarin have been proposed as a 
means of improving INR control [1]. In limited studies to date, Bayesian methods 
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show the potential to increase the TTR to 80% or more [2, 75, 134, 135]. In 
addition, Bayesian algorithms can easily be integrated with decision support 
tools for use in the clinic (see Hamberg et al. 2015 [136] for an example).  
A published Bayesian forecasting method for warfarin therapy has been 
developed and implemented in a software called TCIWorks [1, 2]. The stated 
intention of the tool was to provide a means of predicting warfarin doses in 
individual patients in the clinic.  In addition, the tool has been proposed as a 
means of predicting warfarin doses without the need for patient-specific 
genotype information, such as CYP2C9 genotype which affects the metabolism 
of warfarin and VKORC1 genotype which encode the enzyme that is responsible 
for recycling vitamin K [1].  An evaluation of the predictive performance of the 
Bayesian dosing tool in  patients initiating warfarin (n=46) found that the 
maintenance doses predicted using the Bayesian dosing tool were unbiased on 
average [3]. However, in a post-hoc analysis it was found that doses for patients 
with VKORC1 (-1639 G>A) GG genotype were positively biased by about 1 
mg/day on average in some patients. In particular, it was noted that doses for 
patients with VKORC1 (-1639 G>A) GG genotype and those taking more than 
about 7 mg daily were poorly predicted.  
Bias in dose predictions of warfarin can have important clinical 
implications. In theory, a Bayesian dosing method, underpinned by  population  
model for warfarin-dose response like the TCIWorks tool [20], should be able to 
predict warfarin response across a range of doses. A positive bias of 1 mg daily 
could result in an increased propensity for adverse effects depending on the 
actual dose requirements. Unbiased and precise maintenance dose predictions 
should improve patient outcome by increasing the time spent within the 
therapeutic range with lesser dose adjustments.  
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The source of the bias in warfarin doses produced by the published 
Bayesian dosing tool is not obvious. The following four possibilities can be 
hypothesised; 
1. This is aberrant finding in a small single centre study 
2. The bias is a dose effect, observable in those subjects who take more 
than about 7mg daily 
3. The bias is a genotype effect 
4. The prior population used to develop the Bayesian dosing tool was 
significantly different from the posterior population 
2.2. Aims and objectives 
This study aims to investigate the source of bias in warfarin maintenance 
dose predictions produced using a published Bayesian dosing tool.  
There are four specific objectives:  
(1) To determine if the previously observed bias in warfarin dose 
predictions could be replicated in a new cohort of patients from a 
different clinical setting,  
(2) To explore the influence of maintenance dose on the predictive 
performance of the Bayesian tool  
(3) To explore the influence of genotype on the predictive performance of 
the Bayesian dosing tool,  
(4) To determine if the prior population used to develop the kinetic-
pharmacodynamic (KPD) model underpinning the Bayesian dosing 
tool was sufficiently different from the test (posterior) population to 
account for the biased dose predictions.  
  




2.3.1. Patient data 
Data available for analysis in this study was collected previously as part 
of two published studies not directly related to this thesis [2, 137]. The current 
chapter concerns the reanalysis of the published data as a means of investigating 
the sources of bias in dose predictions.  
The study data is described briefly here. The data consisted of warfarin 
dose and INR values from patients initiating warfarin therapy for any indication. 
INR values were recorded from the start of therapy until a stable INR had been 
achieved. A stable INR was defined as the second INR within 20% of the INR 
target (2.5 in most cases) as described elsewhere [3]. Patients were genotyped for 
VKORC1 (–1639 G>A rs9923231) and CYP2C9 *1, *2 (430C>T, rs1799853) and *3 
(1075A>C, rs1057910) as described elsewhere [3, 138]. Ethical approval was 
obtained from the Lower South Regional Ethics Committee, New Zealand 
(LRS/10/11/056) and West of Scotland Research Ethics Service, Glasgow, 
Scotland. All participating patients gave written informed consent. 
Data from a total of 153 patients from two centres were available for 
analysis. These are designed data set I and data set II as follows;  
i. Data set  I - Dunedin Hospital, Dunedin, New Zealand (n=55) [2] 
ii. Data set II – Glasgow Royal Infirmary, Glasgow, Scotland (n=98)  
[137] 
Thirteen of the original 153 patients were excluded from the analysis; 12 
who were not genotyped and 1 who did not reach a stable INR. The demographic 
details of the remaining 140 patients are summarised in Table 2.1. The 
distributions of both genotypes were consistent with the Hardy-Weinberg 
equilibrium (p>0.05). Median (range) age was 62 years (23-87) and 65 years (15-
85) for data sets I and II, respectively. 
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Table 2.1 Patient characteristics and a summary of maintenance dose and stable INR 
 Data set I 
(n = 46) 
Data set II 




Age (years) 62 (23-87) 65 (15-85) 64 (15-87) 
Male/Female (number of patients) 19/27 48/46 67/73 
Time to reach first stable INR (days) 38 (11-118) 24 (9-64) 28 (9-118) 
Number of INR observations to reach 
stable INR  
11 (6-21) 9 (6-24) 10 (6-24) 
Stable INR value  2.4 (2 – 3.1) 2.3 (2-3) 2.4 (2-3.1) 
Dose at stable INR (mg/day) 
Interquartile range [Q1 – Q3] 
5 (1.5 – 11) 
[4-7] 




CYP2C9 genotype (number (%) of 
patients) 
   
*1*1  28 (61%) 60 (64%) 88 (63%) 
*1*2 8 (17%) 19 (20%) 27 (19%) 
*1*3 9 (20%) 10 (11%) 19 (14%) 
*2*2 - 2 (2%) 2 (1%) 
*2*3 - 2 (2%) 2 (1%) 
*3*3 1 (2%) 1 (1%) 2 (1%) 
VKORC1(-1639 G>A, rs9923231) 
genotype, (number (%) of patients) 
   
GG 23 (50%) 45 (48%) 68 (49%) 
AG 18 (39%) 38 (40%) 56 (40%) 
AA 5 (11%) 11 (12%) 16 (11%) 
Values are expressed as median (range) unless specified otherwise 
Data set I = patients recruited from Dunedin Hospital, Dunedin, New Zealand 
Data set II = patients recruited from Glasgow Royal Infirmary, Glasgow, Scotland 
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2.3.2. Maintenance dose predictions 
Details of the development of the Bayesian dosing tool (TCIWorks) have 
been published previously [1, 2]. The underpinning model that describes the 
warfarin dose and anticoagulant response is a KPD model developed by 
Hamberg et al. [20]. Briefly, a KPD model is a pharmacokinetic-
pharmacodynamic model where the pharmacokinetic parameters are estimated 
solely from the pharmacodynamic data. This means that no warfarin 
concentration data are required to predict the INR response. The KPD model 
developed by Hamberg et al [20] consists of two transit compartment chains with 
three compartments in each chain to describe the time course of INR response. 
An Emax model was used to describe the link between pharmacokinetics and 
pharmacodynamics. The KPD model also included a covariate model for 
VKORC1 on EC50 (concentration of s-warfarin at 50 % of maximum drug effect) 
and age and CYP2C9 on clearance parameters. Note that  genotype was not 
included as a covariate in the published Bayesian dosing tool examined for this 
chapter [1]. The model implemented in TCIWorks (Hamberg et al. [20]) used an 
additive model for residual variance on log-transformed data to remain 
consistent with the published model [20].   
The full dosing history for each patient from warfarin therapy initiation to 
a stable INR and all measured INR observations up to the final dose change were 
entered into the TCIWorks software. The Bayesian dosing tool was then used to 
predict the daily dose required to achieve the observed stable INR for each 
patient. The patients were assumed to be taking their prescribed dose at 6 pm 
and INR was assumed to be sampled at 10 am.  
2.3.3. The predictive performance of the Bayesian dosing tool 
The predicted maintenance doses were compared to the observed 
maintenance doses using measures of bias (mean prediction error [k^O]) and 
imprecision (mean squared error [kO] and root mean squared error [#kO]). 
k^O, kO, and #kO were calculated as follows:  




k^O = r ∑ ^Oqr , 
Equation 2.1 Mean prediction error 
 
kO = r ∑ (^O)'qr , 
Equation 2.2 Mean squared error 
 
#kO =  √kO 
Equation 2.3 Root mean squared error 
 where k^O  is the mean prediction error, N is the number of patients, 
^O  is the prediction error (predicted minus observed maintenance dose) of the 
eth individual. No statistical bias was concluded if the 95% confidence interval 
(CI) of the k^O  included zero. kO  is the average of the sum of squared 
differences between predicted minus observed maintenance dose, and #kO is 
the square root of kO . #kO  provides an estimate of the variability of the 
prediction errors given in the same units as the predicted dose (mg/day). 
2.3.4. Replication of bias in a new cohort of patients from a different clinical 
setting 
Two data sets were used to evaluate the predictive performance of the 
Bayesian dosing tool. The first data set was a re-analysis of a data collected from 
Dunedin Hospital, New Zealand and reported previously [3]. In the original 
analysis, only the first four INR values were used for dose prediction. In this 
analysis, all measured INR observations up to the final dose change was used to 
predict the maintenance dose. The second data set was collected at Glasgow 
Royal Infirmary, Scotland.  These data were used to confirm if bias in warfarin 
dose predictions was also observed in data collected from a different site.  
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Predictive performance in terms of k^O and #kO were assessed as above for 
each data set and as a combined data set. 
2.3.5. The impact of dose requirement on the predictive performance of the 
Bayesian dosing tool 
The data set was stratified by observed maintenance dose into two groups; 
those who required ≥ 7 mg/day and those who required < 7 mg/day. A cut off 
of 7 mg/day has been used in other studies [68, 139] to categorize patients 
requiring a higher than average daily dose and therefore was used here. k^O 
and #kO were assessed as above for each dose group. 
2.3.6. The impact of genotype on the predictive performance of the Bayesian 
dosing tool 
The influence of genotype on warfarin dose predictions was assessed by 
stratifying the study cohort into different VKORC1 and CYP2C9 genotypes. 
Three methods are used:  
1.) by measuring k^O and #kO, as above, for each genotype group,  
2.) a scatter plot of the observed and predicted dose data according to 
VKORC1 and CYP2C9 genotype are plotted for visual comparison, and  
3.) the influence of VKORC1 genotype on Bayesian dose predictions was 
tested by altering the mean prior parameter values of EC50 to reflect the 
observed genotype in each patient. This is intended as a diagnostic aid 
to understand a possible source of bias and not how the Bayesian tool 
would normally be used.  The prior parameter values were normally 
set to the wild-type (GG) value for all patients (see Wright and Duffull 
[1]). For the purposes of this analysis the mean EC50 was changed 
manually for each patient prior to predicting the maintenance dose. 
The parameter values chosen corresponded to the observed genotype 
effect reported in the published model by Hamberg et al [20], i.e. an 
EC50 of 4.01 mg/L for those with VKORC1 GG genotype, 3.01 mg/L for 
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individuals with VKORC1  GA genotype, and 1.92 mg/L for the 
VKORC1 AA genotype. The initial parameter estimates of CYP2C9 
were set to the wild-type (*1*1) and was not changed. The influence of 
CYP2C9 will only be tested further if there were any significant 
improvement in bias were observed by changing the VKORC1 prior 
parameter estimates. 
2.3.7. The impact of the prior population on predictive performance of the 
Bayesian dosing tool 
The hypothesis that the bias may be caused by inherent differences in 
warfarin dose-response within the study population compared to the population 
used to develop the KPD model by Hamberg et al [20] was explored. To address 
this, the published KPD model was fitted to the data set using a nonlinear mixed 
effects modelling methodology in NONMEM (version 7.2 (Icon Inc. [PA, USA]). 
Initial parameter estimates were the values reported by Hamberg et al [20]. A 
non-parametric bootstrap was carried out to assess the precision of the 
parameter estimates. A total of 1000 bootstrap data sets were generated by 
randomly sampling the original data set and simulated from the model to obtain 
the 95% CI of each parameter estimate. The mean and 95% CI of the estimated 
model parameters from the study cohort were compared to the values from the 
published KPD model and considered not significantly different based on two 
criteria; 1) if the means were within 20% of the published values, and, 2) if the 
mean observed value fell within the 95% confidence interval of the bootstrap.  
2.4. Results 
2.4.1. Replication of bias in a new cohort of patients from a different clinical 
setting 
A summary of the k^O  and #kO  results for each data set analysed 
separately and combined is presented in Table 2.2. The Bayesian dosing tool, on 
average, produced positively biased dose predictions (k^O mg/day [95% CI]; 
0.32 [0.14, 0.50]). When analysed separately, dose predictions for both the 
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Dunedin (data set I) and Glasgow data sets (data set II) were also both positively 
biased (k^O mg/day [95% CI]; 0.53 [0.11, 0.94] and 0.22 [0.04, 0.39] respectively).  
Table 2.2 A summary of average bias (mean prediction error (95% CI) and root mean 
squared error (#kO) of the dose predictions. 
 Data set I Data set II Combined data set 
k^O (95% CI) 0.53 (0.11, 0.94) 0.22 (0.04, 0.39) 0.32 (0.14, 0.5) 
#kO 1.52 0.88 1.13 
k^O  mean prediction error (mg/day), CI confidence interval, #kO  root mean 
squared error (mg/day). Data set I = Dunedin, New Zealand (n=46); Data set II = 
Glasgow, Scotland (n=94); Combined data set (n=140);  
2.4.2. The impact of dose requirement on the predictive performance of the 
Bayesian dosing tool 
The k^O  mg/day [95% CI] for patients requiring ≥7 mg/day was 1.15 
[0.43, 1.87] which represents an average over-prediction of approximately 18%, 
while the k^O  mg/day [95% CI] for patients requiring <7 mg/day was 0.18 
[0.009, 0.34] (see Figure 2.1).  #kO values for patients requiring <7 mg/day and 
≥7 mg/day were 0.94 mg/day and 1.90 mg/day, respectively. 
 
Figure 2.1 Mean prediction error according to data set and magnitude of dose 
requirement. The horizontal lines represent 95% CI of the prediction error and the centre 
vertical line is the mean prediction error. The vertical dotted line indicates a prediction 
error of zero. 
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2.4.3. The impact of genotype on the predictive performance of the Bayesian 
dosing tool 
Dose predictions for patients with the VKORC1 GG genotype in the 
combined data set were found to be positively biased (see Table 2.3). Dose 
predictions for patients with VKORC1 AG and AA were unbiased. Visual 
plots of the observed versus prediction maintenance dose according to 
VKORC1 is presented in Figure 2.2 
Table 2.3 A summary of average bias (mean prediction error (95% CI) and root mean 
squared error (S) of the dose predictions according to VKORC1 genotype. 
VKORC1 Data set I Data set II Combined 
 k^O (95% CI) #kO k^O (95% CI) #kO k^O (95% CI) #kO 
GG 1.13 (0.48, 1.77) 1.85 0.23 (-0.05, 0.52) 0.97 0.53 (0.21, 0.86) 1.34 
AG -0.05 (-0.67, 0.56) 1.21 0.23 (-0.03, 0.5) 0.84 0.14 (-0.11, 0.4) 0.97 
AA -0.13 (-0.68, 0.43) 0.42 0.08 (-0.37, 0.54) 0.65 0.02 (-0.28, 0.32) 0.59 
k^O mean prediction error (mg/day), CI confidence interval, #kO root mean squared 
error (mg/day). Data set I = Dunedin, New Zealand (n=46); Data set II = Glasgow, Scotland 
(n=94); Combined data set (n=140); 
 
 
Figure 2.2 Scatter plot of the observed versus predicted maintenance dose according to 
VKORC1 (-1639 G>A, rs9923231). The solid line is a line of identity. Filled symbols 
represent data set I (Dunedin, New Zealand) and open symbols represent data set II 
(Glasgow, Scotland) 
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Dose predictions for patients with CYP2C9 *1*1 were positively biased in 
the combined data set. Dose predictions for all other CYP2C9 genotype 
combinations were unbiased in the combined data set (Table 2.4). A visual plot 
of the observed versus prediction maintenance dose according to CYP2C9 is 
presented in Figure 2.3. 
Table 2.4 A summary of average bias (mean prediction error (95% CI) and root mean 
squared error (#kO) of the dose predictions according to CYP2C9 genotype. 
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MPE mean prediction error (mg/day), CI confidence interval, RMSE root mean 
squared error (mg/day). Data set I = Dunedin, New Zealand (n=46); Data set II = 
Glasgow, Scotland (n=94); Combined data set (n=140); NA, not available 
 
 
Figure 2.3 Scatter plot of the observed versus predicted maintenance dose according to; 
CYP2C9. The solid line is a line of identity. Filled symbols represent data set I (Dunedin, 
New Zealand) and open symbols represent data set II (Glasgow, Scotland) 
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To explore the influence of genotype further, the k^O  for patients with 
VKORC1 GG genotype who had CYP2C9 *1*1 and those who were not CYP2C9 
*1*1 and found a positive bias for both combinations were compared. However, 
when patients with CYP2C9 *1*1 patients who were not VKORC1 GG were 
grouped, the dose predictions were not biased (Figure 2.4). This suggests that 
the source of the bias is more likely to be VKORC1 genotype. 
 
 
Figure 2.4 Mean prediction error by subgrouping according to VKORC1 or CYP2C9 
genotype combination. The horizontal lines represent 95% CI of the prediction error and 
the centre vertical line is the mean prediction error. The vertical dotted line indicates a 
prediction error of zero. Red horizontal lines indicate that the 95% CI of the prediction 
error does not cross zero (i.e. is biased). 
The Bayesian dose predictions conducted using individual values of EC50 
for each patient, corresponding to their observed genotype, were found to 
produce positively biased results overall (Table 2.5). It is noteworthy that those 
subjects with reduced EC50 values (i.e. VKORC1 AG and AA genotypes) had 
unbiased dose predictions. The k^O  for the VKORC1 GG genotype group 
remained the same since the wild-type values were used previously. Based on 
these results, the influence of prior parameter estimates of different individual’s 
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CYP2C9 genotype (on clearance) were not tested as there was no improvement 
observed by using the values of EC50 that corresponds to the observed genotype 
of the patient.  
Table 2.5 A summary of k^O and #kO using the individual’s genotype to determine 
the prior value of EC50 used in the population model 
VKORC1 (-1639 G>A) 
 Genotype 
S (mg/day) [95% CI] S 
All data 0.28 (0.09, 0.46) 1.14 
GG 0.53 (0.21, 0.86) 1.34 
AG 0.08 (-0.18, 0.35) 1.01 
AA -0.11 (-0.46, 0.23) 0.65 
2.4.4. The impact of the prior population on the predictive performance of 
the Bayesian dosing tool 
The results of the estimated parameters and bootstrap runs using the model 
to estimate into a new population are summarized in Table 2.6. 93.8% of the 
bootstrap runs minimized successfully. Mean parameter estimates for EC50 (G 
allele and A allele) and between subject variability for EC50, were within 20% of 
the published value. The mean published values for the parameters fell within 
the 95% CI of the bootstrap in all cases expect for MTT1 and proportion residual 
error. These parameters would not be considered likely to be a cause of bias in 
predictions because MTT1 partly describes the delay between pharmacokinetic 
and pharmacodynamic effect (as there is another MTT2 which describes delay in 
the second chain) and proportion residual error describes the individual 
differences between model prediction and individual patient. Both of these 
parameters are not expected to systematically deviate across the dosing 
requirements.  
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Table 2.6 Parameter estimates from the published prior kinetic-pharmacodynamic 
(KPD) model (as a comparison) and bootstrap resampling 
Parameter Published prior KPD 
model [95% CI] 
Bootstrap mean 
estimate [95% CI] 
OPQG (mg/L) 2.05 [1.64, 2.46] 2.24 [1.32, 3.64] 
OPQA(mg/L) 0.96 [0.78, 1.14] 1.10 [0.63, 1.82] 
MTT1 (hours) 28.6 [27.25, 29.95] 34.92 [29.25, 45.50] 
MTT2 (hours) 118.30 64.86 [1.43, 140] 
Proportional residual error 
(f) CV % 
20.00 14.70 [13.50, 15.90] 
 1.15 [1.05, 1.25] 1.51 [1.14, 2.01] 
BSV OPQ (CV %) 34 [29.93, 38.07] 29.73 [25.78, 33.98] 
BSV CL (CV %) 29.83 [17.9, 41.76] 44.18 [21.48, 67.72] 
BSV V (CV %) 23.23 [10.17, 36.31] 49.46 [15.01, 79.96] 
OPQG and OPQA concentration of s-warfarin at 50 % of maximum drug effect for G 
and A allele, MTT mean transit time, CV coefficient of variation,  Hill coefficient, BSV 
between subject variability, rQ first-order elimination rate constant, CL clearance, V 
volume of distribution of s-warfarin 
2.5. Discussion 
In this study, the possible causes of bias in warfarin maintenance dose 
predictions with a Bayesian dosing tool were explored. A previously reported 
over-prediction of warfarin maintenance dose requirements was successfully 
replicated using two data sets from different clinical centres. Furthermore, dose 
predictions were carried out in the Bayesian dosing tool using all available INR 
measurements for each patient which should provide the most accurate estimate 
of the patient’s response. The biased warfarin dose predictions were only 
observed in patients requiring ≥7 mg/day. 
Several publications on the application of Bayesian methodologies to 
warfarin dose individualisation have been reported previously [75-80]. A 
summary of previous Bayesian dosing tools for warfarin and how they differ 
from the dosing tool in this study have also been reviewed [1, 2]. Vadher et al. 
[79] compared the observed dose to the predicted maintenance dose and found 
that their Bayesian dosing tool was negatively biased on average. A scatter plot 
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of the observed dose versus predicted dose reported by Vadher et al [79] also 
showed biased predictions in patients requiring higher daily doses, although in 
a different direction (under-prediction in higher dose patients). Other 
publications on Bayesian dosing tools for warfarin did not analyse the predictive 
performance of the dosing tool in a way that would allow comparison with this 
work.  
Four possible explanations for the bias were explored in this study. First, 
the hypothesis that it was an aberrant finding only observed in a single 
population. This study found that the observed bias can be replicated in a 
different population and therefore suggests that the bias is not due to an aberrant 
population. The second and third hypothesis was that the bias is driven by a 
dose-effect relationship or due to the influence of VKORC1 genotype. VKORC1 
was the primary focus since it was identified as a candidate in previous work [3] 
but in the present study it was found to have no influence on dose predictions. 
In addition, the direction of dose prediction error (i.e. over or under-predicted 
dose) in each patient requiring ≥ 7 mg/day was the same despite changing the 
EC50 priors to the values as per published prior model. This suggests that the 
influence of VKORC1 is not a primary driver of the observed bias. Furthermore, 
the initial apparent association of bias and VKORC1 GG may be explained by a 
higher proportion of patients with VKORC1 GG in this dose category and 
therefore, the initial link between VKORC1 GG and bias was more likely to be an 
association rather than a cause.  
The possibility that the population used to derive the prior population 
parameter estimate for the KPD model had a different dose-response to our 
study population which would mean that the model could not be extrapolated 
to the study population was also explored. The results suggest that the prior and 
posterior populations were not sufficiently different to be a plausible cause of 
the observed bias.   
As noted above, the bias in warfarin dose predictions was evident only for 
those patients taking ≥ 7 mg/day. The reason for this is not currently clear. Since 
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it was found that it is not likely to be the parameter values used as the basis of 
the prior, then this suggests it could be the structure of the prior model.  It is 
known the coagulation network is complex [36]. It is therefore plausible that the 
use of empirical transit chain model to describe the time course of warfarin 
response may not be sufficiently flexible to account for the inherent feedback and 
feedforward mechanisms of the coagulation network. This being the case, bias 
may be apparent in those patients taking higher than average warfarin doses.  
2.6. Conclusion 
In two patient cohorts, the Bayesian dosing tool resulted in positively 
biased warfarin dose predictions. By combining both data sets, a positive bias 
dose prediction of 0.32 mg/day (95% CI; 0.14, 0.5) was found. Warfarin doses 
were over-predicted for patients requiring ≥ 7 mg/day by 1.15 mg/day on 
average. The bias in dose predictions was not found to be due to the influence of 
VKORC1 genotype. The prior and posterior populations were not sufficiently 
different to be the source of bias.  
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In the previous chapter, a Bayesian forecasting tool was found to produce 
biased dose predictions for those patients who required ≥ 7mg daily. While the 
source of the bias could not be determined, it was proposed that empirically-
derived and semi-mechanistic models for warfarin dose-response may not 
adequately capture the complexity of the coagulation network and therefore 
cannot capture the warfarin-INR response at the extremes. This chapter 
examines other type of dosing tools that are designed to predict the maintenance 
dose of warfarin at initiation to learn if doses can be predicted accurately in 
patients requiring higher daily doses. 
3.1. Introduction 
There have been a large number of publications exploring strategies to 
improve INR control and to predict warfarin dose requirements. A variety of 
nomograms, computerised decision-support tools and Bayesian dose prediction 
tools have been proposed to aid dosing decisions in the clinic [76, 79, 140, 141]. 
In recent years, the use of patient characteristics to predict warfarin dosing 
requirements prior to the initiation of therapy has been advocated by 
researchers, clinicians, and the Food and Drug Administration (FDA). These 
algorithms are developed by regressing patient characteristics, including age, 
body size, ethnicity, concomitant drug use and genetic variability in warfarin 
metabolism (via CYP2C9 genotype) or vitamin K recycling (via VKORC1 
genotype) [4, 24, 30, 68], against maintenance dose requirements. The algorithms 
therefore provide a means of rapidly predicting warfarin dosing requirements at 
the initiation of therapy [24, 68, 139, 143]. The algorithms have been shown to 
accurately predict dosing requirements for warfarin on average [30, 68], and 
have been implemented in some clinical settings [135, 144]. To date however, 
clinical trials have not consistently demonstrated that dose prediction using 
warfarin algorithms improves anticoagulant control or patient outcomes 
compared to other methods [84, 85, 145-149].  
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The average maintenance dose requirement for warfarin is reported to be 
4-5 mg daily [68], with an interquartile range of 3-6 mg daily [68, 150]. The need 
for dose reduction in some patients due to factors such as increasing age [24], 
drug interactions [24, 30], and genetic factors [24, 68] are well documented. 
Factors that predict higher warfarin dose requirements are less well understood 
and the management of these patients presents a challenge for prescribers. This 
is particularly the case at the initiation of therapy when doses are being titrated 
to the anticoagulant response and the risk of over-anticoagulation has been 
found to be at its highest [150, 151]. Equally, overly cautious dose escalation for 
patients who require higher doses may unnecessarily prolong the time to reach 
stable anticoagulation, requiring extended periods of parenteral anticoagulant 
cover for patients with acute thromboembolism.  
It could be argued that the patients who might receive the most benefit 
from the use of warfarin dosing aids in the clinic are those who require doses 
outside the normal dose range of 3-6 mg daily. However, published algorithms 
are developed largely using patient characteristics that predict a reduction in 
warfarin dose while factors associated with higher dose requirements are not 
considered or are restricted to smoking status, concomitant use of enzyme 
inducers, or African-American ethnicity (see Gage et al. [24] for an example).  
In the previous chapter, a Bayesian dosing tool was found to produce 
biased maintenance dose predictions in patients requiring higher daily doses. 
There is published evidence to suggest that warfarin dosing algorithms under-
predict dose requirements in those patients who require doses in the upper 
quartile of dose requirements [3, 152-154]. It is therefore unclear whether bias in 
dose prediction in this subgroup of patients (i.e. patients requiring ≥ 7 mg daily) 
are merely isolated problems with a few dosing tools or if a systematic bias may 
exist across different dosing tools. 
  




To determine if warfarin dosing algorithms produce accurate maintenance 
dose predictions for those patients who require ≥ 7 mg daily. 
3.3. Methods 
3.3.1. Identifying published warfarin maintenance dose prediction 
algorithms 
Medline (1946 – September 2015) and Embase (1947 – September 2015) was 
searched to identify all studies that evaluated the predictive performance of 
algorithms designed to predict the maintenance dose of warfarin. These included 
genotype-driven algorithms, Bayesian algorithms and warfarin decision-
support tools. The Medline MeSH terms included: “warfarin”, “algorithm*”, 
“regression analysis”, “statistical models”, “Bayes theorem”, “Dose-Response 
Relationship, Drug or dose response”, “international normalized ratio”, 
“pharmacogenetics” and keywords “dose predict*”, “regression”, and “dose 
calculation” were used. The search was limited to articles published in English 
and human studies. Key review publications were also identified and mined for 
further relevant studies. In addition, the reference lists from the identified 
studies were further examined for potentially relevant studies as well as citations 
of the studies identified.  
3.3.2. Inclusion and exclusion criteria 
Studies that were identified from the database search were screened based 
on the title and abstract. Full-text assessment was carried out on all studies that 
evaluated the ability of a dosing algorithm to predict the maintenance dose of 
warfarin. The unit of analysis in this meta-analysis was a unique algorithm.  
Studies were included if they (1) provided an evaluation in the form of a 
scatterplot of observed versus predicted maintenance doses, and (2) the 
published scatterplot included observed doses from a validation data set. Here 
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the term ‘validation data set’ is used to refer to data external to the development 
of the algorithm.  
Studies were excluded if (1) the published scatterplot was of insufficient 
resolution to allow the data to be extracted, and (2) there were less than five 
patients requiring ≥7 mg/day in the data set. Similar to the previous chapter, a 
cut off ≥7 mg/day was used to define patients requiring ‘higher than average’ 
dose as this definition has been used in several other large studies [68, 152]. 
3.3.3. Data extraction 
For each scatterplot, data points for patients requiring ≥7mg/day were 
digitized using the MATLAB® script, GRABIT [155]. 
The reproducibility of the extracted data was evaluated by replicating the 
extracted data in a sample of 5 scatterplots (approximately a 10% sample). This 
was done by a researcher who was not involved in this study.  The relative 
difference between the original and replicate of the extracted data points were 
compared. A difference of 10% was considered to be acceptable. 
3.3.4. Meta-analysis 
The null hypothesis was that dosing algorithms would produce unbiased 
dose predictions so that overall there would be an equal proportion of dose 
predictions on either side of the line of identity in the published scatterplots. 
Therefore, the null proportion of 0.5 (50% of predicted doses would be expected 
on either side of the line of identity) was used to test for bias. A minimum of 5 
samples was required to obtain a binomial probability p value <0.05. This can be 
calculated using: 
 1(0): 2t07 1
  (1 − 1)!3 
Equation 3.1 The binomial probability 
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where 1(0) is the binomial distribution for variable 0, t is the number of trials 
(total number of patients requiring ≥7mg/day), 0  is the number of success 
(number of under-predicted doses), t − 0  is the number of failures, 1  is the 
probability of success in any given trial (i.e. 0.5). 
The proportion of over- and under-predicted doses was quantified. The 
primary outcome of interest for the meta-analysis was the proportion of over- or 
under-predicted warfarin doses for patients requiring a maintenance dose of 7 
mg/day or more (the upper quartile of warfarin dosing requirements). 
Several dosing algorithms were evaluated, and published, in more than one 
study was noted. This was considered to be a repeated measure.   
The meta-analyses was performed using MedCalc for Windows, v15.10 
(MedCalc Software, Ostend, Belgium) [156]. A random effects model was used 
given an a priori assumption of significant heterogeneity between studies [142]. 
The meta-analysis was conducted using a three-stage hierarchical meta-
analytical model. Algorithms with repeated measure were first pooled across to 
provide an overall estimate for the individual algorithm. Then an estimate of t 
and 1 that would provide the same pooled proportion and 95% CI for each of the 
algorithm (with repeated measure) was obtained using a search algorithm in 
MATLAB® (see appendix A3.1). Herein, the algorithms with repeated 
evaluations are termed ‘pooled’ algorithms. The proportion of over and under-
predicted doses for the pooled algorithms (i.e. with repeated measures) were 
then pooled with the rest of the whole population of algorithms. Therefore, stage 
one refers to the whole population of algorithms, stage two the individual 
algorithm and stage three the individual study.   
Heterogeneity among studies were explored at the first stage using the I2 
statistic, where an I2 of 25%, 50% and 75% is considered to have low, moderate 
and high heterogeneity respectively [157, 158]. Note that, since a priori a random 
effects model was used (to account for the various stages in the hierarchy), the 
analysis for heterogeneity is for descriptive purposes to quantify the 
homogeneity across algorithms.  
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3.3.5. Estimating the average prediction error 
The average prediction error was calculated by dividing the sum of 
prediction error (predicted maintenance dose minus observed maintenance dose 
of each patient requiring ≥7 mg/day) by the total number of patients requiring 
≥7 mg/day.  
3.4. Results 
3.4.1. Literature search results  
Ninety-five studies that evaluated the predictive performance of warfarin dosing 
algorithms was found. Seventy-nine studies were excluded because they did not 
meet the inclusion/ exclusion criteria. Twenty-three evaluations were excluded 
on grounds that they were not evaluating dose predictions against external data, 
six evaluations had insufficient resolution to allow data extraction, and thirteen 
evaluations had no or less than five patients requiring doses ≥ 7mg/day (see 
Table 3.1). Figure 3.1 shows a flow diagram for the study selection process.  
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Table 3.1 A breakdown of the excluded scatterplots from the meta-analysis 
Algorithm Scatterplot Reason for exclusion 
Botton 2011 [159] Botton 2011 [159] Not evaluating against external data 
Doi 2001 [160] Doi 2001 [160] Not evaluating against external data 
Ekladious 2013 [161] Ekladious 2013 [161] Not evaluating against external data 





Not evaluating against external data 
Le Gal 2010 [164] Le Gal 2010 [164] Not evaluating against external data 
Lenzini 2008[165] Lenzini 2008 [165] Not evaluating against external data 
Lenzini 2010 [30] Lenzini 2010 [30] Not evaluating against external data 
Michaud 2008 [166] Michaud 2008 [166] Not evaluating against external data 
Millican 2007 [66] Millican 2007 [66] Not evaluating against external data 
Pavani 2014 [167] Pavani 2014 [167] Not evaluating against external data 
Perini 2010 [168] Perini 2010 [168] Not evaluating against external data 
Roper 2010 [169] Roper 2010 [169] Not evaluating against external data 





Not evaluating against external data 
Suprianata 2011 [172] Suprianata 2011 
[172] 
Not evaluating against external data 
Takahashi 2006 [173] Takahashi 2006 [173] Not evaluating against external data 
Vadher 1999 [79] Vadher 1999 [79] Not evaluating against external data 
Voora 2010 [174] Voora 2010 [174] Not evaluating against external data 
Wei 2012 [175] Wei 2012 [175] Not evaluating against external data 
Wells 2010 [164, 176] Wells 2010 [164, 176] Not evaluating against external data 
Yoshizawa 2009 [177] Yoshizawa 2009 
[177] 
Not evaluating against external data 
Zhu 2007 [178] Zhu 2007 [178] Not evaluating against external data 
Gage 2008 [24] Voora 2010 [174] Insufficient resolution 
Sconce 2005 [143] Roper 2010 [169] Insufficient resolution 
Klein 2009 [68] Roper 2010 [169] Insufficient resolution 
Roper 2010 [169] Roper 2010 [169] Insufficient resolution 
Gage 2008 [24] Roper 2010 [169] Insufficient resolution 
Saleh 2014 [179] Saleh 2014 [179] Insufficient resolution 
Haug 2008 [180] Harada 2010 [181] no patients requiring doses ≥ 
7mg/day 
Harada 2010 [181] Harada 2010 [181] no patients requiring doses ≥ 
7mg/day 
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Huang 2009 [182] Wang 2012 [183] no patients requiring doses ≥ 
7mg/day 
Kim 2009 [184] Kim 2009 [184] no patients requiring doses ≥ 
7mg/day 
Lu 2013 [185] Lu 2013 [185] no patients requiring doses ≥ 
7mg/day 
Sconce 2005 [143] Sconce 2005 [143] no patients requiring doses ≥ 
7mg/day 
Sconce 2005 [143] Harada 2010 [181] no patients requiring doses ≥ 
7mg/day 
Zhang 2010 [186] Lu 2013 [161] * no patients requiring doses ≥ 
7mg/day 
Tan 2012 [187] Tan 2012 [187] <5 patients requiring doses ≥ 
7mg/day 
Huang 2009 [182] Huang 2009 [182] <5 patients requiring doses ≥ 
7mg/day 
Sasaki 2009 [188] Sasaki 2009 [188] <5 patients requiring doses ≥ 
7mg/day 
Klein 2009 [68] Lei 2012 [189] <5 patients requiring doses ≥ 
7mg/day 
* had two evaluations




Figure 3.1 Study selection process 
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The final analysis included 47 evaluations of 22 unique algorithms [24, 30, 
31, 64, 65, 68, 74, 143, 145, 159, 164, 167, 170, 178, 190-193] from 17 studies 
(scatterplots from [3, 31, 64, 68, 84, 167, 169, 170, 190, 192, 194-199]). Eleven 
algorithms  [24, 30, 68, 143, 145, 164, 178, 190, 191] were evaluated in multiple 
studies (between 2-6 times). 
3.4.2. Characteristics of the eligible studies 
The study population included patients taking warfarin for atrial 
fibrillation, venous thromboembolism, heart valve replacement, transient 
ischaemic attack, and cardiomyopathy (Table 3.2). Patient characteristics used to 
predict dose requirements included measures of body size, age, race, co-
medication, indication of warfarin use, and CYP2C9 and VKORC1 genotype 
information. Data from 1492 patients were available for analysis. On average, 








Table 3.2 Summary of the studies and algorithms included in the meta-analysis 
Algorithm, year Variables in the 
algorithm 
Validation study‡, 
figure from which the 
data was extracted in 
the published article 
Warfarin indication for 
patients in the validation 
cohort 
n Estimated number 
(%) of patients 
requiring  
≥7 mg/day 
Klein 2009  [68] age, height, weight, 
VKORC1, CYP2C9, 
race, co-medications 
Klein 2009 (S8) [68] DVT/PE, AF, HVR, TIA, OS, 
Others 
1008 125 (12.4) 
Pathare 2012, 3 [192] AF, DVT/ PE, HVR 212 30 (14.15) 
Pavani 2014, 2C [167] HVR 115 9 (7.83) 
Ramos 2012, 2B [64] AF, PE, others 55 12 (21.82) 
Santos 2015, 4B [170] AF, CVA, DVT/PE, HVR, others 133 8 (6.02) 




VKORC1, and height 
Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2014, 2 [194] AF, VTE 133 23 (17.29) 
Langley 2009, 1D [196] NA 75 22 (29.33) 
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Zhu 2007  [178] age, sex, weight, 
VKORC1, CYP2C9 
Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2014, 2 [194] AF, VTE 133 23 (17.29) 
Langley 2009, 1C [196] NA 75 22 (29.33) 
Linder 2009, 2 [197] NA 137 18 (13.14) 
Gage 2008  [24] VKORC1, CYP2C9, 




Gage 2008 in 
Corrigendum [24, 198] 
AF, DVT/PE, others 295 73 (24.75) 
Shaw 2010, 1 [199] AF, DVT/PE, others 71 27 (38.03) 
Saffian 2015, 1(G1) [3] AF, DVT/PE 46 14 (30.43) 
Langley 2009, 1A [196] NA 75 22 (26.67) 






Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2014, 2 [194] AF, VTE 133 23 (17.29) 










age, sex, weight 
Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2015, 2 [194] AF, VTE 133 23 (17.29) 




CYP2C9, BSA, target 




Ramos 2012, 2C [64] AF, PE, others 55 12 (21.82) 
Saffian 2015, 1(G3) [3] AF, DVT/PE 46 14 (30.43) 
Kimmel 2013, S4 [84] AF, DVT/PE, others 514 97(18.87) 
Le Gal 2010 
[164] 
cumulative dose, INR Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2014, 2 [194] AF, VTE 133 23 (17.29) 
Solomon 2004 
[191] 
age, total loading 
doses, INR, co-
medication 
Francis 2014, 1 [194] AF, DVT/PE, CVA, others 508 40 (7.87) 
Francis 2014, 2[194] AF, VTE 133 23 (17.29) 




Saffian 2015, 1(C1) [3] AF, DVT/PE 46 14 (30.43) 















Saffian 2015, 1(C3) [3] AF, DVT/PE 46 14 (30.43 







Santos 2015, 4A [170] AF, DVT/PE, HVR, TIA, CVA, 
others 
133 8 (6.02) 
Klein 2009* [68] age, height, weight, 
race, co-medication 
Saffian 2015, 1(C2) [3] AF, DVT/PE 46 14 (30.43) 
Pathare 2012 
[192] 
age, weight, sex, 
indication, CYP2C9, 
VKORC1 
Pathare 2012, 21 [192] AF, DVT/PE, HVR 70 13 (18.57) 
Pavani 2012 
[167] 
age, sex, BMI, 
CYP2C9, VKORC1, 
vitamin K intake 
Pavani 2012, 23 [167] AF, DVT, HVR 115 9 (7.83) 
Perini 2008 [65] age, weight, co-
medication, CYP2C9, 
VKORC1, indication 
Santos 2015, 4D [170] AF, DVT/PE, HVR, TIA, CVA, 
others 
133 8 (6.02) 
 
 









Santos 2015, 4A [170] AF, DVT/PE, HVR, TIA, CVA, 
others 
133 7 (5.26) 





Langley 2009, 1B [196] NA 75 22 (29.33) 
Lenzini 2007 
[31] 
INR, blood loss, 
previous warfarin 
doses, co-medication 
Lenzini 2007, 1 [31] OS 105 17 (16.19) 
Horne 2012 [74] VKORC1, CYP2C9, 
co-medication, BSA, 
target INR, previous 
warfarin doses, INR, 
stroke, duration of 
therapy 










target INR, previous 
warfarin doses, INR, 
stroke, duration of 
therapy 
Saffian 2015, 1(C4) [3] AF, DVT/PE 46 14 (30.43) 





Ramos 2012, 2A [64] AF, PE, others 55 12 (21.82) 
AF atrial fibrillation, VTE venous thromboembolism, HVR heart valve replacement, OS post orthopaedic surgery, TIA transient 
ischaemic attack, CVA cerebrovascular accident, DVT/PE deep vein thrombosis/pulmonary embolism, NA information was not 
available. ‡ validation study refers to an evaluation of dose predictions against external data. * denotes clinical algorithm.  
 
Chapter 3:  An evaluation of warfarin dosing tools in patients requiring ≥ 7mg daily 
98 
 
3.4.3. Predictive performance of warfarin dosing tools in patients requiring 
≥ 7 mg daily 
Figure 3.2 presents a forest plot showing the proportion of warfarin doses 
that were under-predicted in patients requiring ≥ 7mg/day. Note that the 
analysis was indexed to each algorithm rather than to the study. The pooled 
proportions of under-predicted warfarin doses was 92.28% (95% CI 90.25 - 94.1) 
for these patients. Heterogeneity between the studies was low (I2=23.99% [95% 
CI 0 - 54.89]). The average prediction error was found to be −2.32 mg/day. Scatter 
plots of the evaluations included in his study are reproduced in Appendix A3.2. 
An evaluation of reproducibility of the extracted data is presented in 
Appendix Table A3.3. The deviation of the replicated data extraction from the 
originally extracted data was found to be between 0.8% to 5.9%. 
 
 
Figure 3.2 Forest plot of included studies 
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A sensitivity analysis was carried out to assess the impact of excluding 4 
algorithms taken from studies with < 5 patients who required warfarin doses of 
7mg daily or more [182, 187-189]. This was accomplished by pooling the data 
from the four excluded algorithms and including the pooled data in the 
estimation of the pooled proportion. The pooled proportion of under-predicted 
doses was 100% (95% CI 54.1 - 100) across the 4 algorithms. The inclusion of the 
pooled results in the meta-analysis did not change the overall pooled proportion 
of under-predicted doses (92.34, 95% CI 90.37 – 94.1 versus 92.28 95% CI 90.25– 
94.10).  
3.5. Discussion 
The ability of warfarin dosing algorithms to predict the observed 
maintenance doses in patients requiring higher than average daily doses was 
assessed in this study. The warfarin dosing algorithms included in this study 
were found to consistently under-predict the maintenance dose in patients 
requiring ≥ 7mg daily. This result was consistent across different algorithms, 
different clinical settings and in different patient populations. The choice of 
patient factors in the algorithm did not appear to influence the performance of 
the algorithm which includes several factors that have been associated with an 
increase in the dosing requirement such as CYP4F2 polymorphism, ethnicity, 
inducing agents and smoking (see Botton et al 2011 [159] and Gage et al 2008 
[24]). The average magnitude of the under-prediction is clinically important at 
approximately 2.3 mg/day or 26.5% relative bias for patients requiring ≥ 7 
mg/day.  
Several previous studies have also found that warfarin dosing algorithms 
perform poorly in patients requiring higher doses. Peng et al [153] compared the 
stable maintenance dose of 586 Chinese patients against maintenance doses 
predicted using nine algorithms. There were 6 patients requiring doses ≥ 7 
mg/day in their study. Peng et al [153] found that the proportion of under-
predicted doses in each of the algorithms were more than 80%. In another study, 
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Marin-LeBlanc et al [152] found that the proportion of under-predicted doses in 
all four algorithms tested requiring > 7 mg/day was > 61%.  
The majority of published warfarin algorithms are designed to aid dose 
prediction at the initiation of therapy. Usually, an average population dose (often 
5mg daily) would be used for all patients at the start of therapy and the dose 
adjusted heuristically according to INR response. In theory, algorithms that 
predict dose requirements prior to the initiation of therapy should minimise the 
need for dose adjustment and maximise the time in the therapeutic INR range. 
The results of this study suggest that patients in the upper quartile of dose 
requirements will not benefit from the use of these dosing tools and may be 
under-dosed which may unnecessarily delay attainment of a stable INR.  
The cause of the bias observed in this study is not known. Of note, the 
direction of bias observed in this chapter is the opposite the observed bias in 
Chapter 2 (over-prediction). All of the dosing algorithms, but one [191], were 
developed using multi-linear regressions methods. Therefore, the algorithms 
will predict a response that follows a linear relationship across the full range of 
doses. Yet the dose-response relationship is only approximately linear in the 
central (20-80% of the maximum response) portion of the dose-response curve 
[200]. It is therefore possible that at higher doses the relationship between 
warfarin exposure and response reaches the non-linear portion of the curve (see 
Figure 3.3). If this were the case then, at higher doses, warfarin algorithms 
developed using linear regression techniques will under-predict dosing 
requirements by design.  




Figure 3.3 A speculative relationship between warfarin dose and INR response. It is 
proposed that at higher doses, the warfarin dose-response relationship may flatten out. 
Therefore, algorithms that predict a linear relationship between dose and INR response 
would under-predict the dose required to achieve the target INR. 
The algorithms included in the analysis were all empirically derived by 
regressing dosing requirements against patient demographics. Using this 
methodology, the physiological and pharmacological mechanisms that underpin 
the warfarin-dose response are simplified into an empirical multilinear 
regression equation. Arguably, this will limit the ability of any given algorithm 
to generalize into new data, particularly data that extends past where the model 
was originally developed. Several warfarin dosing algorithms developed in a 
non-linear setting have been proposed including; support vector regression 
[201], boosted regression tree [202], artificial neural networks [191] and several 
other algorithms [203]. Li et al [154] evaluated several of these non-linear models 
and found that more than 59% of the maintenance doses were under-predicted 
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for patients requiring higher doses (defined as maintenance dose >30.66 
mg/week).  
This study reaffirms the assertion proposed in the previous chapter in that 
all current models to predict warfarin dose may be possibly too simple to capture 
the complexity of the coagulation network. A proposed solution might be a 
warfarin pharmacokinetic model linked to a systems pharmacology model for 
the coagulation network (see Wajima et al [36]). Further research to explore this 
mechanistic model is beyond the scope of this thesis. 
 There are several limitations to this study. Firstly, the extraction of data 
points depended on the clarity of the scatterplot. It was possible that overlapping 
data points were missed or digitised inaccurately. However, the error is expected 
to be relatively small overall and unlikely to have any significant influence on 
the results or conclusions. The three-stage hierarchical meta-analytic technique 
is not automated in the software used and incorporation of the repeated 
measures results included into the third stage of the hierarchy as a post-hoc step. 
In addition, the studies examined here did not consistently report adherence 
rates for the patients included. It is possible that some patients may have 
appeared to require larger doses because they were not adhering to the 
prescribed therapy. It is not possible in this setting to evaluate the impact of this 
on the findings.   
3.6. Conclusion 
Published warfarin dosing algorithms cannot be relied upon to accurately 
predict maintenance doses for patients who are likely to require higher than 
average daily doses. At therapy initiation, this is will not be known and hence 
the use of warfarin dosing tools may result in a prescribed dose that is 2.3 
mg/day, on average, less than what is required to achieve therapeutic 
anticoagulation. This may increase the time to reach steady-state INR and may 
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This chapter arose from a problem faced in the previous two chapters (in 
Figure 2.2 and Section 3.4.3). It was observed that dose predictions may appear 
to follow the line of identity quite well at lower values, but systematically deviate 
away from the line of identity in one direction at higher values. This chapter will 
propose an approach to evaluate bias associated with such data. 
4.1. Introduction 
When a mathematical model has been developed to predict observed data, 
a test of its predictive performance is warranted. It is typical to evaluate the 
model in terms of how close the model predictions are to the observed data and 
this may be achieved by plotting the observations against the model predictions. 
Here the observed data is considered the standard and is assumed to be an 
unbiased representation of the system, although will contain various levels of 
noise such as errors associated with imperfect measurement and imperfect study 
execution. A model that accurately captures the observed data, in some sense, is 
therefore the goal. There are of course situations in which the data are not an 
unbiased representation of the system, often due to confounding in the 
experiment, but this is not the case for consideration here. The differences 
between the predicted data and observed data are termed the residuals and in 
essence, the test of predictive performance of a model can be understood as a 
method for analysing residuals.  
Several methods for analysing residuals have been proposed. One 
approach for analysing residuals is by fitting a smooth curve through the 
residuals using a non-parametric local regression known as lowess or loess [204, 
205]. The lowess (or loess) curve are smoothing processes that can be understood 
as the moving average method where each of the smoothed values is determined 
only by the data points within a defined span. This approach is useful for 
visualizing the average scatter of residuals across the x-axis and therefore can be 
used to qualitatively assess where the residuals deviate systematically from the 




line of identity. However, it lacks the ability to test whether the departure is 
statistically significant. 
Another approach for analysing residuals is the Bland - Altman plot [206]. 
Although it was developed for a different purpose (i.e. agreement between two 
measurement methods), the method used in the Bland-Altman plot is similar in 
principle (i.e. analysis of residuals). In the Bland-Altman plot, the difference 
between the measurement of two methods are plotted against the mean of the 
two methods (on the x-axis). One advantage of the Bland-Altman plot is that it 
provides visualization of the relationship of the differences between 
measurements against the magnitude of measurement and therefore allows 
visual inspection of the existence of systematic difference between the two 
measurements. If there is no evidence that the differences between 
measurements are related to the magnitude of the measurements, then the mean 
of the difference between two measurements provide the measure of average 
bias between the two methods. In a later publication, Bland and Altman [207] 
further suggested an approach to test if bias is constant or not (the change in the 
difference between measurement of two methods is related to the magnitude of 
measurement). The approach involves regressing the difference between two 
measurement methods against the mean of the two measurements using linear 
regression. If the slope is significant, which was deliberately not defined by 
Bland and Altman [207], then the difference between measurements is estimated 
by the regression equation.   
Perhaps the most common method for measuring the predictive 
performance of a model in clinical pharmacology is the method suggested by 
Sheiner and Beal in 1981 [5]. The method provides an estimate of bias using the 
mean prediction error (k^O ) and imprecision using the mean squared error 
(kO) or the root mean squared error (#kO). In Chapter 2, bias was measured 
using the Sheiner and Beal 1981 [5] mean prediction error method. This chapter 
proposes an extension to the method of Sheiner and Beal to analyse bias that 
systematically deviates in relation to the magnitude of the predicted values.  




4.2. The problem 
The mean prediction error ( k^O ) is calculated using the following 
equation: 




Equation 4.1 Mean prediction error 
where ^O is prediction error (the predicted data (z((, 0)), minus the observed 
data (n) for eth experimental run (in this example it is an observation from an 
individual)), and  is the number of residuals. z(θ, 0) is used to denote a model 
(linear or otherwise) that is defined by a 1 ×  1 vector the parameters (() and 
some independent variables 0. Usually, the residuals are assumed to follow a 
normal distribution and therefore the 95% confidence interval is calculated using 
U% T = S ± . SS 
Equation 4.2 Calculation of the 95% confidence interval of the MPE 
where O  is the asymptotic standard error of the mean prediction error. If the 
95% CI includes zero, then no bias is concluded.  
By reporting the k^O and its 95% CI, one can estimate the overall measure 
of bias as well as the direction of the bias (i.e. under- or over-prediction by the 
model). Inherently, the k^O measures the average prediction error across the 
entire observed data where, for the purposes of the calculation, the data are 
assumed to arise from a single bin and all residuals within a bin are 
exchangeable. However, a problem arises when the relationship between 
prediction error and the observed data is not random and itself shows a 
systematic trend over the range of the observations. An example of this situation 
is shown in Figure 4.1. During this thesis, examples of such scatter plots have 
been seen in Chapters 2 and 3. To illustrate this problem better, an example of a 
plot that is reproduced (see Figure 4.1) from a previous publication [3] that is not 
described in this thesis. The y-axis is the observed maintenance dose of warfarin 




and the x-axis is the predicted dose using a dosing software. Further details of 
the study are omitted.  
 
Figure 4.1 Scatter plot showing systematic deviation from the line of identity as the 
magnitude of the data predictions increase. The red line is a loess smoothing function. 
Reproduced from Saffian et al. 2015 [3] with permission from Wolters Kluwer Health, 
Inc. 
The k^O for this analysis was +0.37 the lower and upper 95% CI was 0.89 
and -0.15 respectively, which indicates that the dosing tool provides unbiased 
predictions. However, it is evident that dose predictions on the lower observed 
dose generally follow the line of identity, although visually, and based on the 
loess line, there is a suggestion of under-prediction. Predictions for the observed 
dose above a ~7mg were mostly over-predicted. 
The aim of this chapter is to propose an approach that can be used to 
numerically test deviations that occur over regions of the observed data. The 
approach is based on a generalised form of the k^O  method.  The method 




proposed in this paper is intended for use in situations in which there are no 
repeated measures over experimental runs. 
4.3. A suggested approach 
It is proposed that the single bin k^O of Sheiner and Beal 1981 (here on 
termed ‘S&B method’) can be extended to multiple bins which can then each be 
assessed for systematic deviation and formally for their asymptotic properties if 
we considered infinite bins.  
The algorithm for the approach involves four steps which can be divided 
into two parts. Figure 4.2 depicts the flow chart of the suggested approach.  
 










is t <  ? 
Regress the values of slopes ({r) against the number of bins and 
estimate the slope at infinite number of bins  
{r =  + (Q − )(013v×!);  j ∈ 2, … , , 
where  is the slope at infinite number of bins, Q is the initial 
slope, ( is a rate constant describing the rate of change of the slope 
vs number of bins, and j is the number of bins 
False 
Create t bins of equal size 
(width) across the x-axis 
Compute the mean prediction error 
(k^O) of each of the t bins 
Regress the k^O  value against the bin number. Let  
n = 2, … , , let  =  1, … , t 
k^O() = {Q N   {r ×  et;;  
where k^O  is the mean prediction error,  {r  is the slope of the 
regression, {Q  is the intercept,   is the bin number in the t th 
iteration 
t = 2 
True 










t is a constant within an iteration and is the number of bins in a particular 
iteration. Since iterations start at 1, then t = 1 + iteration number. It is cycled 
through until the value of t equals the total number of allowable bins (). For 
practicality, the choice of values of the vector t and total number of bins, , 
may be optimised (not considered here). In Part 1, each iteration will provide a set 
of slope parameters ({r). Here βr is now considered as if it were data and there 
are  – 1 values of {r. If the value of {r  is constant for all t, then no evidence 
of systematic trend in the bias of the residuals is concluded. However, in the 
presence of systematic bias the value of {r  will change monotonically to an 
asymptotic value as t approaches ∞.   
The second part is to fit an exponential model to the slope coefficients ({r), 
and determine the asymptotic properties of the systematic bias in residuals. The 
value of  is the value of the asymptotic systematic bias.  If the 95% CI of  
includes zero, then this indicates that there is no systematic trend in the bias of the 
residuals. The 95% CI of   tests if there is bias in the residuals that is 
monotonically systematic. Further explanation with respect to the rationale of 
using the 95% CI of  to test for a systematic trend in the bias of the residuals 
will be presented in the Discussion (Section 4.6). 
There are also occasions where the model produces bias, but the bias is not 
systematically related to the magnitude of the measurement and will described in 
the following section. See Table 4.1 for a step schematic of a setting with both 
systematic deviation of residuals versus not. 
  




Table 4.1 Step schematic of the proposed approach 
Description of the 
algorithm 
Model prediction with no 
systematic deviation of 
residuals 
Model prediction with 
systematic deviation in the 
residuals 
1. Create t (t > 1) 
bins of equal size 
on the x-axis  
  
2. Compute the mean 
prediction error 
(k^O) of each of 







bin 1 -0.10 0.12 








bin 1 0.06 -0.24 
bin 2  0.52 
 
3. Regress the k^O 
value against the 




Increment t and 
repeat step 1 to 
step 3. Stop when 
t >  . In this 








4. Fit an exponential 




properties of the 
systematic bias in 
residuals   




4.4. Evaluation of the Approach 
This section will proceed by illustrating the suggested approach using 
simulated data. All data sets comprised 50 values of x and y and were generated 
using MATLAB® (2015a, The Math Works, Natick, MA). The MATLAB® code 
used to implement the scenarios this analysis is attached in Appendix A3.1. 
Seven scenarios were considered as follows: 
A. No systematic deviation of predicted from observed data, 
B. Constant positive deviation of predicted from observed, 
C. Proportional deviation of residuals (i.e. the value of the deviation of the 
residuals was proportional to the magnitude of the observations), 
D. Nonlinear deviation of residuals associated with the magnitude of the 
observed data, 
E. Nonlinear deviation of residuals associated with the inverse of the 
magnitude of the observed data, 
F. A combination of constant and nonlinear deviation of residuals, 
G. Curvilinear deviation of residuals. 
Figure 4.3 depicts scenario A to G created without any noise so that readers can 
see the scenarios simulated. In the simulations, however, random noise was 
added by randomly generating 50 values using the following equation: 
f  ~ (0, &') 
Equation 4.3 The distribution of random noise 
where f is the residual error of the eth data point,  is used to denote a normal 
distribution with a mean of zero and variance (&'). A &' of 0.25 was used as this 
value was sufficient to provide random variability but still maintain the shape 
of bias. Each scenario was only simulated once.  




A. B.  C.  
D.  E. F.  
G.    
Figure 4.3 Scatterplot of data created without noise to simulate six scenarios (scenario B 
to G) where deviation from the line of identity may be observed. Scenario A is where there 
is no deviation from the line of identity. 
 
In all 7 scenarios, the single bin k^O approach as suggested by Sheiner and 
Beal (1981) [5] will be analysed and compared with the suggested approach.  




4.5. Results/ Application 
The results for of calculating bias using the single bin k^O (S&B) approach 
versus the suggested approach for scenarios A – G are presented below. The full 
working for each scenario can be found in Appendix 3.2-3.8. For all the scenarios 
simulated below, the scatter plots are observed versus predicted data in arbitrary 
units, the blue line is the line of identity, k^O  is the mean prediction error in 
arbitrary units and  is the asymptotic slope (at infinite number of bins). 
  
Figure 4.4 Scatter plot with no systematic deviation of predicted from observed 
data 
A. In this scenario, the predicted values were randomly scattered around the 
line of identity. Visually, there is no evidence that the prediction values 
systematically deviate from the line of identity. k^O (S&B) [95% CI] was 
-0.06 [-0.2, 0.07] and ? [95% CI] was -0.02 [-0.04, 0.01]. The total bias is the 
sum of k^O  and , therefore when  is 0 (i.e. 95% CI includes zero) 




then total bias is the k^O.  The 95% CI k^O included zero, hence it can 
be interpreted as no bias and constant deviation in residuals. 
  
 
Figure 4.5 Scatter plot of constant positive deviation of predicted from observed 
 
B. Scenario B is similar to scenario A, except that all of the predictions were 
shifted below the line of identity. Therefore, the deviation from the line of 
identity was constant across the magnitude of the observed data. The 
k^O (S&B) [95% CI] was 1.94 [1.80,2.07] and ? [95% CI] was -0.015 [-0.04, 
0.01]. As  is statistically not different from zero, the total bias is the 









Figure 4.6 Scatter plot with proportional deviation of residuals 
 
C. In this scenario, the predictions systematically deviated from the line of 
identity across the observed data. At lower observed values, the deviation 
from the line of identity is negative but at higher observed values the 
deviation is positive. Summing all the prediction error as a single bin may 
cancel out the overall bias as seen here where the k^O (S&B) [95% CI] was 
0.11 [-0.16, 0.39]. When the data was binned, the  [95% CI] was 0.25 
[0.21, 0.30]. It can be interpreted as there is no bias on average, but there 
is a statistically significant systematic non-constant deviation associated 
with the magnitude of observation. 
  





Figure 4.7 Scatter plot of nonlinear deviation of residuals associated with the 
magnitude of the observed data 
 
D. The scenario that was simulated here shows a systematic deviation from 
the line of identity in a non-linear way that is related to the magnitude of 
the observed values. The k^O (S&B) [95% CI] was 0.21 [-0.03,0.46], which 
included zero and therefore it would be concluded that the model is 
unbiased. Yet from the scatterplot, it is apparent that lower x- and y-
values followed the line of identity well, while as the y-axis values 
increase, the bias systematically shifts in one direction to under the line of 
identity. The   [95% CI] was 0.11 [0.03, 0.19] which does not include 
zero. It can be interpreted as there is no bias in the residual on average, 
but there is non-constant bias. 
 
 





Figure 4.8 Scatter plot of nonlinear deviation of residuals associated with the 
inverse of the magnitude of the observed data. The red line is a loess smoothing 
function 
 
E. Scenario E is similar to scenario D but is in the inverse order. Deviation 
above the line of identity is seen at the lower y-values, but as the y-value 
increased, the predictions followed the line of identity well. A loess 
smoothing function was added for this scenario as it is harder to see bias 
at lower values since the axes are naturally compressed due to the limited 
range that the data can deviate. The k^O (S&B) [95% CI] was -0.19 [-0.31, 
0.001] and  [95% CI] was 0.07 [0.02, 0.1]. It can be interpreted as there is 
no bias in the residual on average, but there is non-constant deviation that 
occurs systematically. 
 





Figure 4.9 Scatter plot of a combination of constant and nonlinear deviation of 
residuals 
F. This scenario is a combination of scenario B and D. The mean of all 
observations is below the line of identity (as in scenario B) and there is 
evidence of a nonlinear deviation that is related to the magnitude of the 
predictions.  k^O (S&B) [95% CI] for this example was 1.21 [0.97, 1.46] 
and  [95% CI] was 0.11 [0.03, 0.19]. It can be interpreted as positive bias 
in the residuals on average and the bias in the residuals is systematic. 
 





Figure 4.10  Scatter plot of curvilinear deviation of residuals 
 
G. In this scenario, the deviation was non-monotonic (different direction 
across the lower and upper values). Y-values for the lower x-values were 
above the line of identity, values of y-variable in the middle region of the 
x-axis was under the line of identity while y-values on the upper x-values 
were above the line of identity. k^O (S&B) [95% CI] was -0.21 [-0.43, 0.01] 
and  [95% CI] was 0.03 (-0.0039, 0.07). No bias on average and no 
systematic deviation from the line of identity, however visual plot 
provides a different interpretation.  
 
 





An approach to numerically test for non-constant deviation from the line 
of identity is presented in this chapter.   
This work arose from a need for a different metric to measure bias. The 
approach principally builds on the mean prediction error approach outlined by 
Sheiner and Beal in 1981 [5] in which their method is considered to be a special 
case of the current work. The suggested approach generalises the Sheiner and 
Beal method by allowing the prediction error to be computed in multiple data 
bins.  Increasing the number of bins from 1 to 2 allows the k^O to be computed 
in each bin and therefore provides the basis for assessing whether the bias is 
constant. Increasing the number of bins further allows a more granular 
assessment of how bias changes with changes in the magnitude of the predicted 
data. Regressing the k^O  values over the bin number provides a measure of 
total bias. If there is no systematic bias, the regression line will remain constant 
as the number of bins is increased. The first step completely captures the 
presence of systematic magnitude-driven bias but does not capture its 
quantitative properties.  The second step effectively determines the asymptotic 
slope of the bias if, in theory, an infinite number of bins had been chosen.  This 
is performed by finding the slope of the linear slopes and its asymptotic 
properties. The assumption that the regression shape will reach a plateau when 
systematic deviation occurs was consistent with the finding of this study. The 
approach presented here is a proposed solution to test whether the deviation 
from the line of identity that is associated with the magnitude of observation is 
significant. Primarily, this approach can be used to improve analysis of 
predictive performance.  
The method proposed in this chapter is able to capture monotonic 
departure from a specific linear model (in this case, the line of identity). The 
application of method proposed is therefore not limited to predictive 
performance analyses. The method of binning and regressing the residual slopes 
and estimating the slope  under conditions of infinite bins () can be applied to 




other statistical methods to test for departure from linearity. For example, the 
Bland-Altman plot [207] analyses the difference between two measurements (y-
axis) on a horizontal line (the mean of the two measurements) and the proposed 
binning method can be applied to test if the two measurements deviates in 
relation to the magnitude of the x-axis. The work completed in this chapter is 
effectively an alternative approach to the method suggested by Bland and 
Altman. 
Several scenarios were simulated to provide examples of how the method 
will work. The chosen examples represent typical scenarios where deviations 
from the line of identity can occur. The motivating example comes primarily 
from the work in Chapter 2 where predictions appear to follow the line of 
identity for lower observed data, but deviate away from the line of identity at 
higher observed values. Likewise, predictions that deviate at the lower observed 
values, but follow the line of identity at higher observed data (Scenario E) can 
also be seen in publications. Several scenarios such as scenarios B and F are 
unlikely to be seen in publications as the standard k^O approach would have 
captured the bias and it is visually clear. However, the reader may be deceived 
if a regression line is plotted instead of the line of identity because the regression 
line measures the association between the x and y variable. The correlation 
between x and y may be good but it does not indicate good predictive 
performance. What is important is the association along the line of identity.  
There are limitations to the current approach which can be divided into two 
types. The first relate to limitations to the method; 1) The approach does not 
capture non-monotonic deviation (Scenario G). It should be noted that the single 
bin k^O  approach by Sheiner and Beal also does not capture non-monotonic 
bias.  In this case, the researcher must visually assess the goodness of fit plot to 
find evidence of such deviation and a loess fitted function may be useful. 2) This 
approach does not work independent of the Sheiner and Beal single bin method, 
but rather is complementary. The flow diagram in Figure 4.11 below describes 




how decisions would be made using the Sheiner and Beal single bin k^O 






Figure 4.11 Flow chart of how decision would be made using the suggested approach  
3) The ?   does not capture the magnitude or direction of non-constant bias 
(positive bias or negative bias). 4) The value of ?  does not capture in which 
region the bias deviates from the line of identity (Scenario D and E deviate at 
opposite ends but the 95% CI of ? were positive for both scenarios) and hence 
provides a statistical interpretation only. 5)An adequate sample size is needed to 
provide a good estimate of ?. A sample size of at least 2 times  is needed 
for this approach to work because at least 2 data points are needed to calculate 
an average prediction error in each bin. 6) The number of bins ( ) is user 
dependent, but may be optimized in the future. In the simulations above, it 
appears that 10 bins are sufficient to provide an estimate for ? and increasing 
the number of bins does not change the inference. The second type of limitation 
relates to assessment of the proposed method. The current work only provides a 
theoretical evaluation of the proposed method. A wider range of scenarios 
should be tested for robustness and sensitivity of the proposed method.   
4.7. Conclusion 
A method for numerically testing non-constant systematic deviations from 
the line of identity based on a generalisation of the mean prediction error has 
been proposed. This proposed approach provides the first numerical test to 
assess for statistically significant non-constant systematic deviation and 
Calculate single bin 
k^O and compute   
Do not interpret the single 
bin k^O value because 
bias is not constant 
Conclude that total bias 
is the single bin k^O 
if  does not include zero 
if   includes zero 




therefore provides an additional interpretation to the standard single bin k^O 
approach. The method can be implemented easily in any statistical software.  















 Part III of this thesis describes two studies where the overarching aim is 
to explore dabigatran concentration monitoring as a means of guiding dose 
selection. Chapter 5 describes an assay to measure the concentration of 
dabigatran and its active metabolite, dabigatran acyl glucuronides, in human 
plasma. Chapter 6 describes a simulation study to select a suitable prior 
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This chapter is based on the following peer-reviewed publication: 
Saffian, S. M., et al. (2015). "Quantification of dabigatran and indirect 
quantification of dabigatran acyl glucuronides in human plasma by LC-
MS/MS." Bioanalysis 7(8): 957-966 
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Dabigatran is administered as the prodrug dabigatran etexilate that 
undergoes sequential hydrolysis in the intestine and liver via CES 1 and CES 2 
to form the active drug dabigatran [98]. Approximately 80% of dabigatran is 
excreted renally unchanged while the remainder is primarily glucuronidated 
and excreted renally [111]. In vitro data indicate that dabigatran and all four 
isomeric forms of dabigatran acyl glucuronides (see Figure 5.1) have equivalent 
anticoagulant effect in terms of the activated partial prothrombin time (aPTT) 
[103]. It is therefore important to measure all active dabigatran entities when 





Figure 5.1 Chemical structures. a. dabigatran; b. dabigatran 1-O-acyl glucuronide 
5.1.1. A brief introduction to acyl glucuronides 
Conjugation by acyl glucuronide is a phase II metabolic pathway that is 
common for drugs containing a carboxylic acid functional group (―COOH) and 
it has been found to be the major metabolic pathway for elimination for 
dabigatran [103]. An ester bond is formed at the β-1-O- position when the 
enzyme uridine diphosphoglucuronyl transferases catalyses the transfer of a 
glucuronic acid, a five-carbon pyranose sugar molecule (molecular weight 176 
g/mol), from uridine 5-diphosphoglucuronic acid to the carboxylic functional 
group of the drug molecule. Generally, acyl glucuronides increase the 
hydrophilicity of the drug to aid in excretion by the kidneys [208].  
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The ester bond of the acyl glucuronide conjugate is susceptible to 
nucleophilic attack which can lead to either hydrolysis or acyl migration, both in 
vitro and in vivo [208-210]. Hydrolysis occurs when water is the attacking 
nucleophile [208], which is catalysed by either high pH, high temperature or β-
glucuronidase enzymes [208, 211] which consequently back-converts (or 
deconjugate) to the parent drug. When the attacking nucleophile is the 
neighbouring hydroxyl group (R―OH) in the glucuronic ring, the acyl group 
(RCO―) migrates from position 1-O to 2-, 3- and 4- sequentially and reversibly 
around the glucuronic ring in the β configuration (Figure 5.2).  
 
Figure 5.2 Positional isomer formation of acyl glucuronide 
 
This reaction is called intramolecular acyl migration. The positional 
isomers 2-, 3- and 4- are more stable towards hydrolysis [212] and β-
glucuronidase [208, 213]. Reformation back to the β-1-O position, although 
possible, is unlikely to occur due to the higher energy requirement for this 
reaction to occur [208]. In theory, the corresponding β migration isomers can 
mutarotate to form an α configuration and further undergo reversible acyl 
migrations [213]. This has been shown for a few drugs such as probenecid [214], 
zomepirac [215] and diflunisal [216], but has not been shown for dabigatran acyl 
glucuronide [100]. Furthermore it is rarely observed in biological fluids [217]. 
Acyl glucuronides can also covalently bind to endogenous proteins through a 
Schiff base reaction [210, 218]. Since this chapter does not consider any biological 
implication of dabigatran acyl glucuronides, and several excellent reviews have 
been published on the topic [209, 219-221], no further discussion is presented 
here. 
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5.1.2. Quantification of acyl glucuronides using liquid chromatography-
tandem mass spectrometry/ mass spectrometry (LC-MS/MS) 
LC-MS/MS is a technique in analytical chemistry that combines physical 
separation of a mixture of analytes in the liquid chromatography column (HPLC) 
and mass analysis in the mass spectrometer (MS). Measuring drug concentration 
in biological fluids using LC-MS/MS can be divided into three steps; 1.) 
removing inferences in biological matrices in the sample preparation, 2.) 
separation of analytes by high performance liquid chromatography and 3.) 
identification of individual components by mass analysis. Care must be taken to 
control hydrolysis and acyl migration as the reaction can occur at any stage of 
the analysis. Separation of acyl glucuronide from the parent compound is 
therefore a key step to ensure accurate quantification of the parent compound 
and a pre-requisite for direct quantification (see next section). In general, 
lowering the pH and temperature will decrease hydrolysis and acyl migration. 
This section will proceed with a brief description of principles of LC-MS/MS and 
methods to optimize quantification of acyl glucuronides. 
Sample preparation for acyl glucuronides should be fast and simple. 
Samples should also be kept as cool as possible. This includes acquisition of 
sample from the patient, centrifuging to obtain plasma and storing in the freezer 
for analysis later. Although several sample preparation techniques such as solid 
phase extraction [222] and liquid-liquid extraction [223] has been used, protein 
precipitation is generally the preferred method due to its simplicity, and has also 
been the choice in other published dabigatran assay methods [224-226]. 
Acetonitrile is generally preferred as an extraction solvent when assaying acyl 
glucuronides as it is more inert. It has been reported that acyl glucuronides can 
react with solvents such as methanol and ethanol, possibly through methylation, 
leading to an increased rate of hydrolysis [227, 228]. 
Separation of acyl glucuronides from the parent drug using high-
performance liquid chromatography is relatively easy to achieve as acyl 
glucuronides are often more polar. Separation of acyl glucuronides from its 
parent compound is important because acyl glucuronides can back-convert 
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usually in the ion source, which results in an over-estimate of the parent 
compound. In contrast, the resolution of the four migration isomers, which is 
required to accurately quantify all four positional isomers if a direct method is 
pursued (see next section), is more difficult. Separation of carboxylic acid 
containing compounds can often be achieved by manipulating the ionic strength 
and the pH of the mobile phase [229-231], while separation of the migration 
isomers can be further resolved by changing the solvent strength and mobile 
phase flow rate [230]. Several studies have repeatedly found that the order of 
elution of the positional isomers remain the same (in the order of retention time 
4β < 1β < 3β < 2β in a reversed-phase column) irrespective of the structure of the 
parent compound [232-236].  
Triple-quadrupole tandem mass spectrometer is a highly sensitive and 
highly specific technique in analytical chemistry. Figure 5.3 is a schematic of a 
triple-quadrupole mass spectrometer set up. After analyte separation by liquid 
chromatography, the sample is first ionized and the analyte of interest is selected 
based on the mass to charge ratio (m/z) which is called the precursor ion. The 
precursor ion is then fragmented in the collision chamber to produce product 
ions that is again selected based on the m/z ratio. Each precursor ion has a 
distinct fragmentation pattern which will provide structural information to 
specifically detect each compound. 
 
  
Figure 5.3 A schematic of a triple-quadrupole mass spectrometer as used in this study.  
 
In the LC-MS/MS set up used in this study, two transition ions are 
monitored; one act as a qualifier and the other as a quantifier. Typically, the 
quantifier is often the product ion with highest response and product ion with 
the second highest product ion is used as a qualifier. The qualifier ratio is used 
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to confirm structural identification and should remain relatively constant 
between calibration samples and unknown samples (i.e. patient samples).  
One drawback in LC-MS/MS analysis is in-source fragmentation which 
is the dissociation of glucuronic acid from the parent drug in the ion source of 
the mass spectrometer [217, 237]. In-source fragmentation will result in ions that 
are identical to the parent compound which results in an overestimation of the 
parent drug if the acyl glucuronides are not well resolved from the parent 
compound chromatographically. Typically, it occurs in molecules with weaker 
bonds such as the ester bond of acyl glucuronide. Several steps can be taken to 
minimize in-source fragmentation. This include controlling the ion source 
temperature, declustering potentials, cone voltage the ionization method [156, 
217, 238, 239].  Electrospray ionization (ESI) is generally the preferred choice of 
ionization method compared to atmospheric pressure chemical ionization as it 
minimizes in-source fragmentation [240, 241].  
5.1.3. Direct and indirect quantification of dabigatran acyl glucuronide 
Dabigatran acyl glucuronides (DAG) can be quantified directly or 
indirectly. The direct method is where the parent dabigatran and dabigatran acyl 
glucuronides are simultaneously quantified from one aliquot. This is only 
possible if reference standards are available and the stability is controlled, as 
dabigatran 1-O acyl glucuronide has an in vitro half-life of 1 hour at 37ºC, pH 7.4  
[103]. DAG can also be indirectly quantified by dividing the samples into two 
aliquots; one aliquot to measure the free dabigatran concentration, and another 
aliquot that undergoes alkaline hydrolysis to release all the glucuronic acid from 
DAG. The post-hydrolysis dabigatran concentration (here termed ‘total 
dabigatran’) is the sum of dabigatran and the contribution from all DAG isomers. 
The DAG concentration can then be inferred from the difference between the 
concentrations of the two aliquots using the following equation:  
 
 ^¢t+|o >z £|eo|+|t |¢ns os¤¢¤>te£ =  (4¥¦¥=§ – 4©ª<<)    4¥¦¥=§  ×  100 
Equation 5.1 Calculation of dabigatran acyl glucuronide using indirect method 
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where   is the concentration of dabigatran after alkaline hydrolysis (i.e. sum 
of conjugated and unconjugated dabigatran concentration) and   is the 
concentration of dabigatran without alkaline hydrolysis (i.e. unconjugated 
dabigatran). 
5.1.4. Rationale for the study 
Since dabigatran and all four isomeric forms of dabigatran acyl 
glucuronides have equivalent anticoagulant effect, an assay to measure 
dabigatran and dabigatran acyl glucuronide in human plasma was needed for a 
clinical study of correlating all active dabigatran entities in plasma with effect. 
At the time when this study was conducted, a few human plasma LC-MS/MS 
assays of dabigatran, with the indirect quantification of DAG, have been briefly 
described in several clinical papers [108, 242, 243]. None of them provide 
sufficient detail for method replication and validation data according to the FDA 
guidelines [244]. Furthermore, while there have been four publications for assays 
of free (unconjugated) dabigatran [224-226, 245], these did not evaluate the 
stability of DAG and its potential influence on the quantification of dabigatran. 
Further, none of these papers describe whether the impact of in-source 
fragmentation of DAG interferes with the quantification of dabigatran. The 
present work therefore demonstrates a simplified and rapid sample preparation 
for the analysis of dabigatran and dabigatran acyl glucuronide in human plasma. 
5.2. Aims 
The initial aim of this study was to develop a direct quantification method 
of all the isomeric forms of DAG simultaneously with free unconjugated 
dabigatran. The assumption was that all four isomers (dabigatran 1-O, 2-O, 3-O 
and 4-O-acyl glucuronide) could be quantified using the 1-O acyl glucuronide as 
the reference standard. This has been the assumption when developing assays 
for acyl glucuronides [217]. However, during development of the assay, it was 
discovered that although the 2-, 3- and 4-O isomers fragment to the same product 
ions as the 1-O-isomer, the product ion to precursor ratios were different (i.e. the 
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qualifier ion ratio between calibration samples and patient samples were 
different). Therefore, direct quantification would require reference standards for 
all four isomers, in addition to approaches to control isomerization of the 
samples and calibrators. As the reference standard for the dabigatran 1-O acyl 
glucuronide was the only standard that was commercially and readily available 
at the time when the study was conducted, an approach to indirectly quantify 
the DAG was pursued. In this paper, a validated assay for the quantification of 
free dabigatran and all active entities of dabigatran (total dabigatran) is 
presented. This allows for an indirect quantification of DAG. Further, data on 
the stability of DAG and measures taken to ensure that DAG hydrolysis does not 
interfere with free dabigatran measurement are presented.  
 
There are 3 specific objectives of this study: 
1. To develop and validate an LC-MS/MS assay for dabigatran and 
dabigatran acyl glucuronides in human plasma 
2. To investigate the impact of temperature and pH on the stability of 
dabigatran 1-O-acyl glucuronide in human plasma 
3. To analyse dabigatran concentrations in patient plasma samples collected 
from a previous clinical study 
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5.3.1. Chemicals & materials  
Accurately weighed dabigatran and [13C6]-dabigatran internal standard 
(Figure 5.4) were purchased from Alsachim (Strasbourg, France) and dabigatran 
1-O acyl glucuronide was purchased as dabigatran 1-O-acyl glucuronide 
trifluoroacetic acid salt from Toronto Research Chemicals (Toronto, Canada).  
The purity of dabigatran and [13C6]-dabigatran was 97% and dabigatran 1-O 
dabigatran acyl glucuronide 95%. HPLC-grade methanol was purchased from 
Merck (Darmstadt, Germany), HPLC-grade acetonitrile was purchased from 
VWR International (IL, USA) and formic acid (analytical grade, 98–100% pure) 
was purchased from BDH (Poole, UK). Analytical grade sodium hydroxide 
(NaOH) and hydrochloric acid (HCl) were purchased from Merck (Darmstadt, 
Germany) and reagent grade ammonium formate from Sigma-Aldrich (St Louis, 
MO, USA). Distilled, de-ionized water was produced in house by a Milli-Q 
Reagent Water System from Millipore Corp. (MA, USA). Blank human plasma 
from healthy volunteers was collected in BD Vacutainer® K2 EDTA tubes for the 
preparation of calibration standards and quality controls.  
 
 
Figure 5.4 Internal standard (13C6 -Dabigatran) 
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5.3.2. Stock solutions, calibration standards and quality control samples  
Two stock standard solutions of dabigatran (one for calibration samples 
and one for quality control (QC) samples) and internal standard [13C6]-
dabigatran (2.0 mg/ml) were prepared by dissolving 10.0 mg of dabigatran or 
[13C6]-dabigatran in a mixture of dimethylsulfoxide (DMSO) & 50 mM aqueous 
HCl (95:5, v/v). Dabigatran 1-O acyl glucuronide stock standard solution (1 
mg/ml) was prepared by dissolving 1.0 mg, accurately weighed, in DMSO. The 
stock standard solutions were aliquoted into smaller quantities and were stored 
at -30ºC.  Intermediate standard solutions (one from calibration stock solution 
and one from QC stock solution) of dabigatran were prepared at 50 µg/ml in 
DMSO & 50 mM aqueous HCl (95:5, v/v). Serial dilutions were made from these 
and used to spike into drug-free K2 EDTA plasma at concentrations of 0, 2.5, 10, 
50, 100, 500 and 1000 ng/ml for calibration standards and 10, 100, and 1000 
ng/ml for QC samples. The internal standard [13C6]-dabigatran (100 ng/ml) 
working solution was prepared in water and stored at 4ºC.  
5.3.3. Sample preparation    
For quantification of free unconjugated dabigatran (without alkaline hydrolysis):  
In an Eppendorf tube, 50 µl of working internal standard solution was 
added to 50 µl of blank, standard, quality control or patient plasma sample. Then 
50 µl of 0.2 M ammonium formate buffer pH 3.5 was added and the mixture was 
vortexed. For protein precipitation, 200 µl acetonitrile was added and the 
mixture was vortexed. After centrifugation at 15,000 g for 5 min at 22±1.0ºC, a 50 
µl aliquot of clear supernatant was transferred to a 96-well plate and mixed with 
200 µl of water. The 96-well plate was centrifuged at 3500 × g for 5 min before 
injecting 20 µl into the LC-MS/MS system. 
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For quantification of total dabigatran (with alkaline hydrolysis): 
In an Eppendorf tube, 50 µl of working internal standard solution was 
added to 50 µl of blank, standard, quality control or patient plasma sample. For 
hydrolysis, 20 µl of 0.2 M NaOH was added and the mixture was vortexed 
thoroughly and incubated for 2 hours at 37ºC. Then the mixture was left to cool 
for approximately 5 minutes and 30 µl of 0.2 M HCl was added. For protein 
precipitation, 200 µl acetonitrile was added and the mixture was vortexed. After 
centrifugation at 15,000 g for 5 min at 22±1.0ºC, a 50 µl aliquot of clear 
supernatant was transferred to a 96-well plate and mixed with 200 µl of water. 
The 96-well plate was centrifuged at 3500 × g for 5 min before injecting 20 µl into 
the LC-MS/MS system. 
5.3.4. LC–MS/MS conditions  
An Agilent 6460 Triple Quadrupole LC/MS System, which consisted of an 
Agilent 1290 Infinity LC coupled to an Agilent 6460 Triple Quadrupole Mass 
Spectrometer with Agilent JetStream was used (Agilent Technologies, Santa 
Clara, CA, USA). A Poroshell 120 EC C18 2.7 µm, 50 × 3.0 mm column (Agilent 
Technologies, Santa Clara, CA, USA) equipped with a SecurityGuard C18 4.0 x 
3.0 mm cartridge (Phenomenex) was used. Mobile phase A consisted of water 
containing 0.2% formic acid and 10 mmol/l ammonium formate and mobile 
phase B was acetonitrile. The flow rate was 0.6 ml/min. Chromatographic 
separation was achieved by a linear gradient of 1-10% mobile phase B within 3 
mins. This was further increased from 10-20% B between 3 and 3.5 min followed 
by a steep increase to 90% B at 4 mins. This level was maintained for 1 min and 
returned to the initial condition from 5-5.2 mins and re-equilibrated for 1.8 min. 
Under these conditions, dabigatran eluted at 4.08 min and dabigatran acyl 
glucuronides at 3.5-3.9 mins. The total time for analysis was 7 min. The auto 
sampler was kept at 5°C. 
The mass spectrometer was operated in the positive ion mode using 
electrospray ionization (ESI). Drying gas temperature and flow rate were 200ºC 
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and 5 l/min, respectively, nebuliser gas pressure was 15 psi, capillary voltage 
was 3000 V, and sheath gas temperature and flow rate were 400ºC and 10 l/min. 
The optimized precursor-to-product ion transitions monitored for dabigatran [M 
+ H]+ and [13C6]-dabigatran [M + H]+  were m/z 472.0/289.1 and m/z 478.0/295.1, 
respectively, with a fragmentor voltage of 160 V, a collision energy of 26 V and 
a dwell time 100 milliseconds for both transitions. Qualifier ions were 
472.0/324.1 for dabigatran and 478.0/330.1 for [13C6]-dabigatran with a collision 
energy of 18 V and a dwell time of 20 ms for both transitions. Two transitions of 
dabigatran 1-O acyl glucuronide [M + H]+ were also monitored for completeness 
of hydrolysis and stability studies. The first transition (m/z 648.2/472.2) is 
specific to dabigatran 1-O-acyl glucuronide as the loss of 176 Da relates to the 
loss of glucuronic acid of 1-O but not the migration isomers [217]. The second 
transition (648.2/289.1) product ion is a fragment of dabigatran and thus 
nonspecific to DAG isomers (dabigatran 1-O, 2-O, 3-O, 4-O acyl glucuronide), 
but allowed for qualitative measurement of the migration isomers. MassHunter 
Workstation Software (B.06.00, Agilent Technologies, Santa Clara, CA, USA) was 
used for instrument control, data acquisition and analysis. 
5.3.5. Assay validation 
The validation was performed on both sample preparation procedures 
(with and without alkaline hydrolysis). Calibration curve samples and QC 
samples (n = 6 at each level) were prepared and analysed on three separate days 
to evaluate linearity, inter- and intra-day precision and accuracy, and recovery 
according to the US FDA guidelines for bioanalytical method validation for 
human studies [10]. Selectivity was evaluated by accessing the absence of 
interference from blank plasma samples obtained from six different individuals. 
The extraction recoveries and matrix effects were evaluated at the three QC 
levels (n = 6). Blank plasma from six different subjects was extracted and spiked 
to concentrations corresponding to the QC concentrations. Absolute extraction 
recovery was determined by comparing the peak areas of QC samples with those 
of the spiked extracted plasma blanks (representing 100% recovery). Matrix 
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effect was determined by comparing the peak areas of spiked extracted plasma 
blanks to peak area of samples spiked at corresponding concentration in a neat 
solution representing 100% (no matrix effect). 
For test of completeness of alkaline hydrolysis of DAG to dabigatran, 13.7, 
137 and 685 ng/ml DAG (the molar equivalent of 10, 100 and 500 ng/ml 
dabigatran) was spiked into blank plasma (n=3) and prepared with and without 
hydrolysis as described above. 
Long-term stability of dabigatran in plasma was assessed by storing a set 
of samples spiked at three concentrations (n = 3 for 50, 200 and 1000 ng/ml) at -
80ºC for 12 months. Evaluation of freeze–thaw and short-term stability were 
combined and was assessed by storing QC samples at -80ºC and thawing up to 
three cycles, after which samples were kept at room temperature for 4 hours 
prior to analysis. The stability samples for dabigatran were not acidified before 
freezing. The stability samples were analysed using free dabigatran sample 
preparation (without hydrolysis) and the results were compared with those of 
freshly prepared samples (n = 3 at each concentration). Post-preparative stability 
was evaluated by determining the concentrations of a set of QC samples and 
storing the samples in the 96-well plate at 5ºC in the auto sampler for 72 hours. 
The QC samples were reanalysed and the results compared with original values.   
Long term stability of DAG towards hydrolysis was assessed by storing a 
set of samples spiked at two concentrations (n = 3 for 100 and 1000 ng/ml) 
at -80ºC for 70 days. Freeze-thaw stability was assessed at two concentrations (n 
= 3 for 50 and 500 ng/ml) by storing spiked samples at -80 ºC, thawing to room 
temperature and repeated in three cycles. These samples were analysed 
immediately. Samples for long term and free-thaw stability of DAG were not 
acidified before freezing. For short term stability, samples were prepared in 
triplicates in a cold room (4ºC) and then kept for 4 hours under the following 
conditions; 4ºC and 22ºC, with and without addition of 0.2 M ammonium 
formate buffer (pH 3.5) and compared with a control set that was analysed 
immediately. All samples were prepared without hydrolysis and the 
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concentrations of dabigatran were measured, allowing the percent hydrolysis of 
DAG to dabigatran to be calculated.  
5.3.6. Assay application 
The assay was used to analyse plasma samples from a previous clinical 
study. A total of 58 patients provided either one (2 hours post-dose), two (2 and 
10-16 hours post-dose) or five (1, 2, 4, 8 and 10-16 hours post-dose) samples 
resulting in a total of 150 samples. The samples were collected in BD Vacutainer® 
K2 EDTA tubes and centrifuged for 15 minutes at room temperature without 
delay and the plasma was immediately stored at -80ºC until analysis. 
5.4. Results and Discussion 
5.4.1. Assay development 
The MS/MS parameters were optimized to produce the most abundant 
fragment ions for dabigatran using ESI in positive mode. The m/z transition of 
472/289 produced the highest signal-to-noise ratio and was used for 
quantification, which was also the case in several other assays [108, 225, 246]. 
Representative chromatograms of dabigatran (without and after alkaline 
hydrolysis) are shown in Figure 5.5 and Figure 5.6. The MS/MS parameters were 
also optimised to reduce in-source fragmentation of DAG to dabigatran, which 
readily occurs due to the thermally unstable ester bond of the glucuronide. It 
was not possible to completely avoid in-source fragmentation as seen in Figure 
5.7C where an earlier peak is seen in the dabigatran m/z 472/289 channel eluting 
at the same retention time (3.78 min) as DAG (Figure 5.7A and B). 
Chromatographic separation of dabigatran and DAG was therefore required to 
avoid overestimation of dabigatran due to in-source fragmentation. This was 
achieved by having a slow organic gradient from 0-3.5 mins.  
Ammonium formate pH 3.5 was used in our study to stabilize DAG 
against hydrolysis to dabigatran. Acyl glucuronides, in general, have been 
reported to be substantially more stable against hydrolysis and acyl migration 
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when the samples are kept below pH 4 [208, 211]. Other acids have been used to 
reduce the pH and stabilize DAG against hydrolysis [208, 237], but were not 
tested in this study.  
5.4.2. Assay validation   
The dabigatran and [13C6]-dabigatran peaks were free of interference from 
endogenous substances present in drug-free plasma (Figure 5.5A, 5.5B and 
Figure 5.6A, 5.6B). Plasma standard curves of dabigatran were adequately fitted 
by 1/x weighted quadratic regressions (r > 0.999) over the concentration range 
of 2.5 to 1,000 ng/ml. The absolute extraction recoveries and matrix effects are 
presented in Table 5.1. Mean extraction recoveries were >98% for both sample 
preparation methods. Some ionization enhancement was observed for 
dabigatran. However, this was corrected for by the isotopically labelled internal 
standard and the internal standard normalised variation between individuals 
was <4% CV. Hemolysed and lipemic samples were not tested in this work. The 
use of an isotopically labelled internal standard and the generally low matrix 
effects observed (Table 5.1) indicate that the internal standard corrects for any 
matrix interferences. Accuracy was demonstrated with the mean values being 
within 101-114% of the spiked values. Imprecision was small, as indicated by 
both intra- and inter-day CV of <9% at all concentrations except at the lower limit 
of quantification, LLOQ (<11%, Table 5.2).  
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Figure 5.5 Representative chromatograms of samples without alkaline hydrolysis. (A, 
B) Blank plasma. (C, D) LOQ = 2.5 ng/ml. (E, F) Patient sample 2 h post dose (219 
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Figure 5.6  Representative chromatograms of samples after alkaline hydrolysis. (A, B) 
Blank plasma. (C, D) LOQ = 2.5 ng/ml. (E, F) Patient sample 2 h post dose (290 
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QC samples that underwent alkaline hydrolysis (total dabigatran sample 
preparation) were within the limits of accuracy and precision observed for QC 
samples without alkaline hydrolysis (free dabigatran sample preparation). 
Therefore, a single standard curve prepared without alkaline hydrolysis could 
be used for both sample preparation methods. 
The incubation conditions for alkaline hydrolysis were sufficient to 
hydrolyse off all DAG to yield free dabigatran (mean recoveries of 101%, 103% 
and 96% for concentrations 10, 100 and 500 ng/ml dabigatran). Figure 5.7 shows 
an example chromatogram before and after hydrolysis.  
 
Figure 5.7  Representative chromatograms before (top) and after (bottom) alkaline 
hydrolysis of 137 ng/ml dabigatran 1-O-Acyl glucuronide in plasma. *Non-specific 
refers to the four isomeric forms of dabigatran acyl glucuronide (dabigatran 1-O, 2-O, 
3-O, 4-O Acyl glucuronide) 
 
Dabigatran was found to be stable (<10% deviation from nominal 
concentration) in plasma (Table 5.3) after three freeze-thaw cycles followed by 4 
hours at room temperature and for 1 year at -80ºC. The long-term stability data 
thus agrees with, and extends, dabigatran stability data reported previously 
[224-226]. The processed samples were stable for at least 72 hours at 5ºC for both 
methods of sample preparation (hydrolysis and non-hydrolysis). 
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% Recovery % Matrix Effect 
Mean ± SD Internal standard 
normalised mean ± SD 
Mean ± SD Internal standard 
normalised mean ± SD 
Dabigatran without alkaline hydrolysis 
LQC 10 104.9 ± 11.1 102.2 ± 5.8 112.7 ± 13.1 99.7 ± 4.0 
MQC 100 98.0 ± 4.9 100.7 ± 0.8 116.2 ± 7.7 101.0 ± 0.5 
HQC 1000 99.4 ± 10.7 99.4 ± 1.4 111.6 ± 4.1 99.8 ± 0.9 
Dabigatran after alkaline hydrolysis 
LQC 10 107.6 ±10.8 111.6 ± 6.2 123.8 ± 14.0 100.3 ±1.1 
MQC 100 98.7 ± 4.7 101.5 ± 1.0 124.3 ± 15.9 100.1±0.5 
HQC 1000 97.8 ± 6.0 100.1 ± 2.9 105.4 ± 8.3 99.5±0.8 
CV: Coefficient of variation; HQC: High quality control; LLOQ: Lower limit of quantification; LQC: Low quality control; MQC: Mid 
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± SD (ng/ml) 
Imprecision 
(%CV) 
Accuracy (%) Mean 
concentration 




Dabigatran without alkaline hydrolysis 
LLOQ 2.5 2.9 ± 0.2 6.1 114.2 2.8 ± 0.3 10.9 110.2 
LQC 10 10.5 ± 0.2 1.7 104.7 10.1 ± 0.8  7.5 101.4 
MQC 100 105.5 ± 2.7 2.6 105.5 102.3 ± 6.9 6.7 102.3 
HQC 1000 1105.3 ± 35.8 3.2 110.5 1049.2 ± 70.7 6.7 104.9 
Dabigatran after alkaline hydrolysis 
LLOQ 2.5 2.7 ± 0.2 7.7 107.1 2.7 ± 0.2 8.6 108.8 
LQC 10 9.5 ± 0.4 3.9 95.0 10.2 ± 0.9 8.4 102.0 
MQC 100 98.6 ± 3.6 3.6 98.6 102.7 ± 4.4 4.3 102.7 
HQC 1000 991.3 ± 35.3 3.6 99.1 1012.7 ± 38.6 3.8 101.3 
CV: Coefficient of variation; HQC: High quality control; LLOQ: Lower limit of quantification; LQC: Low quality control; MQC: Mid 
quality control; SD: Standard deviation 
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Table 5.3 Stability of dabigatran (n=3) in human plasma  









3 freeze-thaw cycles 
and 4 hours at 22°C 
(ng/ml) 
50 47.3 10 9.1 
200 200.2 100 94.7 
1000 976.2 1000 929.1 
 
Table 5.4 Stability of dabigatran 1-O-acylglucuronide (n=3) in human plasma 
(expressed as % hydrolysis to dabigatran) 



















100 6.9 50 3.2 0 5.1 1.0 16.9 
1000 6.9 500 3.4 0.4 4.2 1.2 15.8 
 
For DAG in plasma, ~7% hydrolysis was found after 70 days at -80ºC and 
~3% hydrolysis was found after 3 freeze thaw cycles (Table 5.4). DAG readily 
hydrolysed at room temperature (~17% after 4 hours), but could be stabilised 
against hydrolysis by adding ammonium formate pH 3.5 and lowering the 
temperature to 4ºC. The DAG acyl migration can be qualitatively observed by 
monitoring the transition m/z 648/289.  Figure 5.8 shows chromatograms of a 
sample that was left for 4 hours at room temperature, with and without 
ammonium formate pH 3.5. Figure 5.8E shows marked isomerization with 
multiple peaks that corresponds to the migration isomers. Besides protecting 
against hydrolysis, the addition of ammonium formate pH 3.5 also stabilises the 
1-O isomer against acyl migration (Figure 5.8B).  
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Figure 5.8 Representative chromatograms of 500 ng/ml dabigatran 1-O-Acyl 
glucuronide in plasma incubated for 4 hours at 22ºC with (top rows) and without 
(bottom rows) addition of 0.2 M ammonium formate pH 3.5. *Non-specific refers to 
the four isomeric forms of dabigatran acyl glucuronide (dabigatran 1-O, 2-O, 3-O, 4-
O acyl glucuronide) 
 
The results for DAG are thus consistent with what is generally reported 
for acyl glucuronides, in that hydrolysis can occur when freezing and thawing 
[208] and that low temperature and pH play important roles in stabilising acyl 
glucuronides [228, 247]. Therefore, for accurate and precise quantification of free 
dabigatran, the samples should be cooled and measured as soon as possible with 
the fewest freeze-thaw cycles, and ideally with the addition of ammonium 
formate to lower pH. In other bioanalytical assay studies of dabigatran in 
plasma, acid was added during sample collection [108, 246, 248]  or during 
sample preparation [225, 226, 249] while in one study, no acid was added [224]. 
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5.4.3. Assay application 
The mean total concentration of dabigatran in 150 patient samples 
measured in duplicates after alkaline hydrolysis was 124 ng/ml (range 0-427 
ng/ml). Deviations on duplicate values were <20% for 96.7% of the samples 
(145/150). QC and calibration samples were within 15% CV and bias. A 
representative chromatogram from a sample taken 2 hours’ post dose is shown 
in Figure 5.5E (without hydrolysis) and 5.6E (with alkaline hydrolysis).  
A subset of 16 samples was measured without alkaline hydrolysis, with a 
mean free dabigatran concentration of 146 ng/ml (range 12-299 ng/ml) and total 
dabigatran concentration of 161 ng/ml (range 11-349 ng/ml) in this subset of 
patients. Deviations on duplicate values were <20% for 87.5% of the samples 
(16/18). The range of DAG indirectly quantified in this subset of samples was 0-
39% of the post-hydrolysis (i.e. total) dabigatran concentration. However, due to 
the samples being collected prior to the development of the assay, the samples 
were not acid stabilized on collection. Therefore, the actual DAG concentration 
is likely to be underestimated, and the free dabigatran concentration 
overestimated. The remaining 132 samples were therefore not measured and the 
measurements obtained from this subset of 16 samples should be viewed only 
as an illustration of the indirect method for quantifying dabigatran acyl 
glucuronide. No inference can be made in terms of the relationship of free and 
total dabigatran concentrations from these data. 
The analysis of the data obtained from this study will be reported in the 
next chapter (Chapter 6). 
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5.5. Conclusion  
A sensitive LC–MS/MS assay with a simple plasma protein precipitation 
step was developed for the quantification of dabigatran, and the indirect 
quantification of dabigatran acyl glucuronide via alkaline hydrolysis. Data 
showing that DAG is unstable at room temperature if the pH is not lowered have 
been presented. It is therefore critical to lower the pH, preferably at sample 
collection, or at least during sample preparation for accurate determination of 
dabigatran. The assay was validated over the range of 2.5 to 1000 ng/ml 
dabigatran. It was found to give accurate and precise reproducible results and 
has been successfully applied to patient samples. 
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In the previous chapter, an LC-MS/MS assay for measuring dabigatran and 
dabigatran acyl glucuronide in plasma was developed. The assay was used to 
measure the sum of dabigatran and dabigatran acyl glucuronide (measured as 
dabigatran) from patient samples collected from a previous study. In this 
chapter, the measured dabigatran concentrations from Chapter 5 are used in a 
simulation based study designed to evaluate published population 
pharmacokinetic models for dabigatran. The purpose of this chapter is to select 
an appropriate prior model to be used for individualising dabigatran doses in a 
future setting. 
6.1. Introduction 
Dabigatran is an orally administered anticoagulant that acts by inhibiting 
thrombin. Dabigatran is a polar molecule (log P, pH 7.4 = −2.4). It is orally 
administered as a prodrug, dabigatran etexilate, which has low fractional oral 
bioavailability of approximately 7% [100]. The absorption of dabigatran etexilate 
is pH dependent and is increased in acidic conditions. In the formulation used 
clinically, dabigatran etexilate is coated onto a tartaric acid core to minimise the 
influence of pH at the absorption site [250].  
The pharmacokinetics of dabigatran have been well summarised in several 
publications [95, 111, 113, 243, 246, 251, 252]. The peak concentration and total 
exposure was found to be proportional over the investigated dose range of 50 to 
400 mg of dabigatran etexilate [111]. The terminal half-life of dabigatran is 
approximately 13 hours [113, 248] and a steady-state concentration is typically 
achieved after 3 days of twice-daily dosing [243, 253]. Approximately 20% of 
dabigatran is conjugated to form the pharmacologically active dabigatran acyl 
glucuronide [103]. Due to the difficulty in measuring dabigatran and dabigatran 
acyl glucuronide separately, as described in the previous chapter, many studies 
(see [111, 248, 251] for example), have measured the sum of (unconjugated) 
dabigatran and de-conjugated dabigatran acyl glucuronides (measured as 
dabigatran).  





For the purposes of this chapter, unless stated otherwise, “dabigatran 
concentration” refers to the sum of dabigatran and dabigatran acyl glucuronides 
(measured as dabigatran). 
Current dosing and monitoring guidelines by the manufacturer have been 
questioned by several authors [40, 254-257]. The contention is whether the 
existing variability between individuals in the dose-response is large enough to 
the extent that there are risks of side effects and treatment failure if the same dose 
is used for most patients. There have been calls for improved anticoagulation 
monitoring especially in patients with renal impairment, at the extremes body 
weight and those who are high risk of bleeding [40, 258]. There are published 
data that relates dabigatran concentrations to stroke and bleeding risk [10, 122], 
which suggests that monitoring and individualising the dose of dabigatran 
etexilate may improve the safety and efficacy of therapy.  
To date, there is no consensus on what constitutes a safe and effective 
therapeutic range for dabigatran plasma concentrations. There have been limited 
published studies exploring this issue to date. Chin et al [116] have proposed a 
target range of steady-state trough concentration for patients with non-valvular 
atrial fibrillation. This target range was derived from secondary analysis of 
published of phase III data [10, 94, 125, 259]. Briefly, Chin et al [116] extracted the 
logistic regression curves for stroke/systemic embolic events and major bleeding 
risk published by Reilly et al [10] and the numbers of subtypes of events 
contributing to ischaemic stroke/systemic embolic events and major bleeding in 
the RE-LY study [10, 94, 125, 259]. They then applied weightings for adverse 
events according to the hazard ratios of death as described by Eikelboom et al 
[118]. The two curves were combined by adding the two equations to produce a 
combined weight-adjusted risk curve. The authors then assessed the combined 
risk curves with different bleed and stroke scores and suggested a general target 
trough dabigatran concentration range of 30 – 130 ng/mL. The steady-state 
trough concentration is therefore an exposure metric of interest to guide dosing 





because it has been correlated with clinical outcomes including thromboembolic 
and bleeding events. 
A population pharmacokinetic model that captures the time course and 
magnitude of drug exposure, and accounts for pharmacokinetic differences 
between individuals as well as the factors which determine these differences can 
be used to individualise dosing [260, 261]. This can be accomplished by using the 
model to predict the dose required to achieve a target exposure metric of interest, 
such as the steady-state trough concentration, in each patient. An example of a 
population model that was used to guide dosing is a tobramycin population 
pharmacokinetic model in paediatric cystic fibrosis patients by Hennig et al [262]. 
The study aimed to assess the need for a target concentration intervention 
approach in the group of patients studied. The authors developed a tobramycin 
population pharmacokinetic model and used it to simulate doses to achieve the 
target area under the curve with 80-125% variability of the target. The authors 
concluded that dose adjustments using a target concentration intervention 
approach is needed to maximize the pharmacokinetic/ pharmacodynamic 
relationship to achieve the target area under the curve and can be achieved using 
their model. Likewise, this strategy can be applied to dabigatran dosing where a 
population pharmacokinetic model of dabigatran is used to predict a dose to 
achieve a certain probability of hitting the target concentration. 
Several population pharmacokinetic models of dabigatran have been 
published [263, 264]. These models were developed using ‘total’ dabigatran 
concentrations which is the same as the measured concentration from Chapter 5. 
Therefore, evaluation of the predictive performance of previously published 
models against our data is a logical first step in determining whether a model 
exists now that may be of value in dose-individualisation.  Such a model may be 
able to replace the need for developing another population pharmacokinetic 
model of dabigatran de novo to be used as a prior for future dose 
individualisation. Note the data generated from Chapter 5 were fairly sparse and 





there would be a significant risk of producing an under-determined population 
pharmacokinetic model.  
The overarching goal of this chapter is to identify the best population 
pharmacokinetic model that adequately describes the data from Chapter 5. If 
such a model is identified, it can be used in future work to inform the dose 
individualisation using Bayesian methodology. There are at least two options of 
how this goal can be achieved. The first option is directly using a suitable prior 
model in a Bayesian forecasting method dosing software. In this case, the 
underlying prior model should have good predictive performance of the 
external data. The parameter estimates for the individual can then be updated 
from the prior as more feedback becomes available so that is more refined and 
individualised to that patient. Equipped with individualised patient parameters, 
an accurate dosing schedule can be selected. If the prior model does not have 
good predictive performance, the second option is to use the best model from 
the literature and apply as a prior for analysis of the current data in a fully 
Bayesian population analysis. This would provide population parameter 
estimates associated with the current data that are stabilised by prior work. 
Stability of the model is important for the identifiability of model parameters 
and reproducibility of the model (i.e. same objective function value) following 
small perturbations in the input data or starting parameter values. The 
subsequent model is then used as a prior in a Bayesian forecasting method for 
dose individualisation for future patients. Option two is therefore, a two-step 
process. Notwithstanding the choice of pharmacometric methods to utilise the 
prior model, there remains a need to identify a suitable prior model. This 
provides the impetus for this chapter where the predictive performance of the 
published dabigatran models will be evaluated against the data generated from 
Chapter 5. 
The specific aims of this study are to identify all previously published 
population pharmacokinetic models of dabigatran and to evaluate the predictive 
performance of each model against the data set from Chapter 5. The prior model 





with good predictive performance can then be used to aid in dose 
individualisation of dabigatran. 
6.2. Methods 
6.2.1. Identification of a population pharmacokinetic models 
Medline and EMBASE databases were searched for published population 
pharmacokinetic models of dabigatran. The search terms included (“dabigatran 
or dabigatran etexilate”) AND (“Models, Theoretical” OR “Models, Biological”, 
“Models, Statistical” OR “algorithms” OR “population pharmacokinetics” OR 
“population analysis” OR “nonlinear mixed effects modelling” OR 
“NONMEM”) AND (“pharmacokinetics” OR “Dose-Response Relationship, 
Drug”). The search was limited to articles published in English and human 
studies. Citation records were searched for potentially relevant papers. The 
inclusion criterion was population pharmacokinetic models for plasma total 
dabigatran concentration. Population models were excluded if there was 
insufficient information in the published paper to enable stochastic simulations 
of dabigatran plasma concentration.  
6.2.2. Data source 
Dabigatran concentrations were measured as described in Chapter 5. This 
is the test data set used in this chapter. The data set was sourced from a previous 
published study by Chin et al [109]. The publication included blood sample 
analysis from 52 patients. Additionally, data from 6 patients were collected as 
part of the study but not published. The aim of the study was to explore the 
relationship between plasma concentrations of parent (unconjugated) 
dabigatran and four coagulation assays (INR, aPTT, thrombin time and diluted 
thrombin time) and to examine the contribution of fibrinogen variability to the 
thrombin time test variability in relation to unconjugated dabigatran plasma 
concentration. The data collected included the prescribed dose dabigatran 
etexilate, the time since the last dose was taken, the duration since initiation of 





dabigatran. Demographic data included weight, height, sex, indication for 
dabigatran and serum creatinine.  
The total number of patients in the data set was 58. Six patients who were 
starting dabigatran (first dose) and these each contributed 5 plasma samples (at 
approximately 1, 2, 4, 8 and 10-16 hours post a morning dose). The remaining 52 
patients had been on a specific dosing regimen of dabigatran for at least 10 days 
prior to sample collection and were assumed to be at steady state. Each patient 
either contributed one plasma sample (pre-morning dose, n=2), two plasma 
samples (pre-morning dose and 2 hours post morning dose, n=44) or five plasma 
samples (at approximately 1, 2, 4, 8 and 10-16 hours post a morning dose, n=6).   
A summary of the key demographic and pharmacokinetic features of the 
patients providing data for this study is provided in Table 6.1. The indication of 
dabigatran for all patients in the data set was thromboprophylaxis for atrial 
fibrillation, although this was not an inclusion criterion for the study.  
  





 Table 6.1 Characteristics of patients in the data set (n=58) 
Characteristics Median [IQR](range)* 
Age, y 67 [58-75] (38-94) 
Male, n (%) 44 (76) 
Total body weight, kg 95 [82-109] (56-187) 
Height, m 1.75 [1.7-1.8] (1.55-1.93) 
Serum creatinine (µmol/L) 93 [83-102] (64-125) 
Creatinine clearance (mL/min) # 64 [55-76] (23-106) 
Dabigatran etexilate MDR at sampling  
75 mg twice daily, n (%) 5 (9) 
110 mg twice daily, n (%) 25 (43) 
150 mg twice daily, n (%) 28 (48) 
Duration on dabigatran etexilate, weeks† 6.0 [4 – 9.5] (0-52) 
Proton pump inhibitor use, n (%) 13 (22.4) 
Drugs affecting P-glycoprotein function  
Amiodarone and/or verapamil, n (%) 10 (17.2) 
Phenytoin and phenobarbitone, n (%) 1 (2) 
Pre-dose plasma dabigatran concentration, 
ng/mL 
68 [45-89] (22-258) 
Number of samples per patient  
1 2 (ss) 
2 44 (ss) 
5 12 (6 ss and 6 initiating) 
* Unless stated otherwise 
† At the same dose-rate as at sampling 
# Creatinine clearance calculated using the method of Cockcroft and Gault  
IQR, interquartile range; MDR, maintenance dose-rate; ss, steady-state 
 





Figure 6.1 Individual profiles of dabigatran concentration versus time after dose. ID is individual subject. IDs 30, 31, 32, 36, 39 and 57 were 
individuals who were newly initiated on dabigatran (first dose), other IDs were patients who have initiated dabigatran for >10 days and were 
assumed to have reached steady-state concentration. Vertical blue dashed lines are when a dose was taken for individuals who contributed two 
samples – note that there are two dosing intervals for these profiles. All concentration profiles were dose-referenced to 150mg twice daily





6.2.3. Model evaluation 
Each pharmacokinetic model was evaluated in terms of its ability to predict 
the observed concentrations from the test data set. For the purposes of this 
analysis, the test data set was divided into the following groups: 
• Group A – All concentration data from patients initiating dabigatran.  
         These patients contributed 5 plasma samples (n=6). 
• Group B – All concentration data from patients assumed to be at  
                          steady-state, who contributed 5 plasma samples (n=6). 
• Group C – All concentration data from patients who contributed one  
or two concentrations at steady state at either pre-dose    
and/or post-dose timing (n=52). Note that this includes  
part of the data from Group B. 
Each of the population pharmacokinetic models were coded in MATLAB® 
(version 2015b, Mathwork, Natick, MA) using the same structural components, 
covariate relationships, error models and parameter values as the published 
model. For each model, one-thousand patients were simulated. 
Covariates were sampled non-parametrically from the demographics of the 
test data set. Covariates that were used in the published models but not available 
in the test data set (e.g. gastrin concentration) were fixed to the null value (see 
Table 6.2 for details). 
The input of the model is either a single dose or twelve doses of dabigatran 
etexilate 150 mg twice daily. Twelve doses were simulated to approximate 
steady-state.  
There was no execution model in this study as adherence and protocol 
violations were not considered in this work.  
For the purposes of comparison with simulated pharmacokinetic profiles, 
each observed concentration was dose-referenced to a 150-mg dabigatran 
etexilate twice daily dosing regimen. 





The predictive performance of each model was assessed by a visual 
predictive check (VPC): 
1. For Group A (full profile first-dose), the models were assessed using 
a VPC of concentration-time profile that covered the full dosing 
interval. The VPC was constructed with the median of the predicted 
and observed data and the 10th and 90th percentiles of the simulated 
data only. The 10th and 90th percentiles of the observed data were not 
included because the data were sparse. 
2. For Group B (full profile at steady state), the models were assessed 
using a VPC of concentration-time profile that covered the full 
dosing interval. The VPC was constructed with the median of the 
predicted and observed data and the 10th and 90th percentiles of the 
simulated data only. The 10th and 90th percentiles of the observed 
data were not included because the data were sparse.  
3. For Group C, the distribution and central tendency of the  pre-dose 
and 2-hour post-dose concentrations of the simulated were 
compared to the binned observed concentrations using box plots. In 
addition, for Group C, a Kolmogorov-Smirnov test (KS test) for two 
samples was used to compare the cumulative density distributions 
(CDF) of the simulated and observed pre-dose and post-dose 
concentrations, separately. A 1 value <0.05 was chosen to reject the 
hypothesis that both simulated and observed data have the same 
distribution.  
The simulation output and all statistical analysis were conducted using 
MATLAB® (version 2015b, MathWorks, Natick, MA).  See Appendix IV, section 
A4.1-4.3 for details of the MATLAB® code used for this analysis. 
  





6.2.4. Model selection 
The primary model selection criteria was driven by how well the model 
predicted the steady-state pre-dose concentrations of the test data set (i.e. the 
trough concentration). Secondarily, consideration was given to VPCs of the 
overall concentration-time profile. 
6.3. Results 
6.3.1. Published population pharmacokinetic models 
Five studies describing five dabigatran population pharmacokinetic 
models were found in the published literature. Two studies were excluded, (1) 
the population model by Delavene 2012 [265], excluded on the basis that the 
model was developed using only plasma unconjugated dabigatran 
concentrations, and (2) the population model by Liesenfeld 2013 [266], excluded 
on the basis that the model was developed from patients who were undertaking 
haemodialysis. The models required to describe extracorporeal elimination, are 
sufficiently different from our population to justify excluding this work. The 
excluded models are summarised in Appendix IV, Section A4.1 (Table A4.1). 
Table 6.2 provides a summary of the three population pharmacokinetic 
models included in the current study. All three models were two-compartment 
disposition model with first-order absorption and elimination. Fractional oral 
bioavailability (9) was fixed to 1 in the models by Liesenfeld et al 2011 and 
Dansirikul et al 2012 although the between subject variability for 9  was 
estimated. The study by Trocóniz et al 2007 did not include estimates of absolute 
or relative 9, or BSV on 9. Note that this is equivalent to a fixed the value to 1. 
All three models found Cockcroft-Gault creatinine clearance (as an estimate of 
renal function) to be a significant covariate on clearance. Typical values for 
apparent oral clearance ranged from 82 L/h to 124 L/h. Other covariates that 
were reported to be significant in specific models were serum creatinine and 
gastrin concentrations (Trocóniz 2007 [267]), atrial fibrillation (Dansirikul [263]), 
heart failure and South Asian ethnicity (Liesenfeld 2011 [264]), body weight 





(Dansirikul [263] and Liesenfeld 2011 [264]), blood haemoglobin (Liesenfeld 2011 
[264]), sex (Liesenfeld 2011 [264] and Dansirikul [263]), age (Trocóniz 2007 [267], 
Dansirikul [263] and Liesenfeld 2011 [264]), sex (Liesenfeld 2011 [264] and 
Dansirikul [263]) and co-medication (proton pump inhibitor and P-gp inhibitors 
in Dansirikul [263]; proton pump inhibitor, amiodarone and verapamil in 
Liesenfeld 2011 [264]).  In all three models, total dabigatran concentrations 
(dabigatran and dabigatran acyl glucuronide) were measured using LC-MS/MS. 
The study by Dansirikul et al 2012 was a population PKPD model, however only 
the pharmacokinetic component was used in this simulation.  PK and PD 
parameters in this study were sequentially estimated.
 
 




Table 6.2 Details of published dabigatran models 




Dose escalation in 





Dose in mg (n): 
12.5 od (27), 25 od 
(28), 50 od (30), 
100 od (40), 150 od 
(29), 200 od (28), 
300 bd (20), 150 od 
(41), 300 (46) qd. 
 
4604 observations 






did not contain 
tartaric acid). 





First order input 
 
Fixed effects ((?) 
 =0.265 h-1 l8l«=0.4 h 
¬/9=13.6 L h-1 
'/9 = 30.8L X/9=136L 8/9= 82.1 L h-1 
 
Covariates ((?) 
«|?+et = 0.633 
 
 
® = 0.363 
 
lo = 0.447 
 
BSV (CV%) 




Additive (ng/mL) = 0.375 
Proportional = 36.61 
 
First order absorption rate constant 
Absorption lag time 
Apparent intercompartmental CL 
Apparent volume of central compartment 
Apparent volume of peripheral compartment 
Apparent clearance (CL) 
 
 
Coefficient for serum gastrin concentration 
effect on 8/9 («|?+et concentration was 
fixed to 34.58 pmol L-1 in this study) 
Coefficient for serum creatinine concentration 
effect on l 
Coefficient for age effect on  
 
 
BSV in the apparent clearance 
BSV in  
 
 
Additive residual variability 
Proportional residual variability 
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! ×
«|?+et
34.58 ) 



























First order input 
 
Fixed effects ((?) 
 =0.754 h-1 l8l« =0.634 h 
9=1 (fixed) 
'/F=673 L X/9=345 L ¬/9 =35.5 L h-1 
8/9 =124 L h-1 
 
Covariates ((?) 
O50 = 56.7 (mL min-1) 
 
^>¹  = 1.29 
 
lo = −0.41 (% year-1) 
O+ℎt = 0.797 
 
»9 = 0.933 








| = 1.23 
 
First order absorption rate constant 
Absorption lag time 
Bioavailability 
Apparent volume of central compartment 
Apparent volume of peripheral compartment 
Apparent intercompartmental CL 
Apparent clearance (CL) 
 
 
CLCR value at which half of the maximum 
clearance is reached 
Power coefficient of the Emax CLCR and 8/9 
relationship 
Coefficient for age effect on 8/9 
Coefficient for South Asian ethnicity effect on 
8/9 
Coefficient for heart failure effect on 8/9 
Coefficient for blood haemoglobin 
concentration effect on 2/9 (»« 
concentration was fixed to 0.143 kg/L in this 
study) 
Coefficient for female effect on 8/9 
Coefficient for proton pump inhibitor effects 
on 9 
Coefficient for amiodarone on 9 
Coefficient for verapamil on 9 
 
 







'/F = 20.5 
9 = 44.3 
 
RUV (CV%) 
Additive (ng/mL) = 6.68 
Proportional = 32.8 
 
 
BSV in the volume of central compartment 
BSV in the relative bioavailability 
 
 
Additive residual variability 
Proportional residual variability 
   Covariate relationship 
8/9 = ((45 × 8#
( vw¦¼<ªv½[¾¿Àw¦¼<ªÁ 454Àw¦¼<ª
)) × (1 + (¸[|o
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 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Data from 4 phase 
I and 4 phase II 
studies containing 
healthy and 
patient data set for 





80 (1031), 1965 
(7931), 762 (7659) 
 
One of the trial 
data had different 
formulation to the 
final product. 3 of 




Others were the 
same as final 
marketed product. 





First order input 
 
Fixed effects ((?  
 
 = 0.754 h-1 
l8l« = 0.634 h 
¬/9 = 35.5 L h-1 
9 = 1(fixed) 
'/9=728 L 
X/9= 345 L 
8/9 = 111 L h-1 
 
Covariates ((?) 
84  = 0.00644 
È+  = 0.0110 
 
lo = –0.00662 
^^" = 0.854 
 
^o^ = 1.150 
 
l9 = 0.939 
 





First order absorption rate constant 
Absorption lag time 
Apparent intercompartmental 8 
Bioavailability 
Apparent volume of central compartment 
Apparent volume of peripheral compartment 
Apparent clearance (8) 
 
 
Coefficient for 84  effect on 8/9 
Coefficient for weight effect on apparent 
volume of central compartment 
Coefficient for age effect on 8/9 
Coefficient for proton pump inhibitors effects 
on 9 
Coefficient for P-glycoprotein inhibitors 
effects on 9 
Coefficient for atrial fibrillation effects on 
8/9 














 = 95.3 
9 = 44.7 
 
RUV (CV%) 
Proportional = 29.4 
 
BSV in the volume of central compartment 
BSV in the first order absorption rate constant 
BSV in the relative bioavailability 
 
 
Proportional residual error 
   Covariate relationship 
If 84>120mL/min: 8/9 = (45(1 + (¸[|o − 68] × (·Æ × (Æ) 
if 84<120mL/min: 8/9 = (45(1 + (454[8# − 120]) × (1 +
(¸[|o − 68] × (·Æ × (Æ) 
2/9 = (6' × (1 + (Ç[Èeoℎ+ − 80])  
9 = (Æ × (¸ × (   





6.3.2. Model evaluation 
6.3.2.1. Model performance against full-profile data from patients initiating 
dabigatran (Group A) 
Figure 6.2 shows the VPC of patients in Group A. Post-dose trough 
concentrations were under-predicted by the models of Trocóniz et al 2007 and 
Liesenfeld et al 2011. The model of Liesenfeld et al 2011 appear to under-predict the 
overall concentration profiles. The VPC plots show that the model published by 
Dansirikul et al appears to capture all other data points well and importantly pre-




Figure 6.2 A visual predictive check showing simulated concentrations at the first dose. 
The shaded area is the 10th to 90th percentile of the simulate and the dashed line in the 
middle is the median of the simulate, the blue line is median of the observed data. The 
dose-referenced observed concentrations are represented by red circles. 





6.3.2.2. Model performance against full profile data from patients at steady-
state, who contributed 5 plasma samples (Group B) 
Figure 6.3 shows the VPC plots for patients from Group B. Post-dose trough 
concentrations were under-predicted by the models of Trocóniz et al 2007 and 
Liesenfeld et al 2011. The model of Liesenfeld et al 2011 and Trocóniz et al 2007 both 
appear to substantially under-predict the overall concentration profiles. The VPC 
plots show that the model of Dansirikul et al appears to capture all data points well 
and the median of the post-dose trough concentrations were the closest to the 
observed data amongst the three models. However, there is greater spread of the 
between subject variability seen with the Dansirikul et al model.  










Figure 6.3 A visual predictive check of concentration at steady state. The shaded area is 
the 10th to 90th percentile of the simulate and the dashed line in the middle is the median 
of the simulate, the blue line is median of the observed data. The dose-referenced observed 
concentrations are represented by red circles  





6.3.2.3. Model performance against data from patients who contributed one or 
two steady state concentrations at either pre-dose or post-dose or both 
(Group C) 
Figure 6.4 shows a comparison of the predicted pre-dose concentration 
and 2 hours post-dose concentration against the test data set. Amongst the three 
models, the Dansirikul et al 2012 model appeared to predict the pre-dose 
concentration the best where the interquartile range overlapped the most out of 
the three models. The Trocóniz et al 2007 and Liesenfeld et al 2011 models appear 
to under-predict the pre-dose concentrations. There was generally close 
agreement between all model-predicted post-dose concentrations and the 
observed data for all three models. 
  
 
Figure 6.4 Box plots of pre-dose (top) and 2-hour post-dose (bottom) concentrations of 
the test data set versus predictions of three published dabigatran pharmacokinetic model. 
Boxes represent the 25th and 75th percentiles and the centre red line is the median. The 
whiskers correspond to approximately +/–2.7σ of the data. The ‘+’ symbols indicate 
outliers. The green horizontal line extends the 25th, 50th and 75th percentiles of the test 
data set.  





6.3.2.4. Kolmogorov-Smirnov test (KS test) for patients in Group C 
The cumulative density distributions of the pre-dose concentrations for all 
three models were statistically different from the test data set (p<0.05). The 
distribution of the 2-hours post-dose concentration of the Dansirikul et al model 
was also significantly different from the test data set (p<0.05). The result of each 
KS test is provided in Table 6.3. Figure 6.5 shows the cumulative density function 
for pre-dose and post-dose concentration for each model compared to the test 
data set. The KS test appears to favour models where the IQR of the model 
predictions are incorporated within the IQR of the data. Hence the post-dose 
predictions preferred Trocóniz et al and Liesenfeld et al. 
Table 6.3 Results of the Kolmogorov-Smirnov test of predicted pre-dose and 2 hours 
post-dose concentrations of dabigatran PK models compared to the data 
 
 
Trocóniz et al  
2007 
Liesenfeld et al  
2011 
Dansirikul et al 
2012 
 Pre-dose Post-dose Pre-dose Post-dose Pre-dose Post-dose 
p-value <0.001 0.70 <0.001 0.26 0.01 0.01 
 
  





     
 
 
Figure 6.5 The cumulative density function plot of predicted pre-dose and 2 hours post-
dose concentrations of the three models compared to the observed concentrations of the 
test data set.  





6.3.3. Model selection 
The primary measure was assessment of the trough concentrations.  
Visually the Dansirikul et al appeared superior to the other two models.  The KS 
test however did not support any model.  The secondary measures were the 
predictive performance over time, in these cases visually Dansirikul et al 2012 
model was preferred. The post-dose concentration, however, was visually better 
predicted by Trocóniz and the KS test rejected Dansirikul et al.  No model entirely 
adequately described the test data set.  However, the key interest were the trough 
concentrations which supported the use of Dansirikul et al as an initial starting 
point. 
6.4. Discussion  
In this study, the predictive performance of three population 
pharmacokinetic model of dabigatran were evaluated against external data in a 
simulation based study. The selection of models was mainly driven by data from 
patients at steady-state because the goal is to predict the maintenance dose and 
not a loading dose, although data from patients initiating dabigatran was still 
used for visual assessment. Three forms of VPC diagnostics (concentration-time 
profiles, box plots and CDFs) were used to determine the best prior model. The 
KS test appear to reject pre-dose trough predictions from all three models. Based 
on the CDFs and box plots, the 2-hours post-dose concentrations were better 
predicted by Trocóniz et al 2007 and Liesenfeld et al 2011, however both models 
under-predicted the pre-dose trough concentrations.  
The KS test has been used to assess predictive performance for model 
selection (see [268, 269]). It is a non-parametric test that is used to determine if 
two distributions (concentrations of the test data set and simulation in this case) 
are different. An advantage of the KS test is that it makes no assumption of the 
distribution of the data. One of the limitations of the KS test is that it tends to be 
more sensitive towards the differences at the center of the two CDFs compared 
to the tail ends. This is evident in Figure 6.5 where the CDFs of the post-dose 





concentrations for the Trocóniz et al and Liesenfeld et al models were close to 
distribution of the test data set at the central region and hence the null hypothesis 
was not rejected. 
In this study, none of the three models satisfactorily described the test data 
set. The Dansirikul et al model was selected on the basis of having the best 
predictive performance compared to the other two models at predicting the 
trough concentration, however the model does not adequately describe the 
entire concentration-time profile (specifically, the post-dose concentration). In 
light of this finding, an appropriate future direction for this research is to use the 
Dansirikul model in a full Bayesian population analysis with subsequent use of 
the resultant model as a prior in a Bayesian dosing tool (i.e. a two-step process). 
 The methods for assessing priors in this study were chosen because of the 
nature of the test data set. The majority of the data were from a sparse design. 
Only pre-dose concentration data were available from all patients and 2-hour 
post-dose concentrations were available from 56 out of 58 patients. Assessing a 
full VPC of the concentration-time profile alone was inadequate because only 6 
patients per group provided five data concentration time points. This makes the 
VPC highly sensitive towards outliers. Box plots were useful as the pre-dose and 
post-dose observed concentrations had differences in the actual timing when the 
samples were collected. By binning, it allows easy comparison between the 
simulated concentrations and the observed concentration in the test data set.  
There have been several similar studies where authors evaluate multiple 
population PK models to select the ‘best prior model’ for dose individualisation. 
Examples include publications by Wright and Duffull 2011 [1] (warfarin),  
Bloomfield et al 2016 [270] (tobramycin) and Zhao et al  2016 [271] (tacrolimus). 
Table 6.4 below summarizes the different techniques used by each study to 
evaluate and select the best model.  
  





Table 6.4 Methods used to select a prior model 
Author, year Models evaluated Diagnostic method 
Bloomfield et al 2016 [270] 8 tobramycin 
models 
MPE and RMSE 
VPC 
NPDE 
Wright and Duffull 2011  [1] 5 warfarin models VPC 





MPE, mean prediction error; RMSE, root mean squared error; VPC, visual predictive 
check; NPDE normalized prediction distribution error; pcVPC, prediction- and 
variability-corrected VPC 
  
As seen in Table 6.4, there are several methods used to select the ‘best prior 
model’.  There is no consensus on the preferred method [272].  The decision to 
select the best prior model is somewhat subjective and purpose-specific. An 
alternative approach to selecting the ‘best model’ is a hybrid model approach 
[273] which will be discussed in the next chapter in Section 7.1.2.3. 
The model by Trocóniz et al 2007 was the first population pharmacokinetic 
model of dabigatran to be published. It was developed with 287 patients who 
had primary elective total hip replacement surgery. The data was from a phase 
IIa dose escalation study (BISTRO I [274]). As noted above, the dosage form of 
dabigatran etexilate in this study was different from the final product used 
clinically (not formulated with tartaric acid). The model prediction showed a 
distinctly sharper peak concentration with steep decline post-peak concentration 
which resulted in over-prediction the observed peak concentrations and under-
prediction of the observed pre-dose concentrations. It is unclear if this could be 
due to the difference in the formulation used for this study.  
Figure 6.6. is a deterministic simulation at the mean parameter values in 
each of all three models overlaid. The simulated concentrations appear to be 
higher in Dansirikul et al model compared to the other two models 4-hours post-
dose onwards. This is mainly driven by differences in parameter estimates of 
clearance (67 L h-1 in Dansirikul model versus 89 L h-1 and 123 L h-1 L for Trocóniz 





and Liesenfeld models respectively). This is likely to be the main difference that 
visually supports Dansirikul et al over the other models in terms of predicting 
into the test data set. 
 
Figure 6.6 A deterministic simulation at the mean parameter values of each model. 
Simulation was for a 67-year-old, male, weighing 95 kg, with creatinine clearance of 64 
mL min-1.  
 
The full model by Trocóniz et al 2007 include different   and 8/9 
parameter values for <24 hours, as patients who have recently undergone 
surgery manifest gastric stasis and flip-flop kinetics. The differences in gastric 
motility within the first 24 hours’ post-surgery was reflected on pharmacokinetic 
parameters of absorption rate constant () (0.022 h-1 <24 hours versus 0.265 h-1 
>24 hours) and 8/9 (43.4 L h-1 <24 hours versus 82.1 L h-1 >24 hours). Figure 6.7 
is a deterministic simulation of parameter values < 24 hours and flip-flop kinetics 
can be observed.  






Figure 6.7 A deterministic of simulation of the Trocóniz 2007 model. The plot shows 
dabigatran plasma concentration versus time profiles after the first dose of 150 mg. 
 
A proportional error model was used for <24 hours post-surgery, but a combined 
error model was used >24 hours post-surgery. For this study, only parameter 
values and error models for > 24 hours post-surgery were used as steady-state 
conditions were simulated.  
The models published by Liesenfeld et al and Dansirikul et al were largely 
similar. Liesenfeld et al 2011 used the base model from the publication by 
Dansirikul et al 2012 in their model development. The Liesenfeld et al model was 
developed using the largest data set (n=9522) from a phase III (RE-LY) clinical 
trial in patients with atrial fibrillation [94] similar to patients in the test data set. 
In contrast, data for Dansirikul et al 2012 was sourced from 3 different data sets 
from eight phase I and phase II clinical trial studies, some of which included 
unpublished data from healthy volunteers and patients. Therefore, the 
heterogeneity in the data used to develop the Dansirikul et al model may have 





captured the variability in the test data set which may explain why the 
Dansirikul et al 2012 model had the best predictive performance. Individual 
parameter estimates may be improved using Bayesian forecasting, however this 
is not within the scope of this thesis but may be explored in subsequent studies.  
For patients who contributed two plasma samples, the samples were 
collected from two sequential dosing intervals. The median [range] of the first 
dosing interval was 13.3 [9.8-19] hours, and the median [range] of the post-dose 
samples were collected at 2.0 [0.7-2.2] hours. Evaluating the model performance 
using VPC is difficult, as the variability of the first dosing interval needed to be 
simulated and individual VPC would need to be generated and compared 
against the observed data. Therefore, this work was not done. Instead, the test 
data set was binned into pre-dose concentrations and 2-hours post dose 
concentrations and the model predictions were evaluated using box plots and 
the KS test. Binning the data may have resulted in some error, which is one of 
the limitations of this study.  
There are several other limitations associated with this study. The study 
was based on data where adherence was not formally assessed. Several variables 
such as serum gastrin concentration (used in the Trocóniz et al model) and blood 
haemoglobin concentration (used in the Liesenfeld et al model) was not available 
in the test data set. Therefore, missing variables were fixed to the null value 
which may have introduced some error. The results of this study are based on 
the assumption that the model was correctly replicated in MATLAB®. The coded 
models were able to be modified and to simulate the data. This is a form of 
quality assurance that the model has been coded correctly for the purposes of 
this study. This study is also based on the assumption that the demographics of 
the data set was collected without error. 
  





6.5. Conclusion  
Three population pharmacokinetic models of dabigatran were evaluated against 
external data. The dabigatran model of Dansirikul et al 2012 was found to have 
the best predictive performance amongst the three models. However, the 
precision of the parameters can be improved by conducting a full Bayesian 
population analysis. Therefore, this model will be used as a prior model in a full 
Bayesian population analysis before implementation in a Bayesian dosing tool 







































7.1.1. Synopsis of the thesis 
In this thesis, methods for predicting the maintenance dose of warfarin 
were evaluated and aspects of dabigatran concentration monitoring were 
explored.  The overarching premise of this thesis was that all anticoagulants will 
require dose individualisation and monitoring to ensure that the use of 
anticoagulants are safe and effective. The research questions addressed in this 
thesis were focused on the challenges that arise when attempting to predict the 
maintenance dose requirements for warfarin and dabigatran. Each drug presents 
a slightly different issue in terms of predicting a safe and effective dose. For 
warfarin, the target INR range has been well established and therefore this 
research focuses on dosing techniques to achieve the target INR. For dabigatran, 
a therapeutic range has been proposed but has not been well established. The 
research conducted in this thesis is an effort to provide dosing guidance if a 
target therapeutic range exist in the future.  
Chapters2 and 3 of this thesis explored the ability of current models to 
accurately predict the maintenance dose of warfarin. In Chapter 2, the predictive 
performance of the Bayesian dosing tool was assessed using data from two 
cohorts of patients. In both data sets, doses were over-predicted in patients 
requiring ≥7mg/day and the source of bias was not found to be a VKORC1 
genotype effect, nor was the posterior population sufficiently different from the 
prior population to be the driving force for the bias. In Chapter 3, the analysis 
was expanded to include a meta-analysis of all published warfarin dosing 
algorithms. It was found that all dosing algorithms studied, under-predicted the 
maintenance dose in patients requiring ≥7mg/day. It was proposed that a 
sufficiently mechanistic systems model is required to accurately and precisely 
predict the maintenance dose over the entire dose range.   
Chapter 4 presented a revised method for assessing the predictive 
performance of a dosing tool. This was a modification of the method for 
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measuring predictive performance originally suggested by Sheiner and Beal in 
1981 [5]. The motivation for this research can be found in Chapter 2 of this thesis 
and a previous work not described in this thesis [3] where the predicted doses of 
warfarin using a Bayesian method were found to be unbiased on average using 
mean prediction error. This was despite an observable systematic deviation at 
higher dose levels. A proposal to numerically test the significance of this 
deviation was described in Chapter 4. 
Chapter 5 describes an assay to measure dabigatran and dabigatran acyl 
glucuronide concentrations in human plasma. The sum of dabigatran and 
dabigatran acyl glucuronides is expected to have a better correlation with 
anticoagulation intensity of the patient and thus clinical outcomes.  The assay 
was used to analyse plasma samples that were available from a previous study 
[109]. The concentration measurements were used in the subsequent chapter. In 
Chapter 6, the predictive performance of published population pharmacokinetic 
models for dabigatran were evaluated against the observed plasma 
concentration data generated in Chapter 5. The goal was to select a prior model 
that could be used in a fully Bayesian forecasting tool in the future.  
7.1.2. This thesis in the context of other works 
7.1.2.1. Warfarin dosing 
The use of mathematical models to aid in dosing warfarin dates back to  
early computerised models developed by Nagashima [275] and  Sheiner [276] in 
1969. Subsequently, several other strategies have been proposed to improve dose 
predictions.  
Warfarin dosing nomograms are commonly used in the clinic to guide 
dosing during initiation. They are simple to use and provide the basis for 
standardising between clinical practice. However, as described in the 
introduction of this thesis, nomograms are usually fairly simple dose adjustment 
guides, usually assuming a linear relationship between warfarin dose and 
anticoagulation effect. 
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In recent years, the research on warfarin dosing has focussed on using 
individual patient genotype (mainly CYP2C9 and VKORC1) to predict the 
maintenance dose. Several published genetic algorithms have been developed 
and published using multilinear regression methods. The systematic review of 
the literature conducted in Chapter 3 included 22 separate dosing algorithms. 
These were generally designed to predict warfarin maintenance dose a priori, 
before therapy is initiated. Seven algorithms included the ability to update the 
dose prediction using a single INR measurement [30, 64, 74, 164, 191]. Several of 
these algorithms [30, 74] have been found to provide more precise and less 
biased dose predictions [3].  
There is conflicting evidence about whether the use of genetic algorithms 
for warfarin to predict the maintenance dose would result in improved INR 
control and patient outcomes (see Pirmohammed et al [85] and Kimmel et al [84]). 
From the research conducted in this thesis, it was found that multi-linear 
regression algorithms cannot accurately predict the maintenance dose for 
patients requiring higher daily doses. It was proposed in Chapter 3 that models 
developed that assume a linear relationship between dose and response are too 
empirical and not sufficiently mechanistic to allow extrapolation into new 
settings. In addition, these models do not appear to predict doses outside of the 
linear portion of the dose-response curve (>80% of maximal effect or < 20%).  It 
is contended that a sufficiently mechanistic model, such a warfarin PK model 
that is tied into a lumped model of the coagulation network [36] is needed to 
predict the maintenance dose across the entire range of dosing requirements [see 
Section 7.2.1].  
Recently, Xue et al [277] developed a warfarin PKPD model. The model 
accounts for the influence of CYP2C9, VKORC1 and CYP4F2 genotype, body size 
and composition. The pharmacokinetics of warfarin was described by a one-
compartment model. A sigmoid Emax model was used to describe the inhibition 
of prothrombin complex activity (a composite of all clotting factors) as a function 
of S-warfarin concentration to predict INR. The model is based on the theory that 
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the time to reach a certain concentration of fibrin so that a clot can form will be 
inversely proportional to the concentration of coagulation factors and 
consequently to prothrombin complex activity [278]. Therefore, this model has 
mechanistic flavours. Furthermore, the model was tied into a Bayesian forecaster 
and can be used to predict the INR or dose. The model has been implemented in 
a dosing software that is freely available online at https://www.nextdose.org/. 
There are several limitations to the research on warfarin dosing conducted 
in this thesis. The models were evaluated in terms of how well they predict the 
observed maintenance dose. However, the maintenance dose may not be the 
only ‘ideal’ dose. It may be better thought as a point estimate of an ‘ideal’ dose 
because there may be a range of maintenance doses that would achieve an INR 
within the therapeutic range of 2-3 for most patients. Furthermore, the 
maintenance dose definition varies between individual studies in Chapter 3. The 
data used in both studies do not account or control for adherence. It is possible 
that patients who are not compliant or are vitamin-K depleted may have 
difficulty maintaining a stable INR and require larger maintenance dose.  
7.1.2.2. Dabigatran assay 
 A bioanalytical assay for measuring dabigatran in human plasma was 
described in Chapter 5 [279].  To date, the research in Chapter 5 is still the only 
publication that fully describes an assay for dabigatran and dabigatran acyl 
glucuronides in human plasma. Additionally, the study provided important 
data on the (in)stability of dabigatran acyl glucuronides which has not been 
previously reported. Several additional assays for dabigatran have been recently 
been proposed [226, 280-284] as this remains an active research area. All of the 
assays measure parent dabigatran and none of the published assays account for  
the instability of dabigatran acyl glucuronide which has been shown to affect the 
concentration of dabigatran [279]. Assays that do not account for dabigatran acyl 
glucuronide will lead to underestimation of the anticoagulant moieties 
associated with use of dabigatran etexilate. It has been reported that the fraction 
of glucuronide conjugate can be high (exceeding 50% in individual patients 
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[101]), which is why it is important to account for the glucuronides when 
measuring dabigatran concentrations. Hence, an assay that properly determines 
total concentrations of dabigatran (i.e. dabigatran and dabigatran acyl 
glucuronide) was developed. The total dabigatran concentrations are expected 
to have a better correlation with anticoagulation intensity of the patient and thus 
clinical outcomes.  It is expected that a clotting screen (such as the thrombin time 
or diluted thrombin time) will predict clinical outcomes better than total 
dabigatran concentrations. However, currently, there are only data correlating 
clinical outcomes with total dabigatran concentrations, but not clotting times. 
When one or more coagulation assays are standardised between laboratories for 
dabigatran (as per warfarin and INR), then clotting times may be used. At 
present, dabigatran concentrations are the best metric to guide dosing. 
A direct quantification of dabigatran acyl glucuronide is potentially better 
than the indirect method as the assay errors with the indirect method may result 
in negative dabigatran acyl glucuronide concentrations. However, the major 
challenge to the development of a direct method is the acquisition of the 
reference standards for all four isomers of dabigatran acyl glucuronide and 
controlling the stability of dabigatran acyl glucuronide against hydrolysis and 
isomerization during sample storage and preparation.  
7.1.2.3. Dabigatran population PK models 
Chapter 6 explores the ability of pharmacometric models for dabigatran to 
predict into data from a new population. It may appear as a contradiction to the 
findings on warfarin dosing conducted in this thesis, where all current models 
for predicting warfarin doses do not work. In this instance, it is proposed that a 
model that is tied into a Bayesian framework (such as a MAP estimator or a full 
Bayesian forecasting method) may provide accurate and precise individual 
parameter estimates and therefore will extrapolate well into a new clinical 
setting.  
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In Chapter 6, three published population PK models of dabigatran were 
evaluated and the model that provided the best prediction of the test data was 
selected for future work. It is not uncommon for several population 
pharmacokinetic models to be published for the same drug. There are several 
reasons for performing repeated population analysis. This includes to quantify 
a specific source of potential variability (e.g. Liesenfeld et al 2013 assessed the 
influence of haemodialysis [266] on clearance) and to describe the 
pharmacokinetics in different populations (e.g. Karlsson et al 2009 [285] 
developed a population PK model of voriconazole in paediatric patients). 
Duffull and Wright 2016 [260] have discussed the benefit of repeated population 
analysis and what value it might add. The authors concluded that the PK of the 
drug is often well characterized within the first few population analysis and that 
future work on the base and covariate model may not be helpful, however, 
studies on special population will continue to add value.  
For this thesis, a de novo population pharmacokinetic model for dabigatran 
was not developed. The data available was sparsely sampled (see Chapter 6) and 
a model would have been under-determined. In this case, one way to avoid 
developing an under-determined model is to collect more concentration data 
from more patients which will incur cost, consume time, and ethics need to be 
considered. Therefore, the work conducted in Chapter 6 provide the means to 
accelerate research towards understanding of the needs for dose 
individualisation of dabigatran using published models. 
McDougall et al [273] proposed an alternative approach using a ‘hybrid’ 
model.  A ‘hybrid’ model incorporates as much information as possible from all 
prior models in a biologically plausible manner. Instead of selecting one ‘best’ 
model, the authors combined 6 prior models of voriconazole by averaging 
parameter values across studies. Several parameters could not be averaged due 
to variability in parameterisation and therefore authors had to handle each case 
separately. Covariate selection was based on biology and availability of data in 
a clinical setting as the model was intended for use in the hospital. This technique 
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of hybridising population models appears to be practical means of incorporating 
information from multiple population studies and is comparable to a meta-
analysis. This technique could be explored in the future. 
The main limitation of the research pertaining to dabigatran dosing in this 
thesis is that there is no consensus of a therapeutic range. If, from the work of 
Chin et al [116] or others, a therapeutic range exists for dabigatran, the 
development of a Bayesian forecasting method for dabigatran should reduce the 
probability of overdosing, resulting in bleeding, and the risk of under dosing, 
leading to potential treatment failures. Secondly, dabigatran etexilate dosage 
forms that exist in the market currently will limit the ability to individualise 
dosing. More clinical studies will be needed to warrant the need for availability 
of different dosage strengths in the future. 
7.1.3. Who benefits the most from dose individualisation tools? 
Dose individualisation in the clinic is a non-trivial process as it requires 
research into defining a therapeutic target and methods to achieve the target. 
Often, there is a paucity of information about improving patient outcomes with 
dose individualisation strategies.   
The main reason for individualising drug doses is that a standard dose will 
not be effective to all patients or will cause harm to some patients. In this regard, 
patients who are significantly different in terms of their dosing requirements (i.e. 
significantly smaller or larger than the average dose in the population) can be 
understood as those who would benefit the most from the use of tools to aid 
doing since these may minimise adverse drug reactions and avoid treatment 
failure. Therefore, methods that can accurately and precisely predict the dose for 
patients who require significantly smaller or larger than the average dose are 
likely to be the ones who would benefit the most. If a dosing tool works well at 
predicting doses for patients who require an average dose but fails to identify 
patients who require extreme doses, then it can be thought that it is a 
shortcoming of its application to those who really need the dosing tool. The 
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findings from Chapter 2 and 3 suggests that all current models for dosing 
warfarin cannot accurately predict the dose in patients at the upper quartile of 
the dose requirement, and therefore patients who need warfarin dosing tools the 
most do not benefit from any of the currently available dosing tools. 
7.2. Future work 
7.2.1. Future work on the dose individualisation of warfarin 
Future work to understand the dose-response relationship specifically in 
patients requiring higher doses is needed. The cause of bias in dose predictions 
in higher dose patients is unknown. It was hypothesized empirically based 
model is not sufficiently flexible to predict the dose. It is known that warfarin 
affects coagulation factors II, VII, XI, X and co-factors protein C and protein S. 
Each of these coagulation proteins has different half-lives and therefore the time 
course of effects on INR are different. It is plausible that the application of a 
single Emax model when used across a large range of dose–response values (as 
seen in the underlying model in Chapter 2) may not be sufficiently flexible to 
account for the inherent feedback and feedforward mechanisms of the 
coagulation network, which may be more apparent in patients requiring larger 
doses. It is proposed that a fully mechanistic is needed to capture the complex 
relationship between warfarin, clotting factors and INR. A mechanistic model is 
where the model is built on known biological and physiological mechanisms in 
which drives the observed drug effects [286]. Because of that, mechanistic 
models are usually better at extrapolation and may be able to account for the 
differences in patients requiring higher doses. 
The development of a mechanistic model for warfarin was not done in this 
thesis, but there has been work that was recently published by our research 
group towards achieving this goal. Ooi et al [287] developed separate models to 
describe the depletion of carboxylated clotting factor (II, VII, IX, X, protein C and 
S) concentrations following warfarin initiation. Each individual model was then 
combined to produce a single joint model. Currently, the model describes the 
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relationship between warfarin dose and the concentration of all six clotting 
factors. The link between depletion of clotting factor concentrations to INR has 
yet to be modelled.  
There are two other coumarins used clinically, which are phenprocoumon 
and acenocoumarol. The genotype influence on the metabolism and sensitivity 
of phenprocoumon and acenocoumarol is also an active research area. Several 
multilinear algorithms have been developed to predict the maintenance dose of 
phenprocoumon [288-290] and acenocoumarol [290-297]. The same technique of 
evaluating the predictive performance of dosing algorithms as conducted in this 
thesis can be applied for phenprocoumon and acenocoumarol dosing 
algorithms. If the same problem exists (i.e. bias at higher doses), this may 
indicate that there may be issues with the vitamin-K cycle of patients requiring 
higher doses that have not been explored. 
7.2.2. Future work on the approach for testing non-constant deviation 
associated with the magnitude of the observation 
Chapter 4 provides a metric for statistical assessment of non-constant 
systematic deviation from the line of identity.  This is the first such metric and 
provides significant value in the assessment of prediction equations. Currently, 
this method must be used in conjunction with the Sheiner and Beal single bin 
k^O method as described previously in Section 4.6.  
The future would warrant a single method that incorporates the Sheiner 
and Beal single bin k^O  metric and the   metric in one overall metric. The 
method should also include a single metric that provides the location of the start 
of the deviation and direction of deviation. Additionally, a method to assess non-
monotonic non-constant systematic deviation would be desirable. Furthermore, 
it would be preferable if the method is automated. 
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7.2.3. Future work on dose the dose individualisation of dabigatran 
The need for an adaptive dosing system must be further established. There is 
evidence that the current covariate based dosing method would result in treatment 
failure and adverse drug effect, but further research is needed.  
Future research that builds on the work conducted in this thesis includes 
pharmacometric research to incorporate the selected pharmacokinetic model to be 
used as a prior and to be applied to the data in a fully Bayesian population analysis. 
The prior model is then tied into a Bayesian forecaster that can then be used to 
determine an appropriate dose to achieve the proposed target concentration with a 
certain level of probability.  
Another research route would be to link the dabigatran model to the 
coagulation network model [36]. The coagulation model can then be used to identify 
a suitable clotting time assay that is sensitive not only to the concentrations of 
dabigatran but also the concentrations and sensitivity of clotting factors. This is 
likely to be a modification of the thrombin time assay which will need to be 
modelled into an existing coagulation model [36]. The coagulation network model 
may need to be simplified (i.e. lumped down) in order to estimate the parameters. 
There is a need for studies to clarify the contribution of anticoagulation effect 
of dabigatran acyl glucuronide. To date, very little information has been published 
about the pharmacodynamics of dabigatran acyl glucuronide. Only two 
publications [100, 103] that specifically studied aspects of dabigatran acyl 
glucuronide could be found. Both were conducted by the manufacturer during drug 
development [100, 103]. Blech et al [100] studied dabigatran metabolism and Ebner 
et al [103] studied the formation, in vitro stability and pharmacological activity of 
dabigatran acyl glucuronide. Ebner et al [103] reported equal pharmacological 
activity of dabigatran acyl glucuronide to the parent dabigatran, however these 
were measured using clotting activity assay (aPTT) and not receptor binding assays. 
There has not been any report on the inhibitory constant () values for dabigatran 
acyl glucuronides. If the  of the individual isomers of dabigatran acyl glucuronide 
have different   values, or dabigatran acyl glucuronide and unconjugated 
dabigatran   values are different, then measuring total concentrations of 
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dabigatran as done here and in other studies will not be appropriate and each acyl 
glucuronide isomer and unconjugated dabigatran should be treated as separate 
species. 
There is an urgent need of a specially designed study to define the target 
concentration for dabigatran. Serial measurements of dabigatran concentrations 
leading up to adverse events (stroke or bleed) or at least at the time of adverse event 
would be helpful to define the therapeutic range. 
A longitudinal study where concentrations of dabigatran are measured after 
several months of therapy will be useful to understand the inter-occasion variability. 
This has been explored in a small study [298], but  larger studies or in a different 
clinical setting is needed. Furthermore, if new plasma samples are collected, 
measurements of dabigatran and dabigatran acyl glucuronide can be obtained and 
a parent-metabolite model can be developed. This can help improve the 
understanding of the pharmacokinetics of all active entities of dabigatran. If 
dabigatran acyl glucuronides were eliminated by biliary excretion and not renally, 
as reported by the manufacturer [104, 252], understanding the pharmacokinetics of 
the glucuronide may be useful in events such as biliary obstructions where the 
model can be used to predict increased glucuronide concentrations that may 
potentially increase the risk of bleeding. 
7.3. Conclusions 
This thesis has identified the limitations of current warfarin dosing 
methods and have explored dabigatran concentration monitoring as a means of 
improving dose individualisation. It was found that all current warfarin dose 
prediction models poorly predict the maintenance dose for patients requiring 
higher than average daily doses. Neither methods based on Bayesian forecasting 
nor methods based on multi-linear regression were found to be able to accurately 
predict the maintenance dose of these patients. While the reason for the poor 
prediction remains unknown, it was hypothesised that all current models to 
predict warfarin dose were conceivably too empirical, and therefore inadequate 
to capture the complexity of the coagulation network in patients requiring higher 
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than average maintenance dose. It was proposed that a mechanistic model is 
needed to accurately predict warfarin doses in the future. 
Studies on the evaluation of the predictive performance of warfarin dosing 
tools identified a specific problem where the common metric used to measure 
predictive performance may not capture. This is where deviations from the line 
of identity are associated with the magnitude of observation. An approach to 
analyse such data was proposed and the method can easily be implemented into 
any statistical software.  
An assay for quantifying dabigatran and dabigatran acyl glucuronide in 
human plasma has been developed. It was found that the metabolite of 
dabigatran, dabigatran acyl glucuronide, was highly unstable and prolonged 
storage and improper handling of plasma samples will affect the accuracy of 
dabigatran concentrations as the dabigatran acyl glucuronides back-convert to 
form dabigatran. Given that the glucuronide is thought to have a similar 
anticoagulation activity to dabigatran, the sum of dabigatran and dabigatran 
acyl glucuronide should be measured to inform clinical decisions.  
The predictive performance of published population pharmacokinetic 
models of dabigatran was evaluated. A population pharmacokinetic model for 
dabigatran which adequately quantified the variability in the magnitude and 
time course of concentration in an external data set was identified. The selected 
pharmacokinetic model can provide a means of predicting the dose of 
dabigatran required to achieve the target concentration range and therefore 
provides a scientific basis of individualising the dose of dabigatran in the future. 
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described in Chapter 5 
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dabigatran and indirect quantification of dabigatran acyl glucuronides in human 
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A 2.1 MATLAB®  code for estimating proportion and 95% CI of a binomial test 
 
Estimating number of success (1) and number of trials (t) that was output by MedCalc 
Run_file 
 
%% Finding n and p that would give the exact proportion and CI as 
calculated by MedCalc software 




theta= [10 10]; % initial estimates for p and n 
  
[theta, fval] = fminsearch(@pkfun, theta)% the search function 
  
p = theta (1) % returns the estimated number of success (p) 
n = theta (1) + abs (theta (2)) % returns the estimated sample size (n) 
  
phat = p/n; % to calculate the 'calculated' proportion 
LCI_hat= betaincinv(0.025, p,n-p+1); % to calculate the 'calculated' lower 
CI 






prop = _____; % enter the proportion (p/n) 
LCI  = _____; % enter the lower CI calculated by MedCalc 
UCI  = _____; % enter the upper CI calculated by MedCalc 
  
p_hat= abs(theta(1)); % estimated success 
n_hat= abs(theta(2))+p_hat; % estimated trials 
  
obj1 = p_hat/n_hat - prop; % estimate the proportion 
obj2 = betaincinv(0.025,p_hat,n_hat - p_hat+1) - LCI; % estimate the lower 
CI 
obj3 = betaincinv(0.975,p_hat+1,n_hat - p_hat)- UCI; % estimate the upper 
CI 
  
objv= obj1^2 + obj2^2 + obj3^2; % minimize the sum of squares 
 
  




A 2.2 Scatter plots of the studies included in the meta-analysis 
Table A2.1 are studies and figures from which the data were extracted. Unless 
specified as per requirement of the copyright holder, all the figures included in Table 
A2.1 were reproduced with the permission from the copyright holder. All scatter plots 
were included except for evaluation by Wadelius et al [190] due to an inability to 
obtain permission to reproduce the figure from the publisher.  
Note that in the text of the chapter, the analysis was indexed according to each 
unique algorithm. Here, the figure is arranged according the published study from 
which the data was extracted from. 
  




Table A2.1 Scatter plots of the studies included in the meta-analysis 
Description Scatter plot 
Study: Kimmel 2013 [84] 
 
Algorithms evaluated:  
Clinical and genotype 
driven algorithms by 
Gage 2008 [24] and 
Lenzini 2010 [30].  
 
 
Reproduced from Kimmel et al 2013, with permission from 
Copyright Massachusetts Medical Society 
Study: Langley 2009 
[196] 
 
Algorithms evaluated:  
Gage 2008  [24], Wu 
2008 [193], Zhu 2007  









Study: Francis 2014   [194] 
 
Algorithms evaluated:  
Solomon 2004 [191] 
Le Gal 2010 [164] 
Anderson 2007 [145] 
Zhu 2007  [178] 
Sconce 2005 [143] 
Wadelius 2009 [190] 
        
 








Study: Santos 2015 [40] 
 
Algorithms evaluated:  
Santos 2015 [40], Klein 
2009 [6], Botton 2011 [36] 








Study: Saffian 2015 [3]  
 
Algorithms evaluated:  
Clinical and genotype 
driven algorithms by 
Gage 2008 [24], Klein 
2009 [69], Lenzini 2010 
[30] and Horne 2012 
[74] 
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Study: Ramos 2012 [64] 
 
Algorithms evaluated:  
Ramos 2012 [64], Lenzini 
2010 [30] and Klein 2009  
[68] 
Study: Pavani 2012 [167] 
 
Algorithm evaluated:  
Pavani 2012 [167] 
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Study: Klein 2009 [68] 
 
Algorithm evaluated:  
Klein 2009 [68] 
 
Reproduced with permission from (Klein et al 
2009), Copyright Massachusetts Medical Society 
Study: Gage 2008 [24] 
 
Algorithm evaluated:  
Gage 2008 [24] 
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Study: Linder 2009 [197] 
 
Algorithm evaluated:  
Zhu 2007  [178] 
 
Study: Shaw 2010 [199] 
 
Algorithm evaluated:  
 Gage 2008  [24] 
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Study: Roper 2010 [169] 
 
Algorithm evaluated:  
Anderson 2007 [145] 
Study: Lenzini 2007 [31] 
 
Algorithm evaluated:  
Lenzini 2007 [31] 
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Study: Pathare 2012 [192] 
 
Algorithm evaluated:  
Klein 2009  [68] and 
Pathare 2012 [192] 
Study: Sconce 2005 [143] 
 
Algorithm evaluated:  
Hatch 2008 [195] 
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Study: Pavani 2014 [299] 
 
Algorithm evaluated:  
Klein 2009  [68] 
 
  
 Appendix 2: Appendices to Chapter 3  
217 
 
A 2.3 Replication and evaluation of the extracted warfarin data from a sample of 5 
scatter plots 
The accuracy of data extraction was evaluated by replicating the data 
extraction for 5 scatterplots (approximately a 10% sample) which by another 
researcher who was not part of the study (Table A2.2). The relative difference 
between the original and replicated data extraction were compared. A relative 
difference of less than 10% and was considered acceptable.  
 
Table A2.2 Replication and evaluation of the extracted scatter plot of warfarin data 
Scatterplot, figure 
from which the data 
was extracted in the 
published article 


















Klein 2009, S8 [68] 0.94 -2.55 0.94 -2.53 
Roper 2010, 3C [169] 0.98 -2.56 0.93 -2.46 
Gage 2008 [24] in 
Corrigendum [198] 
0.97 -2.16 0.95 -2.20 
Francis 2011, 1F [194] 0.93 -2.07 0.93 -2.05 
Francis 2011, 1D 
[194] 
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A3.1 MATLAB® code to test for systematic deviation from the line of identity 
 
% Code for analysing systematic deviation from the line of identity 
% Shamin Saffian 
% last updated 22/02/2017 
clear; clc; clear all; close all; 
  
%% Create data 
n=50; % observations 
rng (63) 
  
%% Simulate scenario 
Scenario_A % no bias 
% Scenario_B % non-systematic +ve bias 
% Scenario_C % off set, and systematic bias 
% Scenario_D % systematic deviation at the top (motivating example) 
% Scenario_E % systematic deviation at the bottom 
% Scenario_F % +ve bias systematic deviation at the top 
% Scenario_G % non-monotonic bias 
% Scenario_1a % no bias 
% Scenario_1b % systematic bias 
%% defining bin edges 
  
topEdge = max(x)+0.0001; % define top edge limits (a small value is 
added... 
                         % so that values that lie exactly on the bin 
Edges are included) 
botEdge = min(x); % define bottom edge limits  
  
nbins = 2; % start with 2 bins 
tnbins =10; % total number of bins 
  
%% Single bin MPE 
PE = x-y; % prediction error 
MPE = sum(PE)/n % mean prediction error 
se= (std(PE))/(sqrt(length(PE))); % std error of each bin 
quantile = se * 1.96; % for 95% confidence interval 
Up_Lim95CI=MPE+quantile % Upper limit 
LowLim95CI=MPE-quantile % lower limit 
  
%% Infinite bin MPE approach 
  
% Step 1 and 2 - Create n number of bins and calculate MPE in each bin 
for j = 1:(tnbins-1)% we start with 2 bins, so tnbins-1 
    binEdges = linspace(botEdge, topEdge, nbins+1); % defined the bin 
edges - linearly spaced vector 
    [h,whichBin] = histc(x, binEdges); % this sorts x-values according 
to the bin 
     
   for i = 1:nbins 
    flagBinMembers = (whichBin == i);% flagging bin members 
    binMembers     = PE(flagBinMembers);% calculate the PE in each bin 
    binMean(i)     = mean(binMembers);% gives MPE of each bin (Step 2) 
   end 
  
MPE_bin=binMean';  % MPE of each bin 
bin_number=(1:nbins)';% bin numbers 
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%% Step 3 regress MPE by bins 
  
X = [ones(size(bin_number)) bin_number]; 




plot(bin_number,MPE_bin,'o');lsline % regression line 
set(gca,'xtick',0:1:tnbins); xlim([1,tnbins]);ylim([-1 1]); 
xlabel('bin number'); ylabel('mean prediction 
error');%saveas(gcf,'Fig3.jpg') 
%% Step 4 - increment n and repeat the loop (Step 1 - 3) 
nbins = nbins + 1; % increment n until it reaches tnbins 
  




figure(2)% plot data with bin edges 
    hold on 
    plot (x,y,'k.','markersize',10);% Plotting x y 
    set(gca,'fontsize',12) 
    line([0,16],[0,16]); 
    ylabel('Observed data','fontsize',15); xlabel('Predicted 
data','fontsize',12) 
    xlim([0 15]);ylim([0 15]) 
for x_edge = binEdges % putting lines on the binEdges 




%% Step 5 - regress slope vs bins  
  
bins=(2:tnbins)'; % bins 
slope= slope';% slope 
  






    {'theta','s_inf','s_init'});% defining model, dependent, 
independent variables, and parameters 
myfit2 = fit(bins,abs(slope),myfittype)  
  
%% Plotting 
figure(4)%plot for slope vs bins 
plot(myfit2,bins,abs(slope),'o') 








noise = randn(n,1); % artificial noise 
x = 0.5+rand(n,1) *14; % random numbers 
y = x+0.5*noise; % Data with noise 
y2= x; % Data without noise 
 
Scenario_B 
noise = randn(n,1); % artificial noise 
x = 0.5+rand(n,1) *14; % random numbers 
y = x+0.5*noise-2; % Data with noise 
y2= x-2; % Data without noise 
 
Scenario_C 
noise = randn(n,1); % artificial noise 
x = 1+rand(n,1) *14; % random numbers 
y = 0.8*x+noise*0.5+1.5; % Data with noise 
y2= 0.8*x+1.5; % Data without noise 
 
Scenario_D 
noise = randn(n,1); % artificial noise 
x = 2+rand(n,1). *12; % random numbers 
y = 1.25*x-0.5*exp(x). ^0.175+0.5*noise+0.25; % Data with noise 
y2= 1.25*x-0.5*exp(x). ^0.175+0.25; % Data without noise 
 
Scenario_E 
noise = randn(n,1); % artificial noise 
x = 1+rand(n,1) *13; % random numbers 
y = x-log10(x)+0.5*noise+0.9; % Data with noise 
y2= x-log10(x)+0.9; % Data without noise 
 
Scenario_F 
noise = randn(n,1); % artificial noise 
x = 2+rand(n,1). *12; % random numbers 
y = 1.25*x-0.5*exp(x). ^0.175+0.5*noise-0.75; % Data with noise  
y2= 1.25*x-0.5*exp(x). ^0.175-0.75; % Data without noise 
 
Scenario_G 
noise = randn(n,1); % artificial noise 
x = 1+rand(n,1). *11; % random numbers 
y = exp(x*0.25). ^0.75+0.35*x+0.5*noise+0.25; % Data with noise 
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A3.2 Workings for Scenario A  
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A 3.3 Workings for Scenario B  
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A 3.4 Workings for Scenario C 
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A 3.5 Workings for Scenario D 
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A 3.6 Workings for Scenario E 
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A 3.7 Workings for Scenario F 
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A 3.8 Workings for Scenario G 
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A4.1 Models for dabigatran population pharmacokinetics not evaluated in Chapter 6 
Table A4.1 Summary of published population pharmacokinetic models for dabigatran not already summarised in Chapter 6 
Author Study details Structural 
model 
Parameter estimates  Description 
Liesenfeld 
2013 [266] 
Data from Phase I 
dialysis [300] 
 
n = 7 
 
A population PK 
model to quantify 










First order input 
 
Fixed effect ((?) 
l =0.821 h-1 
l8l«=1.67 h 
l8l«X =1.67 h ¬/9=152L h-1 
'/9 = 531 L X/9=499 L 8/9= 12.4 L h-1 
9= 1 
O50 = 0.556 h 
 
 
9ÉÊË _ = 0 
 
»ess = 6.10 
 
Ql= 313 mL min-1 
 
 
First order absorption rate constant 
Absorption lag time 
Absorption lag time of the third dose (fasted) 
Apparent intercompartmental 8 
Apparent volume of central compartment 
Apparent volume of peripheral compartment 
Apparent total body clearance (8) 
Absolute bioavailability 
Time between dose administration and food 
intake at which the effect on bioavailability is 
half of the maximum effect 
Minimum bioavailability when time between 
dose administration and food intake (fixed) 
Hill factor describing the steepness of the 
relation between time to food intake and the 
relative bioavailability 
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  BSV (CV%) 
8/9  = 40.4 









Proportional = 8.5 
 
BSV in the apparent total body clearance 
BSV in the apparent volume of distribution of 
the central compartment 
 
Interoccasion variability in the relative first-
order absorption rate constant 




Proportional residual variability 
  Covariate relationship 
TÍÎÏÎÐÑ/Ò = TÍÓiÐÑÔÕiÕ/Ò  N ÖTÍ/Ò  
9X _  = (Æ!_ _   
N  (1 − (Æ!_ _)  × z>>£v×Ø§§_©¦¦Ù¥ØÚ<
/((4PQ vÅ  N z>>£_+e~vÅ ) 
 
 











300mg DE or  
300mg DE + 500mg 
Clarithromycin 
 
A PKPD model to 


















.9Û ·Ü'Ý46Þßà  ×
01á
(¥áâãä)ß






passes into the 
central 
compartment 
during the time 
interval dt, D is 
the dose 
administered at 
time t  
Fixed effect ((?) 
kl}=1.65 h 
Z=0.622  9=0.065 
9 ∗=0.101 
'=48.3 L X=68.7 L ¬=20.6 L h-1 

















Mean absorption time 
Relative dispersion of absorption time 
Bioavailability (fixed) 
Bioavailability in presence of clarithromycin 
Volume of central compartment 






BSV in the mean absorption time 
BSV in the relative dispersion of absorption 
time 
BSV in the bioavailability  
BSV in the bioavailability in presence of 
clarithromycin 




Proportional residual variability 
Additive residual variability 
CV, coefficient of variation; SD, standard deviation, BSV, between subject variability, RUV, residual unexplained variability
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A4.1 A MATLAB® code for simulating dabigatran population PK models 
1. MATLAB® code for simulating the Troconiz 2007 model 
Run file (go_dabi_Troconiz.m) 
%% simulating dabigatran popPK model by Troconiz et al 2007 
clear all; close all; clc; tic 
rng(63) % random number generator seed 
rep=1000;% number of patients to simulate 
  
data_ori = xlsread('data_dabi_all.csv');%original data set 
[rows, columns] = size(data_ori); 
ID = datasample(1:rows,rep,'Replace',true);%resample 1000 IDs with 
replacement 
data = data_ori(ID,:);% resampled dataset 
[rows1, columns1] = size(data); 
%% dosing  
dose=150*10^3; % in mcg 
dose_number=12;% dose number 
di=12; 
options = odeset('RelTol',1e-6,'AbsTol', 1e-6);% ignore 
  
%% run the model 
init_PK_param_dabi_troco % initialises PK parameters 
  
   for i=1:rep;% first loop through each patient 
    pt_data = data(i,:); 
    get_patient % simulates a patients' PK parameter  
     
    start=1;% start 1 dose  
    D =[dose 0 0];% dosing in gut compartment 
    inits = [dose 0 0];% initial condition in the compartment also can 
code as inits = D; 
    time_dose=0+ALAG(i); % start dose 1 
     
    for jj=1:dose_number % loops through each dose and calculates the 
concentration 
              
        TT=[0:1:di];% this is to tell MATLAB to solve the ODE for each 
TT 
        stop=start+length(TT)-1;% defining when to stop 
        sol=ode45(@ode_dabigatran,[0 
di],[inits],options,KA(i),CL(i),V2(i),Q(i),V3(i));% differential 
equation solver nonstiff, medium accuracy 
        A2=deval(sol,TT,2); % amount in compartment 2 
          
        conc=A2./V2(i); % concentration of dabi 
        inits=deval(sol,di)'+D;% updates inits and adds another dose 
in the gut compartment 
  
%         EPS1=normrnd(0,sigma1,size(conc));% prop error <24hrs  
        EPS2=normrnd(0,sigma2,size(conc));% prop error >24hrs 
        EPS3=normrnd(0,sigma3,size(conc));% add error >24hrs 
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% if jj<3 
%         C2(i,start:stop)=conc+conc.*exp(EPS1); %adding in prop RUV 
to concentration 
% else 
        C2(i,start:stop)=conc.*exp(EPS2)+EPS3; %adding in prop RUV to 
concentration 
% end 
        T(i,start:stop)=TT+time_dose;% time 
         
        if jj==12 
            C_post=C2(i,start+2); 
            C_peak(i,:)=C_post;        
        end 
         
        start=stop;% updates the start point for the next iteration 
starting from where it stops 
        time_dose=time_dose+di;% add the next dose time 
         
        if jj==11 
            C_pre=C2(i,stop); 
            C_trough(i,:)=C_pre;        
        end 
    end 
   end 
  
   plot_graph % calls plotting code 
   stats2 % calls statistics code 
    
% xlswrite('Percentiles_Troco.xlsx', Conc3); 
% xlswrite('Time_Troco.xlsx', T); 
toc 
 
Initialisation file (init_PK_param_troco.m) 
%% Defining THETA AND ETA 
THETA=[0.022 0.4 13.6 30.8 136 43.4 0.265 82.1];% KA, ALAG, Q, F, V2, 
V3, CL KA24 CL24 
MEANETA=[0 0 0 0 0 0 0 0]; 
OMEGA_parTroco=[ 0 0 0 0 0 0       0        0; % KA 
                 0 0 0 0 0 0       0        0; % ALAG  
                 0 0 0 0 0 0       0        0; % Q 
                 0 0 0 0 0 0       0        0; % V2 
                 0 0 0 0 0 0       0        0; % V3 
                 0 0 0 0 0 1.086^2 0        0;% CL <24 
                 0 0 0 0 0 0       0.2983^2 0;% KA>24 
                 0 0 0 0 0 0       0        0.4604^2];% CL 
           
ETA = mvnrnd(MEANETA,OMEGA_parTroco,rep); 
  
%% variance 
sigma1=0.669; % Proportional error <24hr 
sigma2=0.3661; % Proportional >24hr 
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get_patient file (get_patient_troco.m) 
%% simulating PK parameters  
ID_COL=1; SEX_COL=3; AGE_COL=4; WT_COL = 5; PPI_COL=6; AMIO_COL=7; 
VERA_COL=8; CLCR_COL=10; SCR_COL=11; DI_COL=19; 
  




%% Simulating individual parameters 
% if jj<3 
%     KA=THETA(1)*exp(ETA(:,1)); 
% else 
    KA=THETA(7)*exp(ETA(:,7))*(1+THETA_AGE*pt_data(AGE_COL)/66.97)*(1-
THETA_SCR*(pt_data(SCR_COL)/88.42)/0.964); 







%% GAST is fixed to the null value 
GAST=34.58; 
  
% if jj<2 
%     CL=THETA(6)*exp(ETA(:,6))*(1+0.633*GAST/34.58); 
% else 





PK=[KA(i) ALAG(i) Q(i) V2(i) V3(i) CL(i)]; 
mat(i,:)=PK;% to check simulated PK parameters 
 







dAdt=[-KA*A(1)% central compartment 
      KA*A(1)-k20*A(2)+k32*A(3)-k23*A(2)%intercompartments 
      k23*A(2)-k32*A(3)]; 
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2. MATLAB® code for simulating the Liesenfeld 2011 model 
Run file (go_dabi_Liesen.m) 
%% simulating dabigatran popPK model by Lisenfeld 2011 
clear all; close all; clc; tic; warning off; 
rng(63); 
  
rep=1000;% number of patients to simulate 
  
data_ori = xlsread('data_dabi_all.csv');% original data set 
[rows, columns] = size(data_ori); 
ID = datasample(1:rows,rep,'Replace',true);% resample 1000 IDs with 
replacement 
data = data_ori(ID,:);% resampled dataset 
  
%% dosing  
dose=150*10^3; % in mcg 
dose_number=12;% doses to simulate 
di=12; % dosing interval 
options = odeset('RelTol',1e-3, 'AbsTol', 1e-6);% ignore 
  
%% run model 
init_PK_param_dabi % initialises PK parameters 
  
for i=1:rep;% for each patient, create 'rep' number of realizations 
(virtual pts) 
    pt_data = data(i,:);% indexing to each row 
     
    get_patient % simulates a patients' PK parameter 
    start=1;% start 1 dose  
            
    time_dose=0+ALAG(i); % start time dose 1 
    D =[dose*F(i) 0 0];% dosing in gut compartment 
    inits = [dose*F(i) 0 0];% initial condition in the compartment 
         
    for jj=1:dose_number % loops through each dose and calculates the 
concentration 
                
        TT=[0:1:di];% this is to tell MATLAB to solve the ODE for each 
TT 
        stop=start+length(TT)-1;% defining when to stop 
        sol=ode45(@ode_dabigatran,[0 
di],[inits],options,KA(i),CL(i),V2(i),Q(i),V3(i));% differential 
equation solver nonstiff, medium accuracy 
        A2=deval(sol,TT,2); % amount in compartment 2 
          
        conc=A2./V2(i); % concentration of dabi 
  
        inits=deval(sol,di)'+D;% updates inits and adds another dose 
in the gut compartment 
          
        EPS1=normrnd(0,var_Liesen(1),size(TT));% prop RUV 
        EPS2=normrnd(0,var_Liesen(2),size(TT));% add RUV 
          
        C2(i,start:stop)=conc.*exp(EPS1)+EPS2; %adding in prop RUV to 
concentration 
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        T(i,start:stop)=TT+time_dose;% time 
          
         if jj==12 
            C_post=C2(i,start+2); 
            C_peak(i,:)=C_post; % Collect 2h post dose       
        end 
         
        start=stop;% updates the start point for the next iteration 
starting from where it stops 
        time_dose=time_dose+di;% add the next dose time 
         
        if jj==11 
            C_pre=C2(i,stop); 
            C_trough(i,:)=C_pre; % Collect pre-dose   
        end 
    end 
end 
     
plot_graph % calls plotting code   
stats2 % calls boxplot, KS test and CDF plot 
  
% xlswrite('Percentiles_Liesen.xlsx', Conc3); 
% xlswrite('Time_Liesen.xlsx', T); 
    toc 
 
Initialisation file (init_PK_param_liesen.m) 
%Fixed effect 
 
THETA=[0.754 0.634 35.5 1 673 345 124]; % KA(1/h), ALAG(h), Q(L/h), F, 
V2(L), V3(L), CL(L/hr) 
  
%% Random effects  
MEANETA=[0 0 0 0 0 0 0]; 
OMEGA_parLiesen=   [0 0 0       0        0 0 0; 
                    0 0 0       0        0 0 0;  
                    0 0 0       0        0 0 0;  
                    0 0 0 0.443^2        0 0 0; % F 
                    0 0 0       0  0.205^2 0 0; % V2 
                    0 0 0       0        0 0 0;  
                    0 0 0       0        0 0 0];  
           




get_patient file (get_patient_Liesen.m) 
%% simulating PK parameters  
  
patient_data % this reads in the data set 
  
%% Individual parameters 
KA=THETA(1)*exp(ETA(:,1)); 
ALAG=THETA(2)*exp(ETA(:,2)); 












PK=[KA(i) ALAG(i) Q(i) F(i) V2(i) V3(i) CL(i)]; 















 if pt_data(SEX_COL)==0 
     THETA_SEX=1;      
 elseif pt_data(SEX_COL)==1      




 if pt_data(AMIO_COL)==0 
     THETA_AMIO=1;      
 elseif pt_data(AMIO_COL)==1      
     THETA_AMIO=1.12; 
 end 
  
 %% VERAPAMIL 
  if pt_data(VERA_COL)==0 
     THETA_VERA=1;      
 elseif pt_data(VERA_COL)==1      
     THETA_VERA=1.23; 
  end 
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 %% PPI 
 if pt_data(PPI_COL)==0 
     THETA_PPI=1;      
 elseif pt_data(PPI_COL)==1      




%% Liesenfeld's model 
  
THETA_HGB=-3.99/100;% change to % 
THETA_AGE=-0.41/100;% change to % 
THETA_WT=0.77/100;% change to % 
  
THETAPWRCLCR=1.29; 
THETAEC50=56.7*60/1000; % %change units from mL min-1 to L/h 
THETA_ETHN=1; % none of the pts were South Asian. value of 0.797 for 
South Asian 
THETA_HF=1;% None of the pts were Heart Failure, otherwise 0.933 
 
 







dAdt=[-KA*A(1)% central compartment 
      KA*A(1)-k20*A(2)-k23*A(2)+k32*A(3)%intercompartments 
      k23*A(2)-k32*A(3)]; 
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A 4.3 MATLAB® code for simulating Dansirikul 2012 model 
Run file (go_dabi_Dansirikul.m) 
%% simulating dabigatran popPK model by Dansirikul et al 2012 
% Shamin last updated May 2017 
clear all; close all; clc; tic 
rng(63) 
rep=1000;% number of replicates 
  
%% reads data and resamples 1000 patients 
data_ori=xlsread('data_dabi_all.csv'); 
[rows1, columns] = size(data_ori); 
ID = datasample(1:rows1,rep,'Replace',true)';%resample IDs with 
replacement 
data = data_ori(ID,:);% resampled dataset 
  
%% dosing  
dose=150*10^3; % dose in mcg 
dn=12;% dose number 
di=12;% dosing interval 
options = odeset('RelTol',1e-3, 'AbsTol',1e-3);% ignore 
%% run PK model 
init_PK_param_dabi_dansirikul % initialises PK parameters 
  
for i=1:rep;% first loop - for each patient, simulate rep profiles 
    pt_data = data(i,:);% indexing pt_data to ith row 
    patient_data % this reads in the data set 
    get_patient % simulates the patient 
  
    start=1;% start 1 dose  
    time_dose=0+ALAG(i); % start dose 1 
     
    A0 = [dose*F(i) 0 0];% initial condition in each compartment; 
    D = A0; % dosing in gut compartment 
         
    for jj=1:dn % loops through each dose and calculates the 
concentration 
%         disp([i,jj])% displays what simulation it is doing right now 
              
        TT=[0:1:di];% this is to tell MATLAB to solve the ODE for each 
TT 
        stop=start+length(TT)-1;% defining when to stop 
        sol=ode45(@ode_dabigatran,[0 
di],[A0],options,KA(i),CL(i),V2(i),Q(i),V3(i));% differential equation 
solver nonstiff, medium accuracy 
        
        A2=deval(sol,TT,2); % amount in central    compartment 2 
         
        conc=A2./V2(i); 
        A0=deval(sol,di)'+D;% updates inits and adds another dose in 
the gut compartment 
         
        EPS=normrnd(0,sigma_RUVJoy,size(conc));%RUV 
                
        C2(i,start:stop)=conc.*exp(EPS); %adding in prop RUV to 
concentration 
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        T(i,start:stop)=TT+time_dose;% time      
  
        if jj==12 
            C_post=C2(i,start+2); 
            C_peak(i,:)=C_post;        
        end 
         
        start=stop;% updates the start point for the next iteration 
starting from where it stops 
        time_dose=time_dose+di;% add the next dose time 
         
        if jj==11 
            C_pre=C2(i,stop); 
            C_trough(i,:)=C_pre;% collecting simulated trough 
concentrations        
        end 
    end% end for dosing loop 
end% end for patient loop 
  
stats2 
plot_graph % calls plotting code    
  
% xlswrite('Percentiles_Joy.xlsx', Conc3); 





Initialisation file (init_PK_param_dansirikul.m) 
 
%% Defining THETA AND ETA 
   
THETA=[0.754 0.634 35.5 1 728 345 111];% KA, ALAG, Q, F, V2, V3, CL 
MEANETA=[0 0 0 0 0 0 0]; 
OMEGA_parJoy=[0.953^2  0 0       0       0   0 0; % KA 
                    0  0 0       0       0   0 0; % ALAG  
                    0  0 0       0       0   0 0; % Q 
                    0  0 0 0.447^2       0   0 0; % F 
                    0  0 0       0 0.261^2   0 0; % V2 
                    0  0 0       0       0   0 0; % V3 
                    0  0 0       0       0   0 0];% CL 
           












dAdt=[-KA*A(1)% central compartment 
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      KA*A(1)-k20*A(2)-k23*A(2)+k32*A(3)%intercompartments 
      k23*A(2)-k32*A(3)]; 
get_patient file (get_patient_Dansirikul.m) 
 
%% simulating PK parameters  










    CL = THETA(7)*(1+THETA_AGE*(pt_data(AGE_COL)-
68))*THETA_AF*THETA_SEX.*exp(ETA(:,7));% 'Healthy' patient 
else 
    CL = THETA(7)*(1+THETA_CLCR*(pt_data(CLCR_COL)-
120))*(1+THETA_AGE*(pt_data(AGE_COL)-
68))*THETA_AF*THETA_SEX.*exp(ETA(:,7));% 'Unhealthy' pt 
end 
  






ID_COL=1; SEX_COL=3; AGE_COL=4; WT_COL = 5; PPI_COL=6; AMIO_COL=7; 
VERA_COL=8; CLCR_COL=10; SCR_COL=11; DI_COL=19; flag_COL=2; 
  
 if pt_data(AMIO_COL)==0 
     THETA_PGP=1.150;     
 elseif pt_data(AMIO_COL)==1 
     THETA_PGP=1; 
 end 
  
 if pt_data(PPI_COL)==0 
     THETA_PPI=1;     
 elseif pt_data(PPI_COL)==1      
     THETA_PPI=0.854; 
 end 
  
 if pt_data(SEX_COL)==0 
     THETA_SEX=1; 
 elseif pt_data(SEX_COL)==1 






THETA_AF=0.939;    
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A4.4  Generic MATLAB® code for plotting VPC 
Plotting (plot_graph.m) – this is a generic code for plotting VPC 
 
%% plotting percentiles 
time_range=120:145; 
Time3=T(i,time_range); 
pink=[1 0.78 0.80];% RGB for pink 
hold on 
figure(1) 
prct=[10 50 90];% percentile 
Conc3=prctile(C2,prct);% median 
  
%% plotting data 
flag_COL=2; 
flag_DUR=13; 
[rows1, columns1] = size(data); 
for i=1:rows1 
pt_data = data(i,:); 
  
if pt_data(flag_COL)== 5 && pt_data(flag_DUR)> 1; % patients at 
steady-state with 5 samples 
    TIME_COL2(i,:) = data(i,14:18); 
    CONC_COL2(i,:) = data(i,19:23); 
     
elseif   pt_data(flag_COL)== 5 && pt_data(flag_DUR)== 0;% patients 
initiating with 5 samples 
    TIME_COL3(i,:) = data(i,14:18); 
    CONC_COL3(i,:) = data(i,19:23); 






subplot(2,3,1)% 5 samples init 










title('Liesenfeld 2011 initial'); 
xlabel('Time after dose(h)');  
ylabel('Dabigatran concentration (ng/mL)') 
hold off 
  







ylim([1 500]);xlim([120 133]); 
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title('Author Year ss'); 
xlabel('Time after dose (h)');  
ylabel('Dabigatran concentration (ng/mL)') 
hold off 
  
% print('-r900', '-djpeg', 'Author Year graph2') 
 
A4.5 Generic MATLAB® code for K-S test and boxplots 
Statistics (plot_graph.m) – this is a generic code for the box plots and Kolmogorov-
Smirnov test 
% statistical analysis of simulations 
 
%% To get pre and post dose pt and simulate 
data_ss=xlsread('data_dabi_ss.csv'); 










pt_data = data_ss(i,:); % pt data 
  
if pt_data(flag_COL)== 5 && pt_data(flag_DUR)> 1;% patients with 5 
samples 
    pt_pre(i,:) = data_ss(i,pt_pre_5); 
    pt_post(i,:) = data_ss(i,pt_post_5); 
elseif pt_data(flag_COL)== 2% patients with 2 samples 
    pt_pre(i,:) = data_ss(i,pt_pre_2); 
    pt_post(i,:) = data_ss(i,pt_post_2); 
else pt_data(flag_COL)== 1;% patients with 1 sample 
    pt_pre(i,:) = data_ss(i,pt_pre_2); 




%% Kolmogorov-Smirnov test 
% Null hypothesis = two samples were drawn from populations with the 
same distribution 
% If h = 1 ;reject the null hypothesis 
  
[h_post, p_post, ks2stat_post] = kstest2(C_peak,pt_post);% 
[h_pre, p_pre, ks2stat_pre] = kstest2(C_trough,pt_pre);  
  




cdfplot(C_peak); cdfplot(pt_post);xlim([0 750]) 
legend('Simulated post','Observed post','Location','SE') 
xlabel(['Dabigatran concentration (ng/mL)']); 
title(‘Author Year 2h post dose') 







cdfplot(C_trough); cdfplot(pt_pre);xlim([0 750]) 
legend('Simulated pre','Observed pre','Location','SE') 
xlabel(['Dabigatran concentration (ng/mL)']); 
title(' Author Year pre-dose') 
hold off 






g = [ones(size(C_peak)); 
2*ones(size(pt_pre));3*ones(size(C_peak));4*ones(size(pt_post))]; 
boxplot(post_pre,g,'Labels',['Simulated post','Observed 
post','Simulated pre', 'Observed pre'], 'positions', [1,2,4,5]); 
ylabel(['Dabigatran concentration (ng/mL)']); 
title('Author Year ss') 
ylim([0 750]) 
hold off 
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